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Summary	
	
Recently,	several	iron	and	2-oxoglutarate	(2OG)	dependent	oxygenases	were	subclassified	as	
ribosomal	 oxygenases	 (ROXs).	 ROXs	 have	 emerged	 as	 enzymes	 that	 affect	 translation	 by	
hydroxylation	 of	 translation	 factors	 like	 the	 eukaryotic	 release	 factor	 eRF11,	 tRNA2,3,	 or	
ribosomal	 proteins.	 Bacterial	 ancestor	 ycfD,	 mammalian	 OGFOD1,	 Myc-induced	 nuclear	
antigen	 (MINA53),	 and	NO66	 target	 the	 ribosome	directly	 and	modify	 different	 ribosomal	
proteins4-6.		
	
In	my	thesis,	ribosomal	oxygenases	ycfD,	OGFOD1,	MINA53,	and	NO66	were	investigated	by	
generating	 knockout	 strains	 and	 CRISPR/Cas9	 knockout	 cell	 lines,	 respectively,	 and	
examining	 those	 in	 growth	 behaviour	 and	 with	 regard	 to	 ribosome	 composition.	 Hereby,	
MINA53	 and	 NO66	 catalyzed	 hydroxylation	 of	 their	 ribosomal	 targets	 were	 confirmed.	
Further,	novel	modifications	on	ribosomal	proteins	can	be	identified	by	the	LC-MS/MS	data	
sets.	Knockout	of	ycfD	did	not	affect	growth	behaviour	of	bacteria	or	ribosome	profiles.	
	
Identification	 and	 characterization	 of	 the	 interaction	 with	 cell	 cycle	 regulator	 CCNA2	
connects	 OGFOD1	 to	 the	 cell	 cycle.	 OGFOD1	 knockout	 was	 not	 viable	 in	 cells,	 further	
indicating	 a	 cell	 cycle	 related	 function	 of	 OGFOD1.	 Also	 interaction	 of	 OGFOD1	 with	
eukaryotic	elongation	factor	2	kinase	(eEF2K)	might	further	strengthen	OGFOD1	function	in	
translation	regulation.	
	
MINA53	 and	 NO66	 share	 several	 similarities	 in	 substrate	 specificity,	 domain	 architecture,	
and	 subcellular	 localization.	 As	 homo-oligomerization	 seemed	 to	 emerge	 as	 a	 common	
feature	 of	 2OG	 oxygenases,	 the	 function	 of	 the	 oligomerization	 of	 both	 proteins	 was	
analyzed	in	more	detail	with	regard	to	substrate	binding.	Indeed,	disruption	of	dimerization	
caused	 a	 loss	 of	 interaction	 of	 NO66	 with	 its	 substrate	 RPL8.	 Phylogenetic	 studies	 were	
conducted	 to	 follow	 evolution	 of	 both	 proteins,	 revealing	 the	 conservation	 of	 the	 protein	
domain	structures.	However,	analyses	on	genomic	level	identified	NO66	as	single	exon	gene	
in	different	organisms.		
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Zusammenfassung	
	
Ribosomale	Oxygenasen	(ROXs)	wurden	kürzlich	als	Unterfamilie	der	Eisen(II)-2-Oxoglutarat	
abhängigen	 Oxygenasen	 (2OG	 Oxygenasen)	 definiert.	 Diese	 beeinflussen	 die	 Translation	
durch	 Hydroxylierung	 von	 ribosomalen	 Proteinen,	 dem	 eukaryotischen	 „release	 factor“	
eRF11	 und	 tRNA2,3.	 Bakterielles	 ycfD,	 humane	 Proteine	 OGFOD1,	 „Myc-induced	 nuclear	
antigen“	(MINA53)	und	NO66	haben	ribosomale	Proteine	als	Substrat4-6.	
	
In	 dieser	 Arbeit	 wurden	 ycfD	 und	 die	 humanen	 Homologe	 OGFOD1,	 MINA53	 und	 NO66	
charakterisiert.	 Hierfür	 wurde	 ein	 bakterieller	 Knockout-Stamm	 für	 ycfD	 und	 für	 die	
humanen	 Proteine	 CRISPR/Cas9	 Knockout	 Zelllinien	 hergestellt	 und	 im	 Hinblick	 auf	
Wachstum	und	ihre	Ribosomen	untersucht.	Anhand	von	LC-MS/MS	konnten	die	publizierten	
ribosomalen	Substrate	von	MINA53	und	NO66	bestätigt	werden.	Zusätzlich	können	mit	den	
produzierten	 massenspektrometrischen	 Daten	 neue	 Modifikationen	 an	 ribosomalen	
Proteinen	 identifiziert	 werden.	 Knockout	 von	 ycfD	 hingegen	 hatte	 keinen	 Effekt	 auf	
Wachstum	oder	ribosomales	Profil.	
	
Zellzyklusregulator	 CCNA2	 wurde	 als	 neuer	 Interaktionspartner	 von	 OGFOD1	 identifiziert	
und	 charakterisiert.	 Eine	 Verbindung	 der	 ribosomalen	 Oxygenase	 OGFOD1	 mit	 dem	
Zellzyklus	 kann	 auch	 hergestellt	 werden,	 da	 Knockout-Zellen	 von	 OGFOD1	 nicht	
überlebensfähig	 waren.	 Die	 Interaktion	 mit	 der	 „eukaryotic	 elongation	 factor	 2	 kinase“	
(eEF2K)	weist	auf	eine	Rolle	von	OGFOD1	in	der	Translationsregulation	hin.		
	
MINA53	und	NO66	teilen	viele	Gemeinsamkeiten.	Beide	modifizieren	 ribosomale	Proteine,	
haben	dieselbe	Domänen-Architektur	und	befinden	sich	im	Nukleolus.	In	den	letzten	Jahren	
kristallisierte	 sich	 Oligomerisierung	 als	 eine	 verbreitete	 Eigenschaft	 von	 2OG	 Oxygenasen	
heraus.	Deshalb	wurde	die	Funktion	der	Oligomerisierung	von	MINA53	and	NO66	im	Hinblick	
auf	 Substratbindung	 näher	 analysiert.	 Mutations-	 und	 Deletionsmutanten	 in	 der	
Dimerisierungsdomäne	 führten	 auch	 zu	 verhinderter	 Substratbindung	 bei	 NO66.	 Zudem	
wurde	anhand	von	phylogenetischen	Untersuchungen	die	Evolution	beider	Proteine	verfolgt.	
Auf	 Proteinebene	 sind	 die	 Domänenstrukturen	 konserviert,	 auf	 Genomebene	 hingegen	
wurde	NO66	als	„Single	Exon	Gene“	in	verschiedenen	Organismen	indentifiziert.	
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1 Introduction	
	
2-oxoglutarate	(2OG)	and	iron	(FeII)	dependent	oxygenases	(2OG	oxygenases)	were	studied	
quite	extensively	over	the	last	decades.	Their	roles	in	collagen	biosynthesis	and	in	regulation	
of	 the	 hypoxic	 response	 assigned	 them	 important	 roles	 in	 the	 cell.	 More	 recently,	
investigations	in	the	epigenetic	field	defined	a	subgroup	of	2OG	oxygenases	as	histone,	DNA,	
and	RNA	modifying	proteins.	With	ongoing	research	to	elucidated	the	roles	of	the	many	not	
yet	 characterized	 2OG	 oxygenases,	 the	 subfamiliy	 of	 ribosomal	 oxygenases	 (ROXs)	 was	
discovered.	These	enzymes	seem	to	regulate	gene	expression	at	the	level	of	translation.	 In	
this	 thesis,	 bacterial	 ancestor	 ycfD	 and	 its	 human	 homologues	 OGFOD1,	 Myc-induced	
nuclear	antigen	(MINA53)	and	NO66	were	studied	in	more	detail.	
	
1.1 Translation	 and	 its	 regulation	 by	 post-translational	
modifications	
1.1.1 The	ribosome	and	translation	
The	 ribosome	 is	 a	 huge	 protein-RNA	 complex	 responsible	 for	 the	 translation	 of	 genes	
encoded	on	messenger	RNA	(mRNA)	into	polypeptide	chains.		
Deciphering	 the	mRNA	code	 is	 carried	out	by	 the	 codon:anticodon	helix	 formed	by	mRNA	
and	transfer	RNA	(tRNA)	in	the	decoding	site	of	the	ribosome.	
Translation	always	follows	a	certain	succession	of	events.	It	starts	with	the	small	ribosomal	
subunit	 binding	 to	 the	 5’	 untranslated	 region	 (UTR)	 of	 the	 mRNA	 and	 scanning	 for	 a	
translation	 start	 side	 on	 the	 mRNA.	 Once	 the	 start	 codon	 AUG	 is	 found,	 three	 initiation	
factor	proteins	bind	to	the	small	subunit	as	well	as	the	initiator	tRNA	methionine	responsible	
for	 decoding	 AUG.	 Thereby	 the	 initiation	 complex	 is	 formed.	 Now	 the	 large	 ribosomal	
subunit	can	bind,	which	results	in	the	release	of	the	initiation	factors.	
The	 large	subunit	provides	 three	 tRNA	binding	sites.	First,	 the	 tRNA	binds	 in	 the	A	 (amino	
acid)	site	where	the	codon:anticodon	formation	of	mRNA	and	tRNA	ensures	the	binding	of	
the	cognate	tRNA	and	thereby	addition	of	the	correct	amino	acid	to	the	growing	polypeptide	
chain.	Following,	the	ribosome	translocates	this	tRNA	to	the	P	(polypeptide)	position.	Here	
the	delivered	amino	acid	gets	transferred	from	tRNA	to	the	polypeptide	chain.	Through	the	
peptide	release	channel,	the	nascent	protein	chain	gets	elongated	out	of	the	ribosome.	From	
the	E	 (exit)	 position,	 the	 tRNA	gets	 released	back	 into	 the	 cytoplasm	where	 it	 is	 recycled.	
Delivery	of	amino	acids	by	tRNAs	drives	the	elongation	of	the	protein.	The	stop	codon	on	the	
mRNA	 signals	 for	 translation	 termination,	 termination	 factors	 help	 to	 complete	 protein	
translation	and	to	release	the	newly	synthesized	protein.	Small	and	large	subunit	dissociate	
from	the	mRNA7,8.	
	
The	aforementioned	basic	translation	concept	gets	expanded	more	and	more.	Not	only	the	
core-ribosome	protein	composition	seems	to	be	distinct	 in	different	 tissues	and	cell	 types,	
also	the	ribo-actome	or	different	translation	factors	with	manifold	modifications	contribute	
to	a	new	field	of	gene	expression	on	the	post-transcriptional	level.	
Dependent	 on	 cell	 type,	 developmental	 stage	 or	 as	 reactions	 to	 changing	 environmental	
conditions,	 the	 core-ribosome	 stays	 the	 same	 whereas	 none-essential	 ribosomal	 proteins	
can	be	interchanged,	resulting	 in	specialized	ribosomes9-11.	Also	modifications	of	ribosomal	
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RNA	(rRNA),	tRNA,	mRNA,	ribosomal	proteins,	or	translation	factor	come	more	into	focus	as	
they	contribute	in	specializing	the	ribosomes9,11,12.	
	
1.1.2 Translation	regulation	by	modifications	
In	 addition	 to	 the	 already	 highly	 complex	 formation	 of	 the	 functional	 ribosome,	
modifications	of	ribosomal	proteins	were	detected	from	bacteria	to	yeast	 to	humans4,13-16.	
The	conservation	indicates	a	universal	function	of	post-translational	modifications	(PTMs)	of	
ribosomal	proteins.	
Many	 of	 the	 discovered	 and	 studied	 modifications	 are	 involved	 in	 different	 steps	 of	
ribosome	maturation	and	assembly.	For	 instance,	 the	 loss	of	 the	methylation	of	L3	 (uL317)	
made	bacteria	cold	sensitive	due	to	 less	efficient	ribosome	assembly13,18.	 Interestingly,	 the	
modification	of	L7/L12	(bL12)	itself	is	temperature	depended	and	increases	with	decreasing	
temperatures.	In	yeast	the	loss	of	the	histidine	methylation	of	Rpl3p	was	shown	to	result	in	a	
deficiency	of	early	rRNA	processing.	This	affected	the	60S	subunit	assembly	and	translation	
initiation14.	 Aditionally,	 methylations,	 acetylation,	 and	 methylthiolation	 were	 identified	 in	
bacterial	ribosomal	proteins13.		
	
However,	not	only	the	assembly	of	ribosomes	is	regulated	by	PTMs	of	ribosomal	proteins	or	
rRNA,	 there	 are	 also	 reports	 of	 PTMs	 on	 the	 ribosome	 affecting	 translation	 directly.	 One	
example	 is	 the	 hydroxylated	 Pro62	 in	 human	 RPS23	 (uS12).	 This	 residue	 is	 located	 in	 the	
PNSA	loop	which	is	part	of	the	platform	for	the	codon:anticodon	minihelix19.	Proline	62	gets	
hydroxylated	 by	 the	 ribosomal	 oxygenase	 (ROX)	 OGFOD1	 and	 this	 modification	 leads	 to	
changes	in	translation	accuracy20.		
	
1.2 Ribosomal	oxygenases	might	regulate	translation	
Hydroxylation	 of	 ribosomal	 proteins	 is	 carried	 out	 by	 ribosomal	 oxygenases	 (ROXs)	 of	 the	
superfamily	of	2-oxoglutarate	(2OG)	and	iron	(FeII)	dependent	oxygenases	(2OG	oxygenases)	
and	is	conserved	throughout	evolution	from	bacteria	to	mammals4.		
	
1.2.1 Superfamily	of	2OG	oxygenases	
2OG	oxygenases	form	an	enzyme	superfamily	that	is	conserved	from	bacteria	to	mammals.	
So	 far	 there	are	 six	2OG	oxygenases	 found	 in	bacteria4,	 in	humans	more	 than	60	proteins	
were	identified21-24.	
Substrates	 are	 manifold	 including	 proteins,	 RNA,	 and	 DNA17,19.	 Therefore	 the	 functional	
range	 of	 2OG	 oxygenases	 in	 mammalians	 covers	 various	 different	 processes	 in	 the	 cell.	
Additional	domains	 like	zink	 finger	domains	 for	DNA	binding	or	protein-protein	 interaction	
domains	contribute	to	their	substrate	specificity23.	
The	 family	 classifying	 feature	 is	 the	 double-stranded	 β-helix	 (DSBH)	 domain	 (Jumonji-C	
(JmjC),	cupin,	or	jelly-roll	domain).	It	consists	of	two	sheets	of	four	β-helices	opposing	each	
other	to	form	a	barrel	like	structure.	Inside	the	barrel,	three	amino	acids	build	the	catalytic	
center	binding	 the	 co-factor	 iron	and	 coordinating	 the	 co-substrate	2-oxoglutarate	 (Figure	
1).	The	iron-coordinating	motif	is	highly	conserved	through	all	2OG	oxygenases	and	consists	
of	HxD/E	...	H21,24.	
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Figure	1:	Representation	of	a	typical	JmjC	domain	with	the	iron	(FeII)	in	green,	N-oxalylglycine	(NOG)	as	co-
substrate	analogue	depicted	in	yellow	sticks,	the	eight	core	β-helices	are	in	red.	From	McDonough	et	al21.	
The	reaction	mechanism	catalyzed	by	2OG	oxygenases	comprises	sequential	binding	of	2OG	
to	the	active	side	followed	by	the	substrate	and	then	oxygen.	This	results	in	a	two-electron	
oxidation	of	the	substrate	and	generation	of	succinate	and	carbon	dioxide	(CO2)	(Figure	
2)21,24,25.	
In	 addition	 to	 the	 oxidation	 of	 proteins	 or	 tRNA	 leading	 to	 stably	 hydroxylated	 residues,	
demethylation	is	another	product	of	some	of	the	2OG	oxygenases.	Demethylation	occurs	as	
a	 two	 step	 reaction,	 starting	 with	 hydroxylation	 of	 a	 Nε-methyl	 group	 followed	 by	
fragmentation,	 which	 results	 in	 the	 demethylated	 product	 and	 formaldehyde	 (Figure	 2	 in	
gray)24,26.		
	
	
Figure	2:	General	enzymatic	reaction	carried	out	by	2OG	oxygenases;	in	the	active	side,	FeII	(orange)	is	bound	
by	the	HxD/E...H	motif,	after	2OG	binding	and	iron	binding,	oxidative	decarboxylation	of	2OG	generates	CO2	
and	 succinate;	 in	 gray	 N-methyl	 demethylation	 via	 hydroxylation	 of	 the	 methyl	 group	 and	 subsequent	
formaldehyd	release.	From	Markolovic	et	al	24.	
An	example	of	2OG	oxygenases	are	PLOD1-3	which	give	collagen	 its	stable	but	still	 flexible	
structure	through	lysine-hydroxylation27,28.	Also	the	hypoxia	response	pathway	is	regulated	
by	oxygenases	sensing	the	oxygen	levels.	Hydroxylation	of	HIF1α	(hypoxia	 inducible	factor)	
by	 asparaginyl	 hydroxylase	 FIH	 (factor	 inhibiting	 HIF-1)	 targets	 HIF1α	 for	 proteasomal	
degradation.	 Low	 oxygen	 levels	 inhibit	 the	 asparaginyl	 hydroxylase	 FIH	 as	 it	 needs	
atmospheric	 oxygen	 as	 cofactor.	 The	 resulting	 loss	 of	 hydroxylation	 of	 HIF1-α	 leads	 to	
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stabilization	of	this	transcription	factor	and	subsequent	translocation	to	the	nucleus.	Here	it	
can	dimerize	with	HIF1-β	and	activate	hypoxia	response	genes29.	
	
2OG	 oxygenases	 emerged	 as	 major	 players	 in	 epigenetic	 regulation.	 More	 than	 20	 2OG	
oxygenases	act	as	histone	lysine	demethylases	(KDMs),	like	the	JARID	family	or	JMJD2	a-d30.	
Additionally,	 the	 Tet	 subfamily	 (Tet1,	 Tet2,	 and	 Tet3)	 catalyses	 the	 oxidation	 of	 5-
methylcytosine	 to	 5-hydroxymethylcytosine	 in	 DNA31-33.	 FTO,	 member	 of	 the	 AlkB	
homologue	(AlkBH)	subfamily	demethylates	the	N6-methyladenosine	in	mRNA34.	TYW5	and	
AlkBH8	are	other	examples	 for	RNA	modification2,35-37	 ,	as	 they	hydroxylate	 tRNAs.	Known	
functions	of	2OG	oxygenases	are	summarized	in	Figure	324.		
	
	
Figure	3:	By	hydroxylation	and	demethylation	reactions,	2OG	oxygenases	are	involed	in	transcriptional,	post-
transcriptional,	 translational,	 and	 post-translational	 processes;	 (ALKBH	 stands	 for	 alkylated	 DNA	 repair	
protein	alkB	homolog;	TET1–3,	ten-eleven	translocation	1–3;	FTO,	fat	mass-	and	obesity-associated	protein;	
TYW5,	 tRNA	 wybutosine-synthesizing	 protein	 5;	 C-P4Hs,	 collagen	 prolyl	 4-hydroxylases;	 C-P3Hs,	 collagen	
prolyl	 3-hydroxylases;	 PLODs,	 pro-collagen	 lysine	 2-oxoglutarate	 5-dioxygenase	 enzymes;	 P4HTM,	
transmembrane	prolyl	4-hydroxylase).	From	Markolovic	et	al24.	
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1.2.2 Ribosomal	oxygenases	
The	identification	of	2OG	oxygenases	hydroxylating	ribosomal	proteins	directly	or	translation	
related	 proteins	 indicates	 a	 novel	 type	 of	 translation	 regulation4,6.	 These	 ribosomal	
oxygenases	 (ROXs)	are	conserved	 from	bacteria	 to	eukaryotes.	 In	bacteria	ycfD	 is	 the	only	
ribosomal	 oxygenase,	 in	 human	 six	 enzymes,	 ALKBH8,	 TYW5,	 JMJD4,	MINA53,	 NO66,	 and	
OGFOD1	(Figure	4)	were	subclassified	as	ROXs38,39.	
	
ALKBH8	 is	 one	 homologue	 of	 the	 bacterial	 AlkB	 enzyme.	 AlkB	 is	 responsible	 for	 repair	 of	
alkylation	damages	of	nucleobases36,40.	The	AlkB	domain	and	the	methyltransferase	domain	
of	ALKBH8	modify	the	uridine	at	position	34	of	the	anticodon	tRNA41,42.	
	
TYW5	hydroxylates	wybutosine	in	position	37	of	phenylalanine	tRNA34,48,	adjacent	to	the	3'	
position	of	the	anticodon.		
	
	
Figure	 4:	 Human	 2-Oxoglutarate	 oxygenases	 targeting	 translation	 by	 hydroxylating	 ribosomal	 protein,	
translation	factors	or	tRNA.	Adapted	from	Ploumakis	et	al43.	
	
Recently,	 Jmjd4	was	 identified	 to	hydroxylate	 a	 lysine	 in	 the	NIKS	motif	 of	 the	 translation	
release	factor	eRF11.	This	motif	is	responsible	for	optimal	translation	termination.	
	
ROXs	 directly	 targeting	 the	 ribosome	 are	 bacterial	 ycfD11	 and	 its	 eukaryotic	 homologues	
OGFOD15,20,44,	MINA53,	and	NO6611,42.	These	four	enzymes	will	be	discussed	in	detail	in	the	
following	subchapters.	
	
1.2.2.1 Bacterial	ancestor	ycfD	
In	1999,	E.coli	ribosomal	proteins	were	analyzed	for	post-translational	modifications	by	mass	
spectrometry45.	 In	 addition	 to	 several	 methylated	 and	 acetylated	 proteins,	 the	 authors	
mentioned	an	„unknown“	modification	in	ribosomal	protein	L16	(RPL16,	uL1617)	at	arginine	
81	 (R81)45.	 Some	 years	 later,	 interaction	 of	 ycfD	 with	 RPL16	 was	 identified	 using	
overexpressed	 GFP-tagged	 ycfD	 in	 bacteria	 and	 also	 the	 RPL16-R81	 modification	 as	
hydroxylation	catalyzed	by	ycfD	could	be	found4.	This	interaction	was	corroborated	and	was	
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suggested	 that	 ycfD-binding	 occurs	 with	 RPL16,	 which	 is	 not	 incoorporated	 into	 the	
ribosome46.		
R81	of	RPL16	 is	 located	 in	closest	proximity	to	the	peptidyl	 transferase	center	 (PTC)	 in	the	
large	 ribosomal	 subunit	 (Figure	 5).	 RPL16	 is	 essential	 for	 the	 association	 of	 the	 large	 and	
small	 subunit	 to	 form	 the	 70S	 initiation	 complex47.	 In	 addition,	 it	 is	 important	 for	 the	
peptidyl	 transferase	activity48	 and	 seems	 to	 stabilize	 the	binding	of	A-site	 tRNA49.	Hereby,	
arginine	 56	 in	 RPL16	 together	with	 others	 coordinate	 tRNA	 binding.	 Distinct	mutations	 in	
RPL16	lead	to	antibiotic	resistance50.	
	
	
Figure	5:	Thermus	 thermophilus	 70S	 ribosome	 (PDB	accession	number	2J02	and	2J03);	 crystal	 structure	on	
the	right	reduced	to	E-,	P-	and	A-site	tRNA	in	blue,	mRNA	in	yellow	and	RPL16	in	green,	by	ycfD	hydroxylated	
arginine	81	in	red	(R81).	
	
The	molecular	function	of	R81	hydroxylation	is	still	unclear.	However,	overexpression	of	His-
tagged	ycfD	led	to	tremendous	growth	defects	whereas	the	knockout	was	viable4,46.	Under	
stress	 conditions	 like	 growth	 in	 minimal	 medium,	 growth	 defects	 for	 the	 knockout	 were	
observed4.	
	
1.2.2.2 Mammalian	homologues	Myc-induced	nuclear	antigen	(MINA53)	and	NO66	
Human	homologues	of	ycfD,	Myc-induced	nuclear	antigen	(MINA53)	and	NO66	are	two	ROXs	
sharing	 some	 striking	 similarities.	 Both	 proteins	 are	 localized	 in	 the	 nucleoli,	 even	 in	 the	
same	nucleolar	subcompartment51,52.	Crystal	structures	revealed	a	JmjC	domain,	a	proposed	
dimerisation	domain38,58,59	and	a	winged	helix	 (WH)	domain	are	highly	conserved	between	
the	two	human	proteins	and	are	also	shared	with	bacterial	ycfD6	(Figure	6).	
	
MINA53	and	NO66	also	modify	ribosomal	proteins.	Both	proteins	catalyze	hydroxylation	of	
histidine	 residues	 (H);	MINA53	hydroxylates	H39	of	 the	 ribosomal	proteins	RPL27a	 (uL15),	
NO66	H216	 in	RPL8	 (uL2)6,17.	 Those	modified	histidine	 residues	 are	 located	 in	 the	peptide	
release	tunnel	close	to	the	peptidyl	transferase	center	(Figure	7)4.		
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Figure	6:	Schematic	drawing	of	ycfD,	MINA53,	and	NO66	domain	structure;	B)	Comparison	of	dimerization	
domains,	residues	essential	for	interaction	in	MINA53	and	NO6653	are	indicated	by	circles;	figure	B	is	adapted	
from	Chowdhury	et	al6.	
	
MINA53	was	inititally	identified	as	myc	target	gene	being	involved	in	proliferation54.	MINA53	
mRNA	 expression	was	 upregulated	 in	 alveolar	macrophages	 from	 coal	miners	 exposed	 to	
mineral	 dust55.	 Following	 this	 initial	 finding,	 higher	 MINA53	 expression	 was	 detected	 in	
various	cancer	types55-70,	similar	to	the	upregulation	of	oncogene	c-MYC71.		
MINA53	is	also	assigned	a	role	in	the	cell	fate	decision	from	naive	CD4+	T	cells.	T	helper	type	
2	(TH2)	bias	correlates	with	interleukin	4	(IL-4)	levels.	IL-4	levels	feed	back	positively	to	drive	
TH2	 development.	 MINA53	 was	 found	 to	 act	 as	 genetic	 determinant	 of	 the	 TH2	 bias	 by	
binding	 the	 interleukin	 4	 (IL-4)	 promoter	 and	 regulating	 IL4	 levels72.	 In	 mice,	 MINA53	
ablation	 led	 to	a	 reduced	allergic	 reaction	potentially	by	 reduced	 IL-4	expression73.	Others	
identified	MINA53	as	regulator	of	the	reciprocal	regulatory	T	cell	(Treg)	to	TH17	balance74,75.	
The	earlier	reported	histone	H3K9me3	demethylase	activity76	could	not	be	confirmed	in	an	
in	vitro	assay77.	A	proteomic	approach	reported	the	interaction	of	MINA53	with	DNA	repair	
and	chromatin	binding	proteins78.	
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Figure	7:	Homo	sapiens	80S	ribosome	(PDB	accession	number	3J3A,	3J3AB	and	3J3D).	Crystal	structure	on	the	
right	reduced	to	E-site	tRNA	in	blue,	RPL27a	with	histidine	39	(H39)	marked	in	red	as	substrate	of	MINA53,	
RPL8	with	histidine	216	(H216)	marked	in	red	as	substrate	of	NO66.	Gray	bar	indicates	probable	location	of	
the	peptide	exit	tunnel	supported	by	RPL4	(in	gray)	localization.	
	
First	reports	described	NO66	as	a	nucleolar	protein	which	cofractionated	with	pre-ribosomal	
particles51.	 However,	 another	 field	 of	 intensive	 research	 about	 NO66	 focuses	 on	 the	
regulation	 of	 the	 osteoblast-specific	 transcription	 factor	 Osterix.	 Osterix	 is	 essential	 for	
osteoblast	 differentiation	 and	 bone	 formation	 and	 was	 shown	 to	 interact	 directly	 with	
NO66.	 Additionally	 NO66	 seemed	 to	 inhibit	 Osterix	 promoter	 activity79-82.	 In	 this	 context,	
NO66	was	shown	to	demethylate	H3K4me3	and	H3K36me3	and	thereby	modify	the	activity	
of	 osteoblast	 specific	 promoters79,83.	 Interaction	 of	 NO66	 with	 the	 Polycomb	 repressive	
chromatin	modifier	pointed	also	towards	a	role	 in	epigenetic	regulation84.	This	 finding	was	
later	 challenged	 by	 the	 identification	 of	 JARID1B/KDM5B	 as	 the	 histone	 demethylase	
regulating	osteoblast	specific	promoters	during	differentiation85.	Like	for	MINA53,	catalytic	
activity	of	NO66	towards	histones	could	not	be	confirmed77.	
	
1.2.2.3 Proline	hydroxylase	OGFOD1	
OGFOD1	 is	 conserved	 from	 yeast	 to	 human86-88.	 Structure-wise,	OGFOD1	 is	 a	 special	 2OG	
oxygenase	as	it	consists	of	two	barrel	like	DSBH	domains.	However,	enzymatic	activity	is	only	
carried	out	by	the	N-terminal	domain	as	it	harbours	the	essential	HxD...H	triad	to	coordinate	
iron	 (Figure	 8).	 The	 two	 DSBHs	 are	 seperated	 by	 a	 domain	 linker.	 An	 N-terminal	 nuclear	
localization	sequence	(NLS)	is	responsible	for	its	nuclear	distribution.	
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Figure	8:	Crystal	structure	of	human	OGFOD1	(PDB	accession	number	4NHX);	barrel-like	DSBHs	are	shown	in	
yellow,	 residues	 in	 red	 show	 the	 catalytic	 center	with	 the	HxD...H	motif,	 the	 domain	 linker	 is	 depicted	 in	
magenta,	the	acidic	loop	is	indicated	as	dashed	line.	
	
2010,	OGFOD1	was	identified	as	stress	granule	component.	 Interaction	proteins	comprised	
some	 stress	 granule	 proteins,	 the	 eIF2alpha	 kinase	 heme-regulated	 inhibitor	 (HRI),	 and	
eIF2alpha	 itself.	 Overexpression	 of	 OGFOD1	 resulted	 in	 decreased	 polysome	 levels	 and	
increased	amounts	of	phosphorylated	eIF2alpha	during	recovery	from	stress.	Knockdown	on	
the	other	hand	 led	 to	 enhanced	 recovery	of	 translation	by	 enhanced	polysome	 formation	
during	the	recovery	from	stress89.	
Under	 ischemic	conditions,	OGFOD1	gene	silencing	seemed	to	mediate	a	resistance	to	cell	
death90.	
In	a	screen	of	B	cells	and	chronic	 lymphocytic	 leukemia	 (CLL),	OGFOD1	was	 found	to	have	
higher	 transcript	 and	protein	 levels91.	 Also	 an	 involvement	 in	 cancer	was	 shown	 in	 breast	
cancer	 cells,	 OGFOD1	 displayed	 a	 high	 expression92.	 Consistent	 with	 this,	 knockdown	 in	
breast	 cancer	 cells	 led	 to	 an	 inhibiton	 of	 proliferation	 probably	 resulted	 by	 an	 observed	
G2/M	 arrest.	 Another	 suggestion	 of	 OGFOD1	 being	 involved	 in	 proliferation	 regulation	 or	
cell	 cycle	 control	was	given	 recently.	Using	a	whole	 cell	 proteomics	approach	quantitative	
values	of	probability	for	proteins	to	function	in	chromatin	biology	were	assessed.	Hereby,	si-
RNA	induced	OGFOD1	knockdown	led	to	a	strong	reduction	of	cells	in	S-phase93.	
	
Three	accompanying	publications	in	2014	found	that	OGFOD1	in	Homo	sapiens	(H.sapiens),	
Sud1	 in	Drosophila	melanogaster	 (D.melanogaster)	 and	 Tpa1	 in	 Saccharomyces	 cerevisiae		
(S.cerevisiae)	 hydroxylate	 Pro62	 (Pro64	 in	 D.melanogaster	 and	 S.cerevisiae)	 of	 RPS23	
(uS12)5,17,20,44.	
The	human	homolog	OGFOD1	was	shown	to	hydroxylate	RPS23	at	proline	625	(Figure	9,	right	
picture).	RPS23	 in	bacteria	 (S12)	 is	 localized	 in	 the	 small	 ribosomal	 subunit	 and	builds	 the	
platform	 for	 the	 codon:anticodon	minihelix	 by	 interaction	 of	 the	 PNSA	 loop	with	 the	 16S	
rRNA19.	The	PNSA	loop	is	essential	for	mRNA	decoding	(Figure	9)5,	mutations	in	this	region	
affect	the	accuracy	of	decoding	and	revealed	P44	(P62	in	humans)	as	absolutely	essential19.		
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Figure	 9:	 H.sapiens	 80S	 ribosome	 (3J3A,	 3J3AB	 and	 3J3D),	 A-	 and	 P-site	 tRNA	 from	 T.thermophilis	 70S	
ribosome	 (PDB:	 2J02	 and	 2J03);	 crystal	 structures	 on	 the	 right	 reduced	 to	 E-,	 P-	 and	 A-site	 tRNA	 in	 blue,	
mRNA	in	yellow	and	RPS23	in	green,	by	OGFOD1	hydroxylated	proline	62	(P62)	in	red.	
	
In	 human,	 only	 one	 hydroxylation	 occurs	 (trans-3-hydroxyproline)	 whereas	 in	 yeast	 the	
RPS23	seems	to	be	hydroxylated	twice.	Translational	accuracy	was	tenfold	reduced	in	yeast	
tpa1	knockout	strains20.	
In	Drosophila,	ubiquitous	RNAi	knockdown	of	OGFOD1	homologue	Sudestada1	 (Sud1)	was	
lethal	in	the	second	larval	stage.	Restricted	knockdown	to	different	Drosophila	tissues	led	to	
reduced	cell	 size	and	 reduced	cell	 number.	Next	 to	a	decrease	 in	protein	 synthesis,	 stress	
granule	formation	and	activation	of	the	unfolded	protein	response	was	observed	upon	Sud1	
knockdown44,94.	
In	 a	 case	 studie	 of	 two	 patients	 suffering	 of	 microcephaly,	 hearing	 loss,	 and	 overlapping	
dysmorphic	 features,	 mutations	 in	 RPS23	 were	 identified.	 The	 severeness	 of	
ribosomopathies	 in	 human	 highlights	 the	 importance	 of	 intact	 and	 correctly	 modified	
ribosomal	proteins	in	general	and	RPS23	specifically95.	
	
S.cerevisiae	 homolog	 Tpa1	 was	 analyzed	 by	 different	 groups.	 Related	 to	 the	 function	 of	
OGFOD1	 in	 hydroxylating	 RPS23	 (uS12),	 Tpa1	 function	 in	 yeast	 seems	 to	 be	 related	 to	
translation.	Increased	readthrough	of	stop	codons	was	observed	upon	deletion	of	Tpa196	as	
well	as	decreased	translation	termination	efficacy	probably	caused	by	increased	stop	codon	
readthrough87.	 Aditionally	 interaction	 with	 the	 translation	 termination	 factors	 eRF1	 and	
eRF3	 as	 well	 as	 with	 poly(A)	 binding	 protein	 Pab1	 indicates	 a	 role	 of	 Tpa1	 in	 correct	
translation	termination96.	More	recently,	another	function	of	Tpa1	was	reported.	Related	to	
bacterial	 homolog	 AlkB,	 deletion	 of	 Tpa1	 causes	 a	methylmethane	 sulfonate	 sensitivity	 in	
S.cerevisiae.	Tpa1	was	shown	to	repair	both	single	and	double-stranded	methylated	DNA97.	
Function	of	Schizosaccharomyces	pombe	Ofd1	seems	to	be	related	to	the	FIH	role	in	hypoxia	
response	in	humans98-102.	
	
	
OGFOD1
RPS23
P62
E-site
tRNA
A-site 
tRNA
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tRNA
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1.3 Aim	of	the	thesis	
	
This	thesis	aimed	to	 investigate	the	ribosomal	oxygenases	(ROXs)	 including	the	prokaryotic	
ycfD	and	human	OGFOD1,	MINA53,	and	NO66	proteins.		
	
Substrate	 specificities,	 mode	 of	 interaction	 with	 substrates,	 and	 characterization	 of	 the	
different	protein	domains	of	 these	proteins	should	be	analyzed.	Hereby	cell	biological	and	
biochemical	approaches	should	be	used,	like	localization	and	immunoprecipitation	assays	of	
different	protein	variants	with	their	respective	substrates,	or	interaction	changes	caused	by	
overexpression	or	knockout.	Generation	of	knockout	 strains/cell	 lines	 should	 further	allow	
characterization	of	 the	 cell	 lines	with	 regards	 to	 their	 ribosome	 composition	 and	 changed	
PTMs	on	ribosomal	proteins.	Knockout	cell	lines	reconstituted	with	different	protein	variants	
could	help	to	characterize	those	variants	in	more	detail.	
Cell	 cycle	 regulator	 CCNA2	 should	 be	 examined	 as	 novel	 interactor	 of	 OGFOD1	 by	
characterizing	 it	 as	 substrate	 and	 defining	 protein	 sequences	 or	 domains	 necessary	 for	
interaction.	
MINA53	and	NO66	form	homo-oligomers	 in	vivo	and	 in	vitro.	The	homo-oligomerization	of	
both	proteins	should	be	investigated	with	protein-protein	interaction	studies	using	deletion	
and	 point	mutants	 affecting	 the	 dimerization	 domain.	 Substrate	 binding	 in	 those	mutants	
should	 be	 further	 analyzed	 by	 immunoprecipitation	 assays	 and	 with	 knockout	 cell	 lines	
reconstituted	with	 different	MINA53/NO66	 constructs.	 In	 a	 long-term	 perspective,	 homo-
oligomerization	should	be	evaluated	as	potential	inhibitor	target.	
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2 Results	
2.1 Characterization	of	bacterial	ycfD	
To	find	out	more	about	the	function	of	RPL16	arginine	81	(R81)	hydroxylation	catalyzed	by	
ycfD,	the	generation	of	different	bacterial	knockout	strains	was	planned.		
The	 comercially	 available	 ycfD	 knockout	 strain	 JW1114-2103	 showed	 growth	 defects	 in	
minimal	media4.	By	generating	genomic	modified	strains	like	a	ycfD	knockout	strain,	a	strain	
carrying	 a	 catalytically	 inactive	 ycfD	 and	 a	 strain	with	 RPL16	mutated	 in	 the	 hydroxylated	
R81	we	planned	to	further	pinpoint	the	mechanisms	causing	this	growth	phenotype.	
	
2.1.1 Generation	of	ycfD	knockout	and	mutant	strains	
BW25113	(rpsL150)	was	used	as	initial	strain	to	generate	BW25113	(rpsL150,	ycfD-neo/kan-
cassette)	 and	 BW25113	 (rpsL150,	 ycfD-H125A,D127A)	 (Figure	 10).	 The	 ycfD	 knockout	
(BW25113	(rpsL150,	ycfD-neo/kan-cassette))	was	generated	by	inserting	a	counter	selection	
cassette.	This	resulted	in	the	deletion	of	nucleotides	51-1071	of	the	ycfD	gene	(Figure	10	B).	
BW25113	(rpsL150,	ycfD-H125A,D127A)	encodes	the	 iron-binding	defective	ycfD	(Figure	10	
C).	The	strains	generated	were	confirmed	by	genomic	PCRs	and	subsequent	sequencing.	
	
	
Figure	10:	Strains	generated	using	"Counter	Selection	BAC	Modification	Kit"	from	Gene	Bridges	
YcfD	hydroxylates	arginine	81	(R81)	in	RPL164.	Thus	we	also	tried	to	generated	a	strain	with	
mutated	 RPL16	 R81	 to	 alanine	 (A).	 However,	 using	 the	 counter	 selection	 kit	 it	 was	 not	
possible	to	exchange	RPL16	with	the	counter	selection	cassette,	most	likely	because	RPL16	is	
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an	essential	gene	and	deletion	would	be	lethal.	Generated	ycfD	defective	strains	were	viable	
under	all	conditions	tested.	
	
2.1.2 Growth	assays	of	different	ycfD	mutated	strains	
Earlier	 studies	 showed	 that	 overexpression	 of	 His-tagged	 ycfD	 led	 to	 tremendous	 growth	
defects,	whereas	 the	 knockout	 is	 viable4,46.	However,	 under	 stress	 conditions	 like	minimal	
medium,	growth	defects	of	the	knockout	strain	were	observed4.	
	
To	examine	the	effects	of	ycfD,	growth	assays	were	performed.	BW25113	(rpsL150)	as	wild	
type	 strain	 was	 investigated	 under	 different	 growth	 conditions	 like	 rich	 medium	 (LB	
medium),	 minimal	 medium	 (M9)	 or	 with	 chloramphenicol	 (CAP)	 (Figure	 11	 A).	 The	 same	
experimental	 setup	 was	 applied	 for	 BW25113	 (rpsL150,	 ycfD-H125A,	 D127A)	 (ycfD	 AxA	
mutant	strain)	and	BW25113	(rpsL150,	ycfD-neo/kan-cassette)	(ycfD	KO	strain)	(Figure	11	B	
and	C).		
	
	
Figure	11:	Bacterial	growth	of	different	strains	at	37°C	in	different	medium	for	23h;	A)	BW25113	(rpsL150)	as	
wild	 type	control,	B)	BW25113	originated	strain	BW25113	 (rpsL150,	ycfD-H125A,	D127A),	and	C)	BW25113	
(rpsL150,	ycfD-neo/kan-cassette)	were	grown	under	in	LB	or	M9	medium	or	with	LB	medium	supplemented	
with	chloramphenicol	(CAP).	
With	 increasing	CAP	concentrations	 in	 the	LB	medium,	bacterial	growth	of	all	 three	tested	
strains	 was	 generally	 reduced	 (Figure	 11).	 However,	 minimal	 media	 diminished	 growth	
significantly	independent	of	genomic	ycfD	background	(Figure	12).	
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Figure	12:	Bacterial	growth	of	different	strains	at	37°C	in	LB	medium	for	23h;	BW25113	(rpsL150)	as	wild	type	
control	and	other	BW25113	originated	strains	were	grown	in	LB	or	M9	medium.	
As	 this	 result	 is	 contradictory	 to	 the	observed	 growth	defects	 of	 the	 ycfD	 knockout	 strain	
JW11144,	this	strain	was	also	included	in	the	growth	assay.	Contrary	to	the	published	data,	
no	growth	phenotyp	of	ycfD	defective	strains	could	be	observed	as	neither	BW25113,	nor	
BW25113	 (rpsL150),	 or	 JW1114	 showed	distinguishably	 different	 growth	 in	 LB	medium	or	
M9	minimal	medium	(Figure	13).	The	reported	recovery	of	the	wild	type	strain	(BW25113)	in	
minimal	medium4	could	not	be	reproduced	(Figure	13).	
	
	
Figure	 13:	 Bacterial	 growth	 of	 different	 strains	 at	 25°C	 in	 LB	 medium	 for	 22h;	 BW25113	 and	 BW25113	
(rpsL150)	as	wild	type	control	and	JW1114	were	grown	in	either	LB	medium	or	M9	minimal	medium.	
Therefore,	 no	 growth	deficiency	of	 bacteria	 lacking	 ycfD	 (JW1114),	 lacking	 ycfD	 in	 nts	 51-
1071	 (BW25113	 (rpsL150,	 ycfD-neo/kan-cassette),	 or	 BW25113	 (rpsL150,	 ycfD-
H125A,D127A)	 harboring	 the	 active	 side	 mutation,	 could	 be	 observed	 in	 the	 used	
experimental	setup.	
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2.1.3 Ribosome	profiles	of	different	ycfD	mutated	strains	
Ribosomes	 of	 the	 different	 aforementioned	 bacterial	 strains	 have	 also	 been	 analyzed	 (in	
collaboration	 with	 Daniel	 Wilson's	 Lab,	 Gene	 Center	 Munich	 with	 the	 help	 of	 Dr.	 Agata	
Starosta).	 Ribosomes	 were	 isolated,	 loaded	 onto	 a	 sucrose	 gradient	 (10-40%)	 and	 the	
fractions	analyzed.	
	
	
Figure	14:	Sucrose	gradient	A260	absorbance	ribosome	profiles;	A)	Bacterial	 lysates	were	 loaded	onto	a	10-
40%	 sucrose	 gradient.	 Following	 ultracentrifugation,	 the	 gradients	 were	 fractionated	 from	 top	 to	 bottom	
while	 continuously	 recording	 the	absorption	profile	at	 λ	=	254	nm;	B-E)	Ribosome	profiles	of	B)	BW25113	
(rpsL150),	C)	JW1114,	D)	BW25113	(rpsL150,	ycfD-neo/kan-cassette),	and	E)	BW25113	(rpsL150,	ycfD-H125A,	
D127A),	the	positions	of	different	ribosomal	species	are	indicated	
The	wild	type	ribosome	profiles	displayed	a	typical	bacterial	polysome	profile	(Figure	14	B).	
The	 first	 peak	 is	 A260	 absorbing	material,	 containing	 no	 ribosomes.	 The	 second	 and	 third	
peaks	 correspond	 to	 the	 small	 (30S)	 and	 the	 large	 ribosomal	 subunits	 (50S).	 The	 largest	
amount	of	ribosomes	appears	as	monosomes	(70S	peak).	Ribosomes	associated	with	mRNA	
appear	in	several	peaks	(polysome	peaks).	Differences	in	peak	size	or	complete	loss	of	one	
ribosomal	 fraction	 in	 the	 gradient	 indicate	 assembly	 defects	 or	 variations	 in	 translation	
activity104.	 Here,	 ribosome	 profiles	 of	 all	 tested	 strains	 did	 not	 show	 obvious	 differences	
(Figure	14).	
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No	differences	were	detected	in	growth	phenotypes	of	the	different	ycfD	mutant	strains	and	
wild	 type.	 Also	 ribosome	 profiles	 of	 the	 corresponding	 strains	 resulted	 in	 no	 detectable	
differences.	 As	 aditionally	 generation	 of	 a	 strain	 mutated	 in	 RPL16	 was	 not	 possible,	 no	
further	experiments	were	conducted	for	ycfD.	
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2.2 Investigations	of	human	ribosomal	oxygenase	OGFOD1	
2.2.1 Characterization	of	Cyclin-A2	 (CCNA2)	as	novel	 interaction	partner	 for	
OGFOD1	
Inital	experiments	based	on	immunoprecipitation	of	GFP-tagged	OGFOD1	performed	by	Dr.	
Alexander	Wolf	(HelmholtzZentrum	München,	experiments	performed	in	C.	Schofield	lab	in	
Organic	 Chemistry	 Department,	 Oxford)	 indicated	 cell	 cycle	 protein	 CCNA2	 as	 novel	
interaction	partner	of	OGFOD1.	
To	validate	CCNA2	as	interaction	partner	of	OGFOD1	and	to	identify	potential	hydroxylated	
prolines	in	CCNA2,	several	assays	were	performed	in	this	thesis.	
	
2.2.1.1 Mode	of	interaction	of	OGFOD1	with	CCNA2	in	vivo	and	in	vitro	
To	 confirm	 interaction	 of	 OGFOD1	with	 CCNA2,	 co-immunoprecipitation	 (co-IP)	 assays	 on	
endogenous	protein	level	and	in	different	overexpression	systems	were	performed.	
	
First,	two	CCNA2	antibodies	were	tested	for	their	capability	to	immunoprecipitate	CCNA2	in	
Hek293T	cells	(Figure	15).	Sc-751	antibody	bound	to	Protein	G	Sepharose	4	Fast	Flow	beads	
could	precipitate	CCNA2,	 as	 the	 signal	 from	 the	eluted	protein	 in	 the	 „Beads“	 fraction	 (B)	
was	 detectable	 (Figure	 15	 B).	 This	 antibody	 binds	 CCNA2	 quite	 efficiently,	 as	 not	 much	
protein	 is	 detected	 in	 the	 flow	 through	 fraction	 (F),	 whereas	 C4710	 antibody	 could	 not	
sufficiently	precipitate	CCNA2,	as	major	protein	fractions	are	lost	in	the	flowthrough	(Figure	
15	C).	Therefore,	sc-751	was	used	for	all	further	endogenous	IP	experiments.		
	
	
Figure	 15:	 Test	 of	 two	 different	 CCNA2	 antibodies	 for	 their	 capability	 to	 immunoprecipitate	 endogenous	
CCNA2	from	Hek293T	cells;	A)	Protein	G	Sepharose	beads	are	pre-incubated	with	B)	anti-CyclinA,	Santa	Cruz	
sc-751	antibody,	C)	anti-CCNA2,	Sigma	C4710	antibody,	D)	no	antibody	before	adding	Hek293T	cell	 lysates.	
Cyclin-A2/CCNA2	and	OGFOD1	were	detected	with	indicated	antibodies	 in	subsequent	Western	blotting.	I=	
Input,	F=	Flow	Through,	W=	Wash	fraction,	B=	Beads	Fraction	
	
OGFOD1	 interaction	with	CCNA2	 can	be	 shown	on	endogenous	 level,	 as	OGFOD1	with	 75	
kDa	 is	 detected	 in	 the	 CCNA2	 IP	 samples	 and	 therefore	 got	 co-precipitated	 with	 CCNA2	
(Figure	15	B,	anti-OGFOD1	staining).	Notably,	with	anti-OGFOD1	staining,	there	is	a	second	
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band	appearing	at	around	100	kDa,	which	can	be	observed	in	all	IPs	using	sc-751	(Figure	15A,	
anti-OGFOD1	 staining,	 B).	 The	 100	 kDa	 band	was	 already	 reported	 before	 as	 high-affinity	
complex	 of	 OGFOD1	 with	 RPS23	 that	 is	 stable	 under	 SDS/PAGE	 conditions5.	 Control	
experiment	with	no	antibody	coupled	to	the	sepharose	beads	did	exclude	unspecific	binding	
of	CCNA2	and	OGFOD1	to	the	beads	(Figure	15	D).	
	
To	analyze	direct	interaction	of	CCNA2	and	OGFOD1,	I	used	recombinant	proteins.	Bacteria	
expressing	 either	GFP,	GFP-CCNA2,	 or	His-OGFOD1	were	 lysed.	GFP	or	GFP-CCNA2	 lysates	
were	mixed	with	His-OGFOD1	lysates	and	subsequently,	GFP-IP	was	performed.	
GFP-CCNA2	co-immunoprecipitated	OGFOD1	(Figure	16	B),	whereas	control	experiment	with	
GFP	and	His-OGFOD1	did	not	show	interaction	(Figure	16	C).	
	
	
Figure	 16:	 Direct	 interaction	 of	 CCNA2	 and	 OGFOD1	 using	 bacterial	 expressed	 proteins;	 A)	 BL21	 were	
transformed	with	GFP-CCNA2,	GFP	and	His-OGFOD1.	Lysates	of	GFP-tagged	proteins	were	preincubated	with	
GFP-Trap_A	beads,	second	lysate	was	added	afterwards	to	the	reaction,	following	GFP-IP	was	performed;	B)	
GFP-CCNA2	expressing	bacteria	were	lysed	and	mixed	with	His-OGFOD1	lysates;	C)	GFP	expressing	bacteria	
were	 lysed	 and	 mixed	 with	 lysates	 with	 His-OGFOD1;	 CCNA2,	 OGFOD1,	 and	 GFP	 were	 detected	 with	
indicated	antibodies	in	subsequent	Western	blotting.	I=Input,	F=	Flowthrough,	B=	Beads	fraction	
	
To	 determine,	 if	 CCNA2	 in	 complex	 with	 CDK1	 or	 CDK2	 is	 bound	 by	 OGFOD1,	 co-
immunoprecipitation	of	CDK1	and	CDK2	with	CCNA2	and	OGFOD1	was	tested.	Therefore,	IP	
of	 CCNA2,	 OGFOD1,	 CDK1,	 and	 CDK2,	 was	 performed	 with	 subsequent	Western	 blotting.	
First,	interaction	of	CCNA2	with	OGFOD1	and	vice	versa	could	be	confirmed	(Figure	17,	A	and	
B).	Binding	of	CCNA2	to	OGFOD1	is	specific,	as	cell	cycle	protein	Cyclin	B1	(CCNB1)	can	not	
be	 detected	 in	 OGFOD1	 IP	 samples	 (Figure	 17	 B).	 CCNA2	 IP	 results	 in	 co-precipitation	 of	
OGFOD1,	CDK1	and	CDK2	(Figure	17	A).	
However,	 the	 interaction	 of	OGFOD1	with	 CCNA2	 seems	 to	 be	 direct	 and	 not	 in	 complex	
with	 either	 CDK2	 or	 CDK1,	 as	 both	 do	 not	 co-precipitate	 with	 OGFOD1	 (Figure	 17	 B).	
Additionally,	neither	CDK1	nor	CDK2	bind	OGFOD1	(Figure	17	C	and	D).	IgG	control	antibody	
IP	proves	specificity	of	OGFOD1	interaction	with	CCNA2	as	well	as	CCNA2-CDK1/2.	
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Figure	 17:	 Interaction	 of	 CCNA2	 and	 OGFOD1	 does	 not	 occur	 in	 complex	 with	 CDK2	 or	 CDK1;	 Protein	 G	
Sepharose	beads	are	pre-incubated	with	A)	anti-CyclinA,	B)	anti-OGFOD1,	C)	anti-CDK2,	D)	anti-CDK1,	and	E)	
Isotype	 control	 for	 anti-CyclinA	 before	 adding	 Hek293T	 cell	 lysates.	 CCNA2,	 OGFOD1,	 CCNB1,	 CDK2,	 and	
CDK1	were	detected	with	indicated	antibodies	in	subsequent	Western	blotting.	I=	Input,	F=	Flow	Through,	B=	
Beads	Fraction	
	
Further	 in	vitro	 studies	even	suggested	a	competition	of	CCNA2	binding	between	OGFOD1	
and	 CDK2.	 For	 these	 experiments,	 bacterial	 lysates	 expressing	 GFP-CCNA2	 was	 first	
incubated	 with	 untagged	 OGFOD1	 and	 subsequently	 with	 His-tagged	 CDK2	 or	 vice	 versa.	
Direct	 CCNA2-binding	 could	 again	 be	 deteceted	 (Figure	 18	 B	 and	 C).	 Established	 CDK2-
CCNA2	 inhibited	 additional	 OGFOD1-CCNA2	 interaction	 (Figure	 18	 E).	 OGFOD1-CCNA2	
complex	 formation	 allowed	 additional	 binding	 of	 CCNA2	 and	 CDK2	 (Figure	 18	 D).	 In	 the	
negative	control	neither	OGFOD1	nor	His-CDK2	can	be	detected	in	the	IP	lane	(Figure	18	F).	
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Figure	 18:	 OGFOD1	 and	 CDK2	might	 compete	 in	 binding	 of	 CCNA2;	 A)	 BL21	were	 transformed	with	 GFP-
CCNA2,	untagged	OGFOD1	and	His-CDK2.	Bacteria	lysates	were	mixed	and	diluted	in	wash	buffer,	GFP-IP	was	
performed;	B),	C)	GFP-CCNA2	expressing	bacteria	were	mixed	with	OGFOD1	lysates	or	His-CDK2	lysates;	D)	
GFP-CCNA2	lysates	expressing	bacteria	mixed	with	lysates	first	with	OGFOD1	lysates	and	following	with	His-
CDK2	lysates	or	in	E)	vice	versa;	F)	shows	the	control	experiment	with	GFP	mixed	with	OGFOD1	and	His-CDK2	
lysates;	 GFP-CCNA2,	 OGFOD1,	 His-CDK2,	 and	 GFP	were	 detected	with	 indicated	 antibodies	 in	 subsequent	
Western	blotting.	I=Input,	F=	Flowthrough,	B=	Beads	fraction	
	
Interaction	 of	 CCNA2	 and	 OGFOD1	 could	 be	 shown	 by	 another	 independent	 interaction	
assay,	the	fluorescent-2-hybrid	(F2H)	assay.	In	this	assay,	genetically	modified	baby	hamster	
kidney	 (BHK)	 cells	 carry	 a	 GFP-anchoring	 platform	 in	 the	 nucleus105.	 Overexpressed	 GFP-
tagged	proteins	get	 localized	to	the	nuclear	platform	and	concentrate	thereby	 in	a	distinct	
spot.	Co-expression	of	a	mCherry-tagged	protein	of	interest	leads	in	case	of	interaction	to	a	
colocalization	in	this	spot,	visible	as	yellow	dot	in	the	overlay	of	both	channels.	
Known	 interaction	 partner	 of	 OGFOD1,	 ribosomal	 protein	 RPS235,	 was	 used	 as	 positive	
control	 for	 this	 assay.	 OGFOD1-RPS23	 binding	 was	 detectable	 (Figure	 19	 B-B’’’),	 whereas	
GFP-NLS	was	not	able	to	recruit	RPS23-mCherry	(Figure	19	A-A’’’).	The	same	is	true	for	GFP-
NLS	and	CCNA2-mCherry	(Figure	19	C-C’’’).	GFP-OGFOD1	and	CCNA2-mCherry	accumulated	
in	the	same	distinct	spot	in	the	nucleus	(Figure	19	D-E’’’),	which	confirmed	OGFOD1-CCNA2	
binding.		
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Figure	19:	Fluorescent	two-hybrid	(F2H)	assay	to	study	interaction	of	OGFOD1	and	CCNA2;	Engineered	baby	
hamster	kidney	cells	(BHK)	were	transfected	with	the	platform	reagent	to	translocate	the	GFP	tagged	protein	
to	 the	GFP-anchoring	platform	 in	 the	 genome	 resulting	 in	 a	distinct	 spot	 in	 the	nucleus	 indicated	here	by	
arrows;	different	combinations	of	GFP-tagged	and	mCherry-tagged	proteins	were	co-transfected:	A-A’’’	GFP-
NLS	and	RPS23-mCherry,	B-B’’’	GFP-OGFOD1	and	RPS23-mCherry,	C-C’’’	GFP-NLS	and	CCNA2-mCherry,	D-D’’’	
GFP-OGFOD1	and	CCNA2-mCherry,	E-E’’’	GFP-OGFOD1	and	CCNA2-mCherry.	Nuclei	were	counterstained	with	
DAPI,	scale	is	the	same	for	all	images	
	
2.2.1.2 In	 vivo	 and	 in	 vitro	 studies	 to	 identify	 OGFOD1	 and	 CCNA2	 interaction	
domains	
To	 further	 characterize	 the	 binding	 of	 CCNA2	 and	 OGFOD1,	 interaction	 domains	 in	 both	
proteins	were	analyzed	in	more	detail.	Therefore,	several	deletion	and	point	mutants	were	
generated	and	tested	for	binding.	
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Figure	 20:	 Schematic	 drawing	 of	 OGFOD1	 domain	 structure	 and	 generated	 mutants;	 nuclear	 localization	
signal	(NLS)	is	colored	in	gray,	DSBH	domains	in	blue,	mutated	amino	acids	are	indicated	in	red.	
Wild	type	OGFOD1	exhibits	the	catalytically	active	N-terminal	DSBH	domain	containing	the	
iron	 coordinating	 HxD...H	motif	 and	 a	 C-terminal	 DSBH	 lacking	 the	 iron-binding	motif.	 N-
terminal	 and	 C-terminal	 DSBH	 domains	 are	 separated	 by	 a	 linker	 sequence.	 The	 very	 N-
terminal	 nuclear	 localization	 signal	 (NLS)	 causes	 the	 nuclear	 localization	 of	 the	 protein	
(Figure	 20	 A).	 The	 OGFOD1	 AxA	 variant	 has	 a	 mutated	 iron	 binding	 motif,	 histidine	 155	
(H155)	 and	 aspartic	 acid	 (D157)	 are	 changed	 to	 alanine	 (A)	 (Figure	 20	 B)	 and	 is	 thereby	
catalytically	 inactive5.	 RxL	 motifs	 were	 identified	 to	 be	 responsible	 for	 CCNA2	 binding	 to	
substrates	 like	cyclin-dependent	kinase	inhibitor	1B	or	CDK-Inhibitor	1106,107.	One	RxL	motif	
was	 identified	 in	OGFOD1	and	mutated	 (arginine	519	 (R519)	 and	 leucine	521	 (L521)	 to	A)	
(Figure	20	C).	
Several	 deletion	mutants	were	 generated.	OGFOD1	1-260	 (Δ261-543)	 lacks	 the	C-terminal	
DSBH	(Figure	20	D),	in	„aa	1-238“	(Δ239-543)	additionally	the	linker	region	is	deleted	(Figure	
20	E).	OGFOD1	1-30+261-542	(Δ31-260)	is	depleted	of	the	N-terminal	DSBH	(Figure	20	F),	„aa	
21-542“	(Δ1-20)	(Figure	20	G)	and	„aa	31-542“	(Δ1-30)	(Figure	20	H)	lack	the	NLS	sequence. 
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Figure	21:	 Interaction	studies	with	GFP-tagged	OGFOD1	wild	type	and	mutants	and	Flag-tagged	CCNA2	;	A)	
Hek293T	cells	were	co-transfected	and	used	for	GFP-IP;	B)-E)	GFP-IP	was	performed	with	cells	overexpressing	
proteins	 as	 indicated;	 F)	MINA53-GFP	was	used	 as	 control;	OGFOD1-GFP	and	mutants,	MINA53-GFP,	 Flag-
tagged	 CCNA2,	 and	 endogenous	 CCNA2	 were	 detected	 with	 indicated	 antibodies	 in	 subsequent	Western	
blotting.	I=Input,	F=	Flowthrough,	B=	Beads	fraction	
Anti-GFP-IP	 of	 OGFOD1-GFP	 co-precipitated	 Flag-tagged	 CCNA2,	 as	 confirmed	 with	 Flag	
antibody	 staining	 in	 Western	 blot	 (Figure	 21	 B).	 Also	 OGFOD1	 iron	 binding	 mutant	 AxA	
showed	 interaction	with	 Flag-tagged	CCNA2	 (Figure	21	C).	 The	OGFOD1	mutant	 1-260	did	
bind	to	CCNA2	(Figure	21	D)	whereas	the	mutant	lacking	those	amino	acids	(OGFOD1	aa	1-43	
and	 261-542	 Figure	 21	 E)	 did	 not.	 Control	 experiment	 (Figure	 F)	 with	 another	 ribosomal	
oxygenase,	MINA53-GFP,	and	Flag-CCNA2	did	not	show	interaction	and	confirmed	a	specific	
interaction	of	CCNA2	and	OGFOD1.	
	
	
Figure	22:	 Interaction	studies	with	GFP-tagged	OGFOD1	wild	type	and	mutants	and	Flag-tagged	CCNA2	;	A)	
Hek293T	cells	were	co-transfected	and	used	for	GFP-IP;	B)-E)	GFP-IP	was	performed	with	cells	overexpressing	
proteins	 as	 indicated;	 OGFOD1-GFP	 and	 mutants	 and	 Flag-tagged	 CCNA2	 were	 detected	 with	 indicated	
antibodies	in	subsequent	Western	blotting.	I=Input,	F=	Flowthrough,	B=	Beads	fraction	
Both	mutants	 lacking	 the	NLS	sequence	still	 interacted	with	OGFOD1.	OGFOD1	 lacking	 the	
first	 20	 amino	 acids	 (Figure	 22	 Blot	 B)	might	 show	 a	 reduced	 ability	 to	 interact,	 whereas	
OGFOD1	 lacking	 amino	 acids	 1-30	 interacted	 comparable	 to	 wild	 type	 (Figure	 22	 Blot	 C).	
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Mutation	 of	 a	 putative	 CCNA2	 interaction	 motif	 (OGFOD1	 RxL)	 also	 showed	 no	 reduced	
binding	capacity	(Figure	22	Blot	D).	Also,	the	 linker	connecting	both	DSBHs	of	OGFOD1	did	
not	 seem	 to	 be	 important	 for	 interaction,	 OGFOD1	 1-238	 is	 potent	 of	 binding	 to	 CCNA2	
(Figure	22	E).		
	
	
The	 interaction	 of	 CCNA2	 and	 OGFOD1	 was	 also	 characterized	 in	 more	 detail	 by	 using	
different	CCNA2	mutants.	
	
	
Figure	23:	Schematic	drawing	of	CCNA2	domain	structure	and	generated	mutants;	destruction	box	(D-Box)	is	
colored	in	red,	the	two	cyclin	boxes	in	orange	
The	CCNA2	protein	harbours	the	so-called	destruction	box	(D-Box)	and	two	cyclin	boxes.	
The	D-Box	is	necessary	for	cell	cycle	dependent	degradation	of	CCNA2	by	the	APC	complex,	
the	cyclin	boxes	are	needed	for	binding	to	cyclin	dependent	kinases	(CDKs)108-111.	
Three	different	deletion	mutants	were	generated,	CCNA2	1-180	 lacks	 the	two	cyclin	boxes	
(Figure	23	B),	CCNA2	181-432	lacks	the	entire	N-terminus	including	the	D-box	(Figure	23	C),	
and	CCNA2	1-46+181-432	is	missing	the	destruction	box	(Figure	23	D).	
	
	
Figure	24:	 Interaction	studies	with	Flag-tagged	CCNA2	wild	 type	and	mutants	and	GFP-tagged	OGFOD1;	A)	
Hek293T	cells	were	co-transfected	and	used	for	GFP-IP;	B)-F)	GFP-IP	was	performed	with	cells	overexpressing	
proteins	 as	 indicated;	 Flag-tagged	 CCNA2	 and	 mutants	 and	 OGFOD1-GFP	 were	 detected	 with	 indicated	
antibodies	in	subsequent	Western	blotting.	I=Input,	F=	Flowthrough,	B=	Beads	fraction	
CCNA2	1-46+181-432	and	CCNA2	181-432	showed	OGFOD1	binding	(see	Figure	24	B	and	C),	
whereas	CCNA2	1-180	did	not	co-precipitate	OGFOD1	in	anti-GFP-IP	experiments	in	Hek293T	
cells.	This	pointed	towards	a	binding	domain	within	the	cyclin	boxes.	
	
In	 an	 in	 vitro	 approach	with	 recombinant	 protein,	 I	 was	 not	 able	 to	 confirm	 this	 binding	
domain.	 In	 this	 assay,	 recombinant	 GFP-tagged	 CCNA2	 or	 variants	 expressed	 in	 bacteria	
were	tested	for	binding	of	recombinant	untagged	OGFOD1	in	anti-GFP-IP	experiments.	Here,	
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contrary	 to	 the	 aforementioned	 cell-based	 assays,	 the	 CCNA2	 mutant	 1-180	 exhibited	 a	
stronger	 OGFOD1	 binding	 (Figure	 25	 D),	 compared	 to	 CCNA2	 181-432	 and	 1-46+181-432	
(Figure	25	E	and	F).	Control	experiment	confirmed	specific	binding	of	OGFOD1	to	CCNA2.	
	
	
Figure	25:	Binding	of	CCNA2	and	mutants	to	OGFOD1;	A)	BL21	were	transformed	with	GFP-CCNA2	wild	type	
or	 mutants	 and	 untagged	 OGFOD1.	 Lysates	 of	 GFP-tagged	 proteins	 were	 preincubated	 with	 GFP-Trap_A	
beads,	 second	 lysate	was	added	afterwards	 to	 the	 reaction,	 following	GFP-IP	was	performed;	B)-F)	GFP-IP	
was	performed	with	bacterial	lysates	expressing	proteins	as	indicated;	GFP-tagged	CCNA2	and	mutants	and	
OGFOD1	were	detected	with	indicated	antibodies	in	subsequent	Western	blotting,	I=Input,	F=	Flowthrough,	
B=	Beads	fraction	
	
These	 experiments	 indicated,	 that	 the	 N-terminal	 DSBH	 in	 OGFOD1	 is	 crucial	 for	 CCNA2	
binding	 independently	 of	 catalytic	 activity.	 For	 CCNA2,	 no	 OGFOD1	 biding	 domain	 was	
identified	with	certainty.	
	
2.2.1.3 Investigations	 to	 identify	 hydroxylated	 prolines	 in	 CCNA2	 modified	 by	
OGFOD1	
After	having	confirmed	OGFOD1-CCNA2	binding	with	different	assays,	CCNA2	was	examined	
in	 regard	 to	 being	 an	 OGFOD1	 substrate.	 Online	 prediction	 programs	 suggested	 different	
prolines	of	CCNA2	to	be	hydroxylated	(see	Table	1).	iHyd-PseAAC	offered	P155	and	P402	as	
hydroxyproline	 sites112.	 PredHydroxy	 proposed	 P402-OH	 with	 a	 probability	 of	 0.61113.	
Predictor	RF-Hydroxysite114	predicted	P135	with	high	significance	(0.78),	P89,	P195	and	P273	
with	lower	significance	(0.5-0.6).	
	
Program	 Prolines	in	CCNA2	
iHyd-PseAAC	 	 	 P155	 	 	 P402	
PredHydroxy	 	 	 	 	 	 P402	
RF-
Hydroxysite	
P89	 P135	 	 P195	 P273	 	
Table	1:	Online	proline	hydroxylation	programs	used	for	prediction	of	CCNA2	proline	hydroxylations;	in	gray	
identified	 potenial	 proline	 hydroxylation	 sites	 with	 low	 probability	 and	 significance,	 in	 black	 with	 higher	
significance;	searches	were	performed	25.08.2016.	
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To	identify	hydroxylation	sites	in	CCNA2,	liquid	chromatography	tandem	mass	spectrometry	
(LC-MS/MS)	 was	 used.	 Different	 experimental	 set-ups	 were	 exhibited	 to	 circumvent	 low	
protein	 coverages.	 Endogenous	 protein,	 overexpressed	 3xFlag-CCNA2,	 and	 recombinant	
GST-CCNA2	 were	 immunoprecipitated	 (Table	 2)	 and	 analyzed	 by	 label-free	 LC–MS/MS	
(Juliane	 Merl-Pham,	 Stefanie	 Hauck,	 HelmholtzZentrum	 München).	 Hydroxylated	 prolines	
could	 be	 detected	 in	 different	 conditions	 like	 co-expression	 of	 OGFOD1	 or	 the	 inactive	
OGFOD1	AxA	mutant	before	immunoprecipitation	(Table	2).	
	
	
Table	2:	Overview	of	performed	LC-MS/MS	experiments,	CCNA2	coverage	 in	each	experiment	and	sample,	
and	by	LC-MS/MS	identified	hydroxylated	prolines	on	CCNA2	
In	the	different	IP	experiments	with	Flag-tagged	CCNA2,	endogenous	CCNA2,	or	in	an	in	vitro	
assay,	different	proline	hydroxylations	were	suggested.	In	the	recombinant	approach	CCNA2	
hydroxylated	 prolines	 were	 also	 suggested	 in	 samples	 containing	 only	 GST-CCNA2.	
Depending	 on	 experiment,	 different	 hydroxylated	 prolines	 were	 identified	 or	 even	 none	
(endogenous	 IP,	 Table	 2),	 therefore	 no	 reliable	 hydroxylation	 could	 be	 detected	 with	 LC-
MS/MS.	
Protein	coverage	of	CCNA2	in	the	three	experiments	ranged	from	41-60%.	Therefore,	several	
peptides	 with	 potential	 hydroxylation	 sites	 were	 not	 detected	 (Figure	 26	 A).	 However,	
attempts	 to	 increase	 CCNA2	 coverage	 by	 combined	 digest	with	 Chymotrypsin/Trypsin	 did	
not	result	in	higher	protein	coverages	(data	not	shown).	
	
In	 order	 to	 specify	 OGFOD1-catalyzed	 proline	 hydroxylation	 in	 CCNA2,	 we	 used	 matrix-
assisted	laser	desorption/ionization	-	time	of	flight	mass	spectrometry	(MALDI-TOF-MS).		
	
Typ	of	IP sample	name CCNA2	
coverage	[%]
Identified	proline	
hydroxylation
1x	P89
1x	P135
1x	P137
Flag-CCNA2+	OGFOD1	AxA 46
1x	P88
1x	P89
anti-CCNA2	(sc-751) 45
no	AB --
GST-CCNA2+	His-OGFOD1 60 1x	P402
GST-CCNA2+	His-OGFOD1	
AxA
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1x	P35
1x	P89
1:10	diluted	GST-CCNA2+	
His-OGFOD1
56 1x	P89
1:10	diluted	GST-CCNA2+	
His-OGFOD1	AxA
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Flag-CCNA2	IP
Flag-CCNA2+	OGFOD1 41
Flag-CCNA2+	OGFOD2i1 44
GST-CCNA2 60
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Figure	 26:	 Schematic	 overview	 of	 domains	 of	 CCNA2;	 A)	 coverage	 of	 CCNA2,	 dashed	 boxes	 indicate	 not	
covered	sequences;	B)	identified	potential	hydroxyprolines	by	LC-MS/MS;	C)	selected	peptides	tested	using	
peptide	hydroxylation	assay	with	MALDI-TOF.	
	
Here	 we	 generated	 peptides	 spanning	 prolines,	 which	 were	 suggested	 by	 preceding	 LC-
MS/MS	 analysis	 to	 be	 hydroxylated	 (Figure	 26	 C).	 These	 peptides	 were	 incubated	 with	
recombinant	OGFOD1	and	co-factors	and	subsequently	analyzed	for	hydroxylation	by	MALDI	
(in	cooperation	with	Cyrille	Thinnes	in	the	C.	Schofield	laboratory	in	the	Chemistry	Research	
Laboratory,	Oxford).	
	
	
Figure	27:	CCNA2	peptide	hydroxylation	assay	by	MALDI-TOF;	A)	control	20-mer	peptide	of	RPS235	shows	a	
16	Da	shift	after	addition	of	OGFOD1	in	vitro,	B)-D)	tested	CCNA2	20-mer	peptides	masses	without	OGFOD1	
and	with	 OGFOD1	 addition;	 Reaction	 Conditions:	 7.7	 µM	 recombinant	 OGFOD1,	 50	 µM	 peptide,	 300	 µM	
2oxoglutarate,	100	µM	Fe(II),	and	1mM	Ascorbate;	reaction	was	incubated	for	3h	at	RT	and	quenched	with	
formic	acid.	
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Recombinant	OGFOD1	was	catalytically	active	as	addition	of	the	protein	causes	a	16	Da	shift	
in	 the	known	substrate	peptide	of	RPS235	 (Figure	27	A).	The	 three	 tested	CCNA2	peptides	
covering	P88	and	P89	(peptide	1),	P114	(peptide	2),	and	P135	and	P137	(peptide	3)	did	not	
show	a	mass	shift	after	addition	of	OGFOD1.	Therefore,	in	this	assay	no	OGFOD1-catalyzed	
hydroxylation	of	the	selected	peptides	could	be	observed	(Figure	27	B-D).	
	
2.2.1.4 Effects	of	OGFOD1-CCNA2	interaction	onto	the	cell	cycle	
OGFOD1	 binding	 of	 one	 of	 the	 major	 cell	 cycle	 regulating	 cyclins	 raised	 the	 question,	 if	
OGFOD1	expression	is	also	regulated	in	a	cell	cycle	dependent	way.	To	address	this,	the	HeLa	
cell	 line	stably	expressing	Cell	Cycle	Chromobody®	fused	to	the	red	fluorescent	protein	Tag	
RFP®	(Chromotek)	were	used	in	immunofluorescence	(IF)	to	monitor	the	OGFOD1	expression	
pattern.	 Additionally,	 Hek293T	 cells	 were	 synchronized	 and	 expression	 levels	 of	 OGFOD1	
through	 the	 cell	 cycle	 were	 checked	 using	 western	 blot.	 Also	 interaction	 of	 CCNA2	 and	
OGFOD1	 throughout	 the	 cell	 cycle	was	monitored.	 Furthermore,	 cell	 cycle	 progression	 of	
synchronized	 cells	 overexpressing	GFP-tagged	OGFOD1	 and	 the	OGFOD1	AxA	mutant	was	
analyzed.	
	
Studies	to	characterize	OGFOD1	and	CCNA2	localization	and	expression	throughout	
the	cell	cycle	
To	determine	the	subcellular	distributions	of	proteins	throughout	the	cell	cycle,	the	HeLa	cell	
line	 stably	 expressing	 a	RFP-tagged	nano-antibody	 against	 endogenous	PCNA115	was	used.	
Proliferating	cell	nuclear	antigen	(PCNA)	localization	provides	a	precise	marker	for	S	phases	
as	 it	 is	 a	 helping	 factor	 for	DNA	 synthesis	 during	 replication.	With	 starting	 S	 phase,	 PCNA	
protein	 gets	 associated	with	DNA	polymerase	 δ	 and	 localizes	 to	 small	 distinct	 dots	 in	 the	
nuclei	corresponding	to	active	sites	of	replication.	With	ongoing	replication,	PCNA	coupled	
to	polymerase	shifts	to	nucleolar	DNA	resulting	in	bigger	dots	during	mid-S	phase.	In	late	S-
phase,	DNA	at	the	periphery	of	the	nucleus	gets	replicated116.	Mitotic	cells	(Pro-,	Meta-,	Ana-	
and	Telophase)	were	distinguished	by	characteristic	DNA	patterns117.	
	
Immunofluorescent	 analyses	 confirmed	 increasing	 CCNA2	 levels	 in	 early	 S	 phase	 and	 the	
sudden	degradation	in	prometaphase109	(Figure	28).	
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Figure	28:	Distribution	of	CCNA2	during	the	cell	cycle	in	HeLa	chromobody	(Chromotek)	cells;	fixed	cells	were	
stained	with	 anti-Cyclin	 A	 antibody	 and	 Alexa-488	 coupled	 secondary	 antibody,	 DNA	was	 counterstained	
with	DAPI.	
In	contrast	to	CCNA2,	OGFOD1	localization	or	expression	did	not	show	any	dependency	on	
the	cell	cycle.	OGFOD1	protein	was	detectable	in	all	cell	cycle	phases	and	there	seemed	to	
be	no	difference	in	protein	amount	(Figure	29).	
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Figure	29:	Distribution	of	OGFOD1	during	 the	 cell	 cycle	 in	HeLa	 chromobody	 (Chromotek)	 cells;	 fixed	 cells	
were	 stained	 with	 anti-OGFOD1	 antibody	 and	 Alexa-488	 coupled	 secondary	 antibody,	 DNA	 was	
counterstained	with	DAPI.	
	
To	 investigate	OGFOD1	 protein	 amounts	 in	 the	 different	 cell	 cycle	 phases	 in	more	 detail,	
Hek293T	and	HeLa	cells	were	synchronized	with	a	double	thymidine	block	which	leads	to	an	
early	S	phase	block	(Figure	30	A).	After	release	from	the	second	thymidine	block,	cells	were	
monitored	 for	 their	 progression	 through	 the	 cell	 cycle	by	 flow	 cytometric	 analysis	 of	DNA	
content	(Figure	30	D)	and	by	western	blot	(Figure	30	C).	In	an	asynchronized	cell	population,	
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most	cells	were	in	G0/G1	phase	with	two	chromosome	sets	(2N),	some	cells	are	replicating	
their	DNA	in	S	phase,	whereas	the	next	peak	displays	cells	 in	G2	or	M	phase	with	4N	DNA	
content	(Figure	30	B).	The	profiles	displayed	here	show	the	early	S	phase	block,	as	cells	from	
0	h	 after	 release	nearly	 completly	were	 concentrated	 in	 a	 peak	 corresponding	 to	 S	 phase	
(Figure	30	D).	Hek293T	cells	progress	from	early	S	phase	to	G1	in	around	9	h,	HeLa	cells	are	
slower	and	reached	G1	after	12h	(for	HeLa,	see	Figure	31).	
	
	
Figure	 30:	 A)	 Experimental	 scheme	 for	 Hek293T/HeLa	 cell	 synchronization.	 Cells	 were	 synchronized	 by	 a	
double	 thymidine	 block	 resulting	 in	 early	 S	 phase	 block;	 B)	 Cell	 cycle	 profile	 of	 a	 asynchronized	 cell	
population,	cellular	DNA	content	allows	classification	of	cells	into	the	different	cell	cycle	phases	as	indicated,	
relative	 DNA	 content	 is	 plotted	 against	 cell	 number;	 C)	 Protein	 levels	 corresponding	 to	 each	 time	 point	
OGFOD1,	Cyclin	A2,	and	Actin	as	loading	control	obtained	from	Hek293T	cells	at	different	time	points	during	
synchronization;	 D)	 Flow	 cytometry	 achieved	 DNA	 profiles	 after	 Hoechst33342	 staining	 of	 synchronized	
Hek293T	cells	(0-9h)	
In	accordance	with	the	immunofluorescence	analysis,	CCNA2	protein	 levels	were	regulated	
by	the	cell	cycle	(Figure	30	C).	Protein	levels	changed	with	the	progession	of	the	cells	from	
early	 S	 phase	 to	mitosis.	 Highest	 levels	 of	 CCNA2	were	 detectable	 from	hour	 4	 to	 hour	 6	
after	release,	which	corresponds	to	late	S-phase	to	mid/end	of	mitosis.	OGFOD1	levels	were	
unchanged	throughout	the	progression	of	the	cell	cycle	(Figure	30	C).	
	
	
Studies	to	analyze	interaction	of	CCNA2	and	OGFOD1	throughout	the	cell	cycle	
Due	to	the	cell	cycle	 independency	of	OGFOD1	protein	 levels,	we	asked	 if	 interaction	with	
CCNA2	 happens	 only	 in	 distinct	 phases	 of	 the	 cell	 cycle.	 For	 this	 purpose,	 synchronized	
Hek293T/HeLa	cells	were	collected	for	9	hours/12	hours	after	release	and	endogenous	anti-
OGFOD1	and	anti-CCNA2	IP	were	performed.	
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Figure	 31:	 Interaction	 studies	 of	 OGFOD1	with	 CCNA2	 in	 HeLa	 cells	 during	 the	 cell	 cycle;	 HeLa	 cells	were	
synchronized	with	 a	double	 thymidine	block.	 Samples	were	 taken	after	 indicated	hours	 after	 release.	 Cell	
cycle	profiles	were	obtained	by	 flow	cytometry	after	NUCLEAR-ID®	Red	DNA	stain	 (ENZO	 life	sicence,	ENZ-
52406)	staining	of	DNA.	In	A)	western	blot	analysis	of	input	fractions,	in	B)	DNA	content	of	cells	harvested	to	
indicated	time	points	determinded	by	flow	cytometry;	C)	western	blot	analysis	of	IP	of	endogenous	CCNA2,	
in	D)	of	 IP	of	endogenous	OGFOD1;	blots	were	stained	with	anti-OGFOD1,	anti-CCNA2,	anti-CDK2	and	anti-
Actin	as	loading	control;	asterisks	indicates	heavy	or	light	chain	of	IP	antibody.	
IP	of	CCNA2	and	OGFOD1	in	HeLa	cells	revealed	cell	cycle	independent	interaction.		
Western	 blot	 analysis	 of	 synchronized	 cells	 showed	 cell-cycle	 regulated	 expression	 of	
CCNA2,	 but	 not	 of	OGFOD1.	CKD2	 levels	were	unaltered	 compared	 to	 the	 loading	 control	
Actin	(Figure	31	A).	Most	cells	were	synchronized	with	the	double	thymidine	block	(Figure	31	
B).	
CCNA2	co-precipitated	CDK2,	but	not	actin	(Figure	31	C).	OGFOD1	monomer	band	at	75kDa	
could	not	be	co-precipitated	by	CCNA2,	however	two	higher	bands	above	100	kDa	appeared	
(Figure	31	C).	A	steric	hinderance	of	the	OGFOD1	binding	site	by	the	CCNA2	IP	antibody	can	
not	 be	 excluded	 in	 this	 assay.	With	 OGOFD1	 being	 precipitated,	 weak	 CCNA2	 interaction	
bands	 appeared	 cell	 cycle	 independent,	 even	 though	 levels	 of	 precipitated	OGFOD1	were	
different.	CKD2	and	Actin	were	not	interacting	with	OGOFD1	(Figure	31	D).	
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Identification	 of	 the	 impact	 of	 OGFOD1	 overexpression	 onto	 CCNA2	 and	 the	 cell	
cycle	
To	analyze	a	potential	 impact	of	OGFOD1	overexpression	onto	the	cell	cycle,	synchronized	
Hek293T	cells	were	transfected	and	analyzed	for	their	cell	cycle	progression	(Figure	32).	
	
	
Figure	32:	Influence	of	GFP-tagged	OGFOD1	on	cell	cycle	progression;	Hek293T	cells	were	synchronized	with	
a	double	 thymidine	block.	Between	 the	 first	 and	 second	block,	 cells	were	 transfected	with	 indicated	GFP-
tagged	 proteins.	 Samples	 were	 harvested	 after	 indicated	 hours	 after	 release.	 Cell	 cycle	 profiles	 were	
obtained	 by	 flow	 cytometry	 after	 NUCLEAR-ID®	 Red	 DNA	 stain	 (ENZO	 life	 science,	 ENZ-52406)	 staining	 of	
DNA.	In	A)	untransfected	cells	B)-D)	overexpression	of	GFP-tagged	proteins	as	indicated	
In	 initial	experiments,	Hek293T	cells	were	transfected	between	first	and	second	thymidine	
treatment	 with	 NLS-GFP,	 OGFOD1-GFP,	 or	 OGFOD1	 (H155A,	 D157A)-GFP.	 After	 the	 final	
release,	progression	through	the	cell	cycle	under	the	different	conditions	was	monitored	by	
flow	cytometry	of	GFP-positive	cells.	At	least	10.000	cells	per	sample	were	recorded,	but	due	
to	technical	problems,	for	time	points	0	h	and	2	h	of	untransfected	cells	(Figure	32	A)	around	
3000	cells	were	recorded	(exact	cell	numbers	 in	Appendix	6.1.1,	Figure	69).	Staining	of	the	
fixed	cells	with	same	amount	of	DNA	dye,	despite	different	cell	numbers	might	lead	to	the	
slightly	shifted	DNA	profiles	(Figure	32	A).	
Overexpression	 of	NLS-GFP	 (Figure	 32	 B)	 seemed	 to	 have	 only	minor	 effects	 on	 cell	 cycle	
progression,	as	the	DNA	profiles	showed	the	block	in	early	S-phase	and	cell	cycle	progression	
comparable	to	not	transfected	cells	(Figure	32	A).	Upon	overexpression	of	GFP-OGFOD1,	the	
cells	seemed	to	remain	longer	in	the	S	phase	block,	a	major	subset	of	cells	seems	not	to	be	
able	to	proceed	further	(Figure	32	C).	In	comparison	to	cells	overexpressing	NLS-GFP	(Figure	
32	 B),	 already	 at	 4	 h	 post-release	 the	 main	 peak	 of	 OGFOD1-GFP	 overexpressing	 cells	 is	
oriented	more	 to	 the	2N	content	 (Figure	32	C).	Also	 the	cells	at	6	and	7	h	 seemed	not	 to	
proceed	to	4N	and	mitosis,	but	might	remain	in	the	intermediate	state	of	S	phase.	However,	
profiles	 at	 9	 h	 were	 similar	 in	 all	 samples.	 Therefore,	 a	 block	 of	 cells	 overexpressing	
OGFOD1-GFP	might	not	be	permanent.		
Overexpression	of	iron-binding	defective	OGFOD1	(OGFOD1-H155A,	D157A)	displays	similar	
profiles	than	NLS-GFP	cells	(Figure	32	D).		
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Overexpression	 of	 OGFOD1	 and	 AxA	mutant	was	 also	 tested	 in	 another	 setting.	 Hek293T	
cells	 were	 co-transfected	 with	 Flag-CCNA2	 and	 either	 OGFOD1,	 or	 OGFOD1	 AxA	 (H155A,	
D157A),	or	OGFOD2I1	 (Figure	33	A	and	more	detailed	 list	 in	Appendix	6.1.1	Figure	71).	An	
anti-Flag	IP	of	CCNA2	was	performed	and	the	CCNA2	interaction	partners	were	analyzed	by	
LC-MS/MS.	
	
	
Figure	 33:	 Selection	 of	 proteins	 with	 highest	 enrichment	 identified	 in	 Flag-CCNA2	 IP	 with	 additional	
overexpression	 of	 OGFOD1	 wild	 type	 (WT),	 OGOFD1	 H155A,	 D157A	 (MUT),	 and	 OGFOD2	 Isoform	 1	
(OGFOD2I1,	„control“)	using	LC-MS/MS;	A)	Anti	Flag-IP	was	performed	with	ANTI-FLAG®	M1	Agarose	Affinity	
Gel	 with	 Hek293T	 cell	 lysates	 overexpressing	 indicated	 proteins	 and	 analyzed	 by	 LC-MS/MS;	 B)	 Proteins	
identified	to	be	highly	enriched	in	the	Flag-CCNA2-IP	versus	the	control	sample.	
Comparison	of	 CCNA2	binding	proteins	 revealed	 several	 proteins	 like	HNRNPH2	or	DDX46	
which	were	enriched	 in	Flag-CCNA2	 IP	 samples	when	OGFOD1	wild	 type	 (WT)	or	OGFOD1	
MUT	(OGOFD1	AxA)	were	overexpressed	(Figure	33	B).	
	
We	 also	 performed	 anti-CCNA2	 IP	 of	 endogenous	 CCNA2	 and	 characterized	 the	 binding	
proteins	 with	 LC-MS/MS.	 Many	 known	 interactors	 of	 CCNA2	 were	 identified	 like	 cyclin	
dependent	kinases	(CDKs)	1	and	2	or	SKP2,	also	SCAPER121,122	was	highly	enriched	in	CCNA2	
IP	versus	the	control	(see	Appendix	6.1.1,	Figure	70).	LC-MS/MS	results	of	the	Flag-CCNA2	IP	
(Figure	 33)	 were	 filtered	 for	 specific	 interaction	 partners	 of	 CCNA2,	 that	 were	 identified	
before	in	mass	spectrometry	results	from	endogenous	immunoprecipitated	CCNA2.		
Using	 these	 parameters,	 RPA2	 and	 RPA1	were	 identified	 as	 proteins	 which	 showed	most	
increased	 binding	 to	 CCNA2,	when	OGFOD1	 or	 OGFOD1	 AxA	mutant	were	 overexpressed	
(Figure	 34	 B,	more	 detailed	 list	 in	 Appendix	 6.1.1	 Figure	 73).	 DExD/H-box	 protein	 DDX46	
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binding	to	CCNA2	was	increased	with	OGFOD1	WT	overexpression,	but	not	with	the	OGFOD1	
AxA	mutant.	CDK2	or	SCAPER	binding	to	CCNA2	on	the	other	hand	seemed	to	be	weakend.	 
	
	
Figure	34:	Selection	of	proteins	 filtered	 for	specific	CCNA2	 interaction	with	highest	 (more	 than	2	 fold)	and	
lowest	(less	than	0.6)	enrichment	identified	in	Flag-CCNA2	IP	with	additional	overexpression	of	OGFOD1	wild	
type	(WT),	OGOFD1	H155A,	D157A	(MUT),	and	OGFOD2	Isoform	1	(OGFOD2I1,	„control“)	using	LC-MS/MS;	A)	
Samples	from	Flag-IP	were	analyzed	by	LC-MS/MS,	the	results	were	selected	by	specific	interaction	partners	
of	 CCNA2	 identified	 by	 endogenous	 CCNA2-IP	 before;	 B)	 Proteins	 identified	 to	 be	 highly	 enriched	 or	
decreased	in	the	Flag-CCNA2-IP	versus	the	control	sample	
	
To	exclude,	 that	changes	 in	CCNA2	binding	where	due	to	OGFOD1	 induced	changes	of	 the	
subcellular	localization	of	CCNA2,	immunofluorescent	stainings	with	overexpressed	OGFOD1	
were	 performed	 (Figure	 35).	 Overexpression	 of	 OGFOD1-GFP	 and	 NLS-GFP	 did	 not	 alter	
endogenous	CCNA2	localization	(Figure	35	B’’	and	C’’),	as	it	is	distributed	like	CCNA2	in	cells	
with	no	transfection	(Figure	35	A’’).	
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Figure	35:	OGFOD1	overexpression	and	endogenous	CCNA2	localization;	with	indicated	construct	transfected	
HeLa	cells	were	fixed	and	stained	with	anti-CCNA2	antibody	and	Alexa-594	coupled	secondary	antibody,	DNA	
was	counterstained	with	DAPI.	
	
2.2.2 Identification	 of	 eEF2K	 as	 potential	 novel	 interaction	 partner	 for	
OGFOD1	
	
Recently,	eukaryotic	elongation	factor-2	kinase	(eEF2K)	was	reported	to	be	hydroxylated	on	
a	 proline	 residue118.	 eEF2K	 phosphorylates	 eukaryotic	 elongation	 factor	 2	 (eEF2),	 this	
modification	 inhibits	 eEF2s	 ability	 to	 interact	 with	 the	 ribosome	 and	 thereby	 impairs	
translation	 elongation.	 Proline	 98	 hydroxylation	 of	 eEF2K	 restrained	 its	 activity	 and	might	
regulate	translation	via	eEF2118.		
As	OGFOD1	 is	 a	 prolyl	 hydroxylase,	we	were	 interested	 if	OGFOD1	 is	 the	 so	 far	 unknown	
enzyme	modifying	eEF2K.	For	this,	GFP-IPs	and	the	F2H	assay	were	performed.	
	
	
Figure	36:	Interaction	studies	with	GFP-tagged	OGFOD1	wild	type	and	Flag-tagged	eEF2K	;	A)	Hek293T	cells	
were	co-transfected	and	used	for	GFP-IP;	B)-D)	GFP-IP	was	performed	with	cells	overexpressing	proteins	as	
indicated;	 OGFOD1-GFP	 and	 Flag-tagged	 eEF2K	 were	 detected	 with	 indicated	 antibodies	 in	 subsequent	
Western	blotting.	I=Input,	F=	Flowthrough,	B=	Beads	fraction.	
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N-/	or	C-terminal	GFP-tagged	OGFOD1	was	coexpressed	with	Flag-tagged	eEF2K	in	Hek293T	
cells	 and	 subjected	 to	GFP-IP	 (Figure	 36).	As	 control,	NLS-GFP	was	 coexpressed	with	 Flag-
eEF2K.	 Interaction	 of	 Flag-eEF2K	 with	 GFP-tagged	 OGFOD1	 can	 be	 observed	 upon	 GFP-IP	
(Figure	36	B	and	C),	whereas	the	GFP	control	did	not	co-precipitate	the	Flag-tagged	eEF2K	
(Figure	36	D).	
	
	
Figure	 37:	 Fluorescent	 two-hybrid	 (F2H)	 assay	 to	 study	 interactions	 of	 OGFOD1	 and	 eEF2K;	 different	
combinations	of	GFP-tagged	and	Flag-tagged	eEF2K	were	co-transfected:	A-A’’	GFP-OGFOD1	and	Flag-eEF2K,	
B-B’’	 OGFOD1-GFP	 and	 Flag-eEF2K,	 C-C’’	 GFP-NLS	 and	 Flag-eEF2K,	 Nuclei	 were	 counterstained	 with	 DAPI,	
Flag-tagged	 eEF2K	 was	 stained	 with	 anti-Flag	 antibody	 and	 corresponding	 Alexa594	 coupled	 secondary	
antibody,	arrows	indicate	location	of	the	GFP	spot	also	in	the	other	channels.	
The	 F2H	 assay	 did	 not	 confirm	 results	 from	 IP	 experiments.	 Coexpression	 of	 GFP-tagged	
OGFOD1	and	Flag-eEF2K	did	not	result	in	a	recruitment	of	Flag-tagged	eEF2K	by	OGFOD1	to	
the	distinct	nuclear	 spot	of	GFP-tagged	OGFOD1	 (Figure	37	A-B’’).	 The	 control	experiment	
with	NLS-GFP	and	Flag-eEF2K	showed	the	same	results	(Figure	37	C-C’’).	
	
2.2.3 OGFOD1	and	stress	granules	
OGFOD1	 was	 initially	 described	 as	 component	 of	 stress	 granules	 (SGs).	 Cellular	 stress	
response	often	inhibits	translation,	the	ribosomes	dissociate	and	the	small	subunits	with	the	
still	bound	mRNA	get	accumulated.	These	cytoplasmic	and	dynamic	RNA-protein	complexes	
are	called	stress	granules119,120.	
Upon	arsenite	treatment,	a	small	fraction	of	OGFOD1	accumulates	in	the	cytoplasm	in	RNA-
binding	protein	TIA1	positive	stress	granules5,89.	
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To	get	more	insights	about	OGFOD1	function	in	stress	granules,	first	translocation	and	timing	
of	OGFOD1	translocation	in	response	to	stress	was	tested.	
	
	
Figure	38:	OGFOD1	and	TIA-1	reorganization	in	arsenite	treated	HeLa	cells	over	time;	A-F’’’	HeLa	cells	were	
treated	with	1	mM	arsenite	for	indicated	times,	then	fixed	and	co-stained	with	anti-OGFOD1		and	anti-TIA-1	
antibodies	and	Alexa-488	and	Alexa-594	coupled	secondary	antibodies;	DNA	was	counterstained	with	DAPI,	
asterisks	indicate	colocalized	stress	granules	in	OGFOD1	and	TIA-1	antibody	staining.	
To	monitor	recruitment	of	OGFOD1	to	the	stress	granules,	cells	were	 incubated	with	1mM	
arsenite	for	various	time	periods	(0,	15,	30,	45	min,	1	h,	1	h	30	min	and	2	h).	Assembly	of	
stress	granules	was	observed	over	 time	by	anti-TIA1	antibody	staining	and	costaining	with	
anti-OGFOD1.	 TIA-1	 positive	 stress	 granules	 appeared	 already	 15	 minutes	 after	 arsenite	
treatment	(Figure	38	B’’).	First	spots	of	OGFOD1	in	the	cytoplasm	colocalized	with	TIA-1	can	
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be	detected	at	the	same	incubation	time	(Figure	38	B’),	however	they	get	more	distinct	with	
longer	arsenite	incubation	(Figure	38	E’).	
	
In	 order	 to	 identify	 a	 domain	 in	OGFOD1	 responsible	 for	 SG	 recruitment,	 GFP	 tagged	 full	
length	 OGFOD1	 and	 variants	 were	 expressed	 in	 HeLa	 cells.	 The	 ability	 of	 GFP-tagged	
OGFOD1	to	translocate	to	SGs	should	have	been	monitored	after	arsenite	treatment.		
Full	length	OGFOD1	with	N-	and	C-terminal	GFP-tag	and	NLS-GFP	as	control	were	expressed	
in	HeLa	cells,	48	h	after	transfection	cells	were	stressed	for	1	h	with	1	mM	sodium	arsenite.	
However,	 cells	 expressing	 GFP-tagged	 OGFOD1	 showed	 TIA-1	 stress	 granules,	 but	 no	
translocation	 of	 GFP-tagged	 OGFOD1	 (data	 not	 shown).	 A	 large	 GFP-tag	 (25	 kDa)	 might	
hinder	SG	recruitment,	therefore	the	smaller	hemagglutinin	tag	(HA-tag,	around	5	kDa)	was	
tested.		
	
	
Figure	 39:	OGFOD1,	HA-OGFOD1,	 and	 TIA-1	 reorganization	 in	 arsenite	 treated	HeLa	 cells	 over	 time,	 A-B’’’	
HeLa	cella	were	treated	with	1	mM	arsenite	for	1	h,	then	fixed	and	co-stained	with	anti-OGFOD1	and	anti-
TIA-1	 antibodies	 and	 Alexa-488	 and	 Alexa-594	 coupled	 secondary	 antibodies;	 C-D’’’	 HeLa	 cells	 were	
transfected	with	HA-OGFOD1,	allowed	to	recover	from	transfection	for	48	h	and	treated	with	1	mM	arsenite	
for	 1	 h,	 then	 fixed	 and	 co-stained	 with	 anti-HA	 and	 anti-TIA-1	 antibodies	 and	 Alexa-488	 and	 Alexa-594	
coupled	secondary	antibodies;	DNA	was	counterstained	with	DAPI.	
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However,	also	HA-OGFOD1	did	not	change	localization	after	stress	(Figure	39	D’)	in	contrast	
to	 the	 stress	granule	marker	TIA-1	 (Figure	39	D’’).	 Endogenous	OGFOD1	 translocates	after	
arsenite	 stress	 to	 TIA-1	 positive	 stress	 granules	 (Figure	 39	 B’),	whereas	 the	 localization	 in	
unstressed	cells	is	restricted	to	the	nucleus	(Figure	39	A’).	
	
The	next	attempt	to	circumvent	the	tag-dependent	inhibition	of	SG	translocation,	OGFOD1	
with	an	 internal	HA-tag	was	generated.	 In	 the	 linker	 sequence	connecting	 the	 two	DSBHs,	
the	amino	acids	248-256	were	exchanged	by	the	HA-tag	sequence.	
	
	
Figure	40:	OGFOD1,	internal	HA-OGFOD1,	and	TIA-1	reorganization	in	arsenite	treated	HeLa	cells	over	time;	
A-C’’’	HeLa	 cells	were	 transfected	with	 internally	HA-tagged	OGFOD1	 (intHA-OGFOD1),	 allowed	 to	 recover	
from	transfection	 for	48	h	and	 in	B-C’’’	 additinally	 treated	with	1	mM	arsenite	 for	1	h,	 then	 fixed	and	co-
stained	 with	 anti-OGFOD1	 and	 anti-TIA-1	 antibodies	 and	 Alexa-488	 and	 Alexa-594	 coupled	 secondary	
antibodies;	DNA	was	counterstained	with	DAPI.	
	
However,	 the	 internal	 HA-tag	 was	 not	 recognized	 by	 anti-HA	 antibody	 in	 IF	 experiments	
upon	 overexpression	 of	 the	 intHA-OGFOD1	 variant	 (data	 not	 shown).	 Therefore,	 anti-
OGFOD1	staining	was	used,	cells	expressing	higher	OGFOD1-levels	were	assumed	to	express	
internal-HA	 tagged	OGFOD1.	However,	expression	of	 internally	HA-tagged	OGFOD1	should	
be	confirmed	by	western	blot.	
Cells	 with	 higher	 level	 of	 OGFOD1	 staining	 were	 mostly	 in	 apoptosis,	 as	 the	 nuclei	 were	
brighter	 and	 deformed	 (Figure	 40	 B).	 Endogenous	 OGFOD1	 identified	 by	 lower	 protein	
expression	 levels	 compared	 to	 overexpressing	 cells,	 localized	 upon	 arsenite	 treatment	 to	
TIA-1	positive	stress	granules	(Figure	40	C’’).	The	internal	HA	tagged	OGFOD1	could	not	be	
observed	 in	 stress	 granules,	 but	 also	no	 cells	with	normal	nuclear	morphology	 and	higher	
2	Results	
48	
OGFOD1	 levels	 could	 be	 detected.	 Therefore,	 the	 tag	 or	 already	 OGFOD1	 overexpression	
seemed	to	cause	induction	of	apoptosis	or	necrosis.	
	
	
2.2.4 Characterization	of	OGFOD1	by	knockout	cell	lines	
Knockout	 cell	 lines	 in	 Hek293	 cells	 were	 generated	 with	 the	 CRISPR	 (Clustered	 Regularly	
Interspaced	Short	Palindromic	Repeats)/Cas9	system121.	With	this	method,	sequence	specific	
double	stranded	DNA	breaks	(dsDNA)	can	be	 introduced	by	guideRNAs	(gRNAs)	coupled	to	
the	RNA	 guided	DNA	endonuclease	Cas9.	 For	 editing,	 the	DNA	 target	 sequence	has	 to	 be	
associated	with	a	protospacer	adjacent	motif	(PAM).	
	
2.2.4.1 Generation	of	OGFOD1,	MINA53	and	NO66	knockout	constructs	
Using	the	online	CRISPR	Design	tool	(http://crispr.mit.edu/),	guide	RNAs	were	designed	and	
cloned	 for	OGFOD1	and	 two	other	ROXs,	NO66	and	MINA53,	according	 to	 the	protocol	of	
Ran	and	colleagues121	(Figure	41).	
	
	
Figure	41:	Schematical	gene	structure	with	intron	and	exon	structures	of	OGFOD1,	MINA53,	and	NO66	and	
selected	 DNA	 sequences	 targeted	 by	 designed	 gRNAs;	 scissors	 indicate	 planned	 cutting	 site	 for	 Cas9,	
underlined	sequences	are	targeted	sequence	by	the	gRNAs,	PAM	sequence	is	in	magenta.	
	
The	chosen	RNA	guides	target	the	locus	of	OGFOD1	and	bind	5’	and	3’	of	the	second	exon	in	
the	intronic	sequences.	CRISPR/Cas9	mediated	dsDNA	break	should	lead	to	excision	of	exon	
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2.	 The	 exclusion	 of	 exon	 2	 results	 in	 an	 premature	 stop	 codon	 in	 the	 protein	 sequence,	
producing	a	shortened	51	amino	acid	peptide	(Figure	41	A).	
MINA53	gene	was	targeted	in	Exon	1,	genomic	modification	leads	to	a	frame	shift	producing	
a	stop	codon	in	exon	1	(Figure	41	B).	
NO66	 is	 a	 one	 exon	 gene	 (single	 exon	 gen,	 SEG)	 containing	 no	 introns.	 Therefore,	 the	
guideRNAs	were	chosen	97	and	222	bp	after	the	start	codon.	As	for	the	other	contructs,	loss	
of	the	nucleotides	leads	to	frame	shift	and	premature	stop	(Figure	41	C).	
	
2.2.4.2 Identification	of	modified	cell	lines	for	OGFOD1	
To	validate	knockouts,	first	clones	were	screened	on	the	genomic	level	by	PCR	amplification	
of	 genomic	 loci	 of	 the	 targeted	 genes.	 Those	 knockout	 strains	 were	 further	 validated	 by	
western	blot.	NO66	and	MINA53	knockouts	are	described	in	a	following	chapter	(2.3.2).	
	
For	OGFOD1,	out	of	15	tested	clones	no	homozygous	clones	were	detected,	but	one	clone	
seemed	 to	 be	 heterozygous	 for	 OGFOD1	 gene	modification.	 PCR	 analysis	 of	 clone	 D2	 for	
OGFOD1	knockout	showed	this	heterozygous	genomic	situation,	as	we	can	see	wildtype	and	
knockout	 band	 in	 PCR	 analysis	 (Figure	 42	 A).	 The	 amplified	 sequence	 revealed	 for	 the	
deletion	allele	(Figure	42	B,	O1D2_DEL)	a	sucessful	editing	at	the	upstream	cutting	site.	For	
the	downstream	cutting	site,	the	sequence	was	not	available.	The	wild	type	allele	(Figure	42	
B,	O1D2_WT)	showed	the	unmodified	genomic	situation.	Even	though	one	allele	of	OGFOD1	
gene	was	 edited	 resulting	 in	 a	 premature	 stop	 codon	 at	 amino	 acid	 52	 (Figure	 42	D),	 the	
general	 protein	 level	 of	 OGFOD1	 seemed	 to	 be	 unchanged	 compared	 to	 wild	 type	 cells	
(Figure	42	C).	
	
	
Figure	 42:	 Validation	 of	 OGFOD1	 heterozygous	 knockout	 strain	 D2;	 A)	 Screening	 of	 genotypes	 by	
amplification	of	the	genomic	locus	of	OGFOD1	for	clone	D2	and	Hek293	untreated	cells	as	control	(WT);	B)	
Sequencing	of	PCR	amplified	targeted	genomic	DNA	locus,	underlined	gRNA	targeting	site,	scissors	indicate	
cutting	 site,	 in	 magenta	 the	 PAM	 sequence;	 C)	 Western	 blot	 analysis	 of	 protein	 amount,	 endogenous	
OGFOD1	and	Actin	as	loading	control	were	detected	with	indicated	antibodies;	D)	Amino	acid	alignment	of	
protein	sequence	after	genome	editing	and	wild	type	sequence.	
The	 heterozygous	 knockout	 cell	 line	 for	 OGFOD1	 (Hek293	 O1D2)	 was	 further	 analyzed	 in	
immunofluorescence	 stainings.	 Also	 IF	 experiments	 using	 antibodies	 directed	 against	
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OGFOD1	showed	that	same	protein	levels	can	be	detected	in	the	wild	type	cells	 like	in	the	
heterozygous	knockout	cell	line	(Figure	43).	
	
	
Figure	43:	OGFOD1	protein	levels	in	Hek293	and	Hek293	OGFOD1	D2	cells;	fixed	cells	were	stained	with	anti-
OGFOD1	antibody	and	Alexa-488	coupled	secondary	antibody,	DNA	was	counterstained	with	DAPI.	
A	 second	 attempt	 to	 generate	 homozygous	 knockout	 cells	 for	 OGFOD1	 starting	 with	 the	
heterozygous	 clone	 D2	 did	 not	 succeed.	 The	 second	 round	 of	 transfection	 with	 CRISPR	
plasmids	and	following	selection	with	puromycin	resulted	in	no	surviving	cells.		
In	 contrast,	 generation	 of	 knockout	 cell	 lines	 for	 NO66	 and	 MINA53	 was	 successful	 and	
several	 knockout	 cell	 lines	 have	been	 established	 (described	 in	 2.3.2).	 These	 results	 imply	
that	homozygous	OGFOD1	knockout	in	Hek293	cells	could	be	lethal.	
	
2.2.4.3 Characterization	of	Hek293	OGFOD1	heterozygous	knockout	cell	line	
	
Growth	assay	of	heterozygous	knockout	strain	Hek293	OGFOD1	D2	
First,	growth	assays	were	performed	to	examine	potential	roles	of	OGFOD1	in	the	cell.	
	
OGFOD1	D2	+/-	and	wild	type	Hek293	cell	growth	was	assayed	under	normoxia	(Figure	44	A)	
and	hypoxia	 (Figure	44	B).	OGFOD1	heterozygous	cells	 (O1D2)	showed	a	slight	decrease	 in	
cell	number,	but	not	significant	(Figure	44	A	and	B).	
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Figure	44:	Growth	assay	 for	OGFOD1	heterozygous	knockout	cell	 line	OGFOD1	D2;	1.1*103	cells	of	Hek293	
O1D2	and	wild	type	Hek293	were	seeded	in	six	biological	replicates	and	for	5	days	measured	for	cell	viability	
using	AquaBluer	(alamar	blue);	mean	values	of	three	technical	replicates	are	shown,	error	bars	represent	the	
standard	deviations	A)	 cells	were	kept	under	normal	oxygen	conditions	 (approx.	21	%);	B)	cells	were	kept	
under	hypoxic	conditions	(0.1	%)	
Results	are	similar	 for	 the	growth	under	hypoxic	conditions	 (Figure	44	B),	although	overall	
cell	numbers	were	lower.	
	
Ribosome	analysis	of	heterozygous	knockout	strain	Hek293	OGFOD1	D2	
To	 adress	 OGFOD1’s	 function	 as	 ribosomal	 oxygenase,	 ribosomes	 of	 the	 cell	 line	 Hek293	
OGFOD1	 D2	were	 isolated	 and	 analyzed	with	 two	methods.	 First,	 ribosome	 profiles	 after	
sucrose	 gradients	 were	 determined.	 Secondly,	 isolated	 ribosomes	 of	 wild	 type	 and	
heterozygous	knockout	cells	were	subjected	to	LC-MS/MS	and	analyzed	for	protein	content	
and	for	changed	PTMs	on	ribosomal	proteins.	
	
The	ribosome	profiles	of	OGFOD1-D2	ribosomes	displayed	no	obvious	changes	compared	to	
the	wild	type	profiles	(see	in	Appendix	6.1.2,	Figure	74	A	and	B).	
	
2	 pmol	 of	 crude	 ribosomes	 were	 additionally	 analyzed	 by	 label-free	 LC	 MS/MS	 (in	
collaboration	with	 Ignasi	 Forné,	Axel	 Imhof	 Lab,	Biomedical	 Center	Munich,	 LMU).	 Results	
are	summarized	in	the	section	2.3.2.2.	
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2.3 Human	ribosomal	oxygenases	MINA53	and	NO66	
2.3.1 Interaction	 studies	 of	 MINA53/NO66	 mutants	 with	 the	 respective	
substrates	
The	human	ribosomal	oxygenases	MINA53	and	NO66	hydroxylate	histidine	 residues	 in	 the	
ribosomal	proteins	RPL27a	and	RPL8,	respectively.	Both	proteins	are	localized	in	the	nucleoli,	
even	in	the	same	nucleolar	subcompartment51,52.	Crystal	structures	also	reveal	a	remarkable	
analogy.	 The	 Fe(II)	 and	 2OG	 oxygenases	 characterizing	 JmjC	 domain,	 a	 dimerization	
domain38,58,59	 and	 a	 winged	 helix	 (WH)	 domain	 have	 been	 proposed	 for	 the	 two	 human	
proteins	and	are	also	conserved	in	bacterial	ycfD6	(see	Figure	45	and	Figure	6	A).	
	
	
Figure	45:	 Schematic	drawing	of	MINA53	and	NO66	domain	 structure	and	generated	mutants;	A)	MINA53	
sequence	consists	of	the	JmjC	domain	(blue)	with	the	iron	coordinating	motif	H179,	D181	(mutated	in	red),	
the	dimerization	domain	(yellow),	and	the	winged	helix	domain	(green);	the	triple	mutant	is	mutated	in	the	
dimerization	domain	in	W264,	F267,	and	L308	to	A;	B)	NO66	consists	of	the	same	domains	as	MINA53,	the	
iron	coordinating	motif	is	H340,	D342	(mutated	in	red),	the	NLS	sequence	is	colored	in	gray;	the	triple	mutant	
is	mutated	in	the	dimerization	domain	in	W428,	F431,	and	L436	to	A.	
Both	 MINA53	 and	 NO66	 form	 dimers	 or	 even	 oligomers	 in	 crystal	 structures6,122,123,	 this	
homo-oligomerization	was	linked	to	the	enzymatic	activity	in	in	vitro	assays6,122.	
In	order	to	corobate	those	results	in	vivo,	dimerization	in	cells	was	tested	and	confirmed	in	
the	 course	 of	 a	 bachelor	 thesis	 by	 Kevin	 Brockers53.	 MINA53	 and	 NO66	 showed	 homo-
oligomerization	 in	cells	and	also	the	proposed	dimerization	domain	 in	crystal	structure	has	
been	 confirmed	 in	 cells.	 Variants	 of	 MINA53	 and	 NO66	 lacking	 the	 dimerization	 domain	
(amino	 acids	 271-339	 for	 MINA53,	 amino	 acids	 439-511	 for	 NO66)	 showed	 no	 homo-
oligomerization.	 Based	 on	 crystal	 structure	 data,	 Kevin	 Brockers	 also	 generated	 MINA53	
Triple	 (W264A,	 F267A,	 L308A)	 and	 NO66	 Triple	 (W428A,	 F431A,	 L436A)	 mutants.	 Those	
mutants	have	been	shown	to	form	no	oligomers	in	cells53.	
	
Within	 this	 thesis,	 experiments	 have	 been	 performed	 to	 gain	 further	 insights	 into	 the	
importance	 of	 homo-oligomerization	 in	 cells.	 Therefore	 GFP-tagged	 wild	 type,	 AxA,	 and	
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Triple	mutant	of	MINA53/NO66	have	been	co-expressed	with	Flag-tagged	RPL27a/RPL8,	and	
subsequently	GFP-IP	was	performed.		
	
	
Figure	46:	Interaction	studies	of	MINA53	with	substrate	RPL27a;	Hek293T	cells	were	co-transfected	and	used	
for	GFP-IP;	A)-D)	GFP-IP	was	performed	with	cells	overexpressing	proteins	as	indicated;	GFP-tagged	MINA53	
and	 mutants,	 and	 Flag-tagged	 RPL27a	 were	 detected	 with	 indicated	 antibodies	 in	 subsequent	 Western	
blotting;	I	=	input,	F	=	flow-through,	B	=	beads.	
	
Using	MINA53	wild	 type,	 the	 iron	 binding	 AxA	mutant	 (MINA53	 H179A,	 D181A),	 and	 the	
triple	mutant	for	MINA53,	no	interaction	of	any	GFP-MINA53	variant	with	Flag-RPL27a	could	
be	detected	(Figure	46	A-C),	although	RPL27a	is	an	established	substrate	of	MinA534.	
	
	
Figure	47:	Interaction	studies	of	NO66	with	substrate	RPL8;	Hek293T	cells	were	co-transfected	and	used	for	
GFP-IP;	A)-D)	GFP-IP	was	performed	with	cells	overexpressing	proteins	as	 indicated;	GFP-tagged	NO66	and	
mutants,	and	Flag-tagged	RPL8	were	detected	with	indicated	antibodies	in	subsequent	Western	blotting;	I	=	
input,	F	=	flow-through,	B	=	beads.	
The	 same	 experimental	 set-up	was	 used	 for	NO66	with	 its	 substrate	 RPL8.	 For	GFP-NO66	
and	Flag-RPL8,	 interaction	could	be	observed	upon	GFP-IP	of	GFP-NO66	(Figure	47	A).	Also	
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for	the	AxA	mutant,	the	 interaction	still	 took	place	(Figure	47	B).	The	triple	mutant,	that	 is	
not	 capable	 of	 oligomerization,	 did	 not	 interact	 with	 RPL8	 (Figure	 47	 C).	 The	 control	
experiment	with	NLS-GFP	also	displayed	no	interaction	(Figure	47	D).	
	
Therefore,	the	triple	mutation	in	the	dimerization	domain	of	MINA53	and	NO66	altered	the	
dimerization	 behaviour	 of	 both	 proteins	 and	 for	NO66	 also	 changed	 the	 binding	 behavior	
towards	the	substrate	RPL8.	
	
2.3.2 Characterization	of	MINA53	and	NO66	by	knockout	cell	lines	
2.3.2.1 Identification	of	modified	cell	lines	for	MINA53	and	NO66	
Before	 described	 for	OGFOD1	 (2.2.4),	 also	MINA53	 and	NO66	CRISPR/Cas9	 knockout	 cells	
were	generated	and	clones	first	screened	by	PCR	amplification	of	genomic	 loci	of	 targeted	
genes.	Later	western	blot	analysis	of	protein	levels	were	performed.		
	
In	 contrast	 to	OGFOD1	where	 knockout	 seemed	 to	be	 lethal	 in	Hek293	 cells	 (see	Chapter	
2.2.4),	 MINA53	 and	 NO66	 were	 positive	 for	 successful	 genome	 editing.	 Four	 out	 of	 five	
MINA53	clones	were	analyzed	and	could	be	verified	to	be	MINA53	knockouts	also	on	protein	
level	(Figure	48	A-C).	In	clone	3,	genome	editing	was	precisely	carried	out	as	planned,	Cas9	
induced	the	double	strand	break	exactly	3	bp	upstream	of	the	PAM	sequence	(Figure	48	B).	
	
	
Figure	48:	Validation	of	MINA53	knockouts;	A)	Screening	of	genotypes	by	amplification	of	the	genomic	locus	
of	 MINA53	 for	 knockout	 clones	 1-4,	 wild	 type	 clone	 #5,	 and	 Hek293	 untreated	 cells	 as	 control	 (WT);	 B)	
Sequencing	of	PCR	amplified	targeted	genomic	DNA	locus,	underlined	gRNA	targeting	site,	scissors	indicate	
cutting	 site,	 in	 magenta	 the	 PAM	 sequence;	 C)	 Western	 blot	 analysis	 of	 protein	 amount,	 endogenous	
MINA53	and	Actin	as	 loading	control	were	detected	with	indicated	antibodies;	D)	Amino	acid	alignment	of	
protein	sequence	after	genome	editing	and	wild	type	sequence.	
Four	tested	clones	for	NO66	genome	editing	were	knockouts	not	only	on	the	genomic	level	
but	also	on	protein	level	(Figure	49	A).	Sequencing	revealed	for	clone	3	that	Cas9	did	cut	in	
the	upstream	region	not	precisely	but	leaving	one	more	basepair	before	the	double	strand	
break	(Figure	49	B,	framed	in	blue).	This	mistake	resulted	in	a	premature	stop	codon	already	
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at	amino	acid	114	instead	of	a	planed	premature	stop	codon	at	amino	acid	131	(Figure	49	D).	
Western	blot	analysis	confirmed	the	knockout	in	all	tested	clones	(Figure	49	C).	
	
	
Figure	49:	Validation	of	NO66	knockouts;	A)	Screening	of	genotypes	by	amplification	of	the	genomic	locus	of	
NO66	 for	 knockout	 clones	 3,	 4,	 6,	 7	 and	 Hek293	 untreated	 cells	 as	 control	 (WT);	 B)	 Sequencing	 of	 PCR	
amplified	targeted	genomic	DNA	locus,	 in	magenta	the	PAM	sequence;	C)	Western	blot	analysis	of	protein	
amount,	endogenous	NO66	and	Actin	as	loading	control	were	detected	with	indicated	antibodies;	D)	Amino	
acid	 alignment	 of	 protein	 sequence	 after	 genome	 editing,	 sequence	 of	 planned	 editing,	 and	 wild	 type	
sequence.	
2.3.2.2 Characterization	of	knockout	strains	for	MINA53	and	NO66	
To	 characterize	 the	 roles	 of	 the	 respective	 ribosomal	 oxygenases,	 knockout	 cell	 lines	 for	
MINA53	 and	 NO66	 were	 further	 analyzed.	 The	 knockout	 was	 confirmed	 by	
immunofluorescence	staining	of	endogenous	protein	levels,	additionally	growth	assays	were	
performed.	Also,	ribosomes	were	isolated	and	analyzed	by	analytical	sucrose	gradients	and	
LC-MS/MS.	
	
Analysis	of	MINA53	and	NO66	knockout	strains	by	immunofluorescence	
MINA53	 knockout	 strains	 #3	 and	 #4	 were	 analyzed	 by	 immunofluorescence.	 Staining	 of	
MINA53	 in	wild	 type	 Hek293	 showed	 the	 nucleolar	 distribution	 (Figure	 50	 A’).	 Consistent	
with	western	blot	protein	levels	(Figure	48	C),	knockout	cells	showed	no	signal	of	remaining	
MINA53	(Figure	50	B’	and	C’).		
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Figure	50:	MINA53	protein	levels	in	Hek293	and	Hek293	KO-MINA53	#3	and	#4;	fixed	cells	were	stained	with	
anti-MINA53	antibody	and	Alexa-488	coupled	secondary	antibody,	DNA	was	counterstained	with	DAPI.	
	
To	test,	 if	nucleoli	are	affected	by	loss	of	MINA53	protein,	MINA53	knockout	#4	cells	were	
counterstained	 with	 upstream	 binding	 transcription	 factor	 (UBF)	 and	 NO66.	 UBF	 plays	 a	
critical	role	in	mediating	the	recruitment	of	RNA	polymerase	I	to	rDNA	promoter	regions	and	
is	a	nuleolar	protein124.	
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Figure	51:	MINA53	and	UBF	protein	 levels	 in	Hek293	and	Hek293	KO-MINA53	#4;	 fixed	 cells	were	 stained	
with	 anti-MINA53,	 anti-UBF,	 and	 anti-NO66	 antibodies	 and	 Alexa-488	 or	 Alexa-594	 coupled	 secondary	
antibody,	DNA	was	counterstained	with	DAPI.	
Knockout	of	MINA53	did	not	change	NO66	or	UBF	localization	in	nucleoli.	Compared	to	wild	
type	 cells,	 stainings	 of	 UBF	 (Figure	 51	 A’’)	 and	 NO66	 (Figure	 51	 C’	 and	 C’’)	 were	 also	
comparable	in	KO-MINA53#4	(Figure	51	B’’,	C’,	and	C’’).	
	
Initial	 NO66-stainings	 in	 the	 knockout	 cell	 lines	 Hek293	 KO-NO66	 #3	 and	 #4	 (Figure	 52)	
revealed	a	different	picture.	Knockout	strain	#3	was	a	complete	NO66	knockout,	as	no	NO66	
was	detected	 in	 IF	 (Figure	52,	B-B’’).	However,	 in	Hek293	KO-NO66	#4	 IF	staining	revealed	
that	around	30-40%	of	cells	still	express	NO66	(Figure	52	C-C’’),	even	though	protein	levels	
detected	 by	 western	 blot	 suggested	 a	 complete	 loss	 of	 NO66	 protein	 (Figure	 49	 C).	 For	
further	experiments	NO66	knockout	cell	line	#3	was	used.	
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Figure	52:	NO66	protein	levels	in	Hek293	and	Hek293	KO-NO66	#3	and	#4;	fixed	cells	were	stained	with	anti-
NO66	antibody	and	Alexa-488	coupled	secondary	antibody,	DNA	was	counterstained	with	DAPI.	
	
MINA53	protein	distribution	in	Hek293	KO-NO66#3	was	not	changed	in	comparison	to	wild	
type	cells	(Figure	53	A’	and	B’).	
	
	
Figure	 53:	MINA53	 protein	 levels	 in	 Hek293	 and	 Hek293	 KO-NO66	 #3;	 fixed	 cells	were	 stained	with	 anti-
MINA53	antibody	and	Alexa-488	coupled	secondary	antibody,	DNA	was	counterstained	with	DAPI.	
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Analysis	of	MINA53	and	NO66	knockout	strains	in	growth	assays	
The	different	knockout	strains	and	wild	type	Hek293	cells	were	grown	under	normoxia	and	
hypoxia	 (Figure	54).	MINA53	knockout	 strain	#3	 (MinA_3)	and	MINA53	knockout	 strain	#4	
(MinA_4)	grew	slower	compared	to	wild	type	 in	normoxic	as	well	as	 in	hypoxic	conditions.	
MinA_4	 showed	 a	 significant	 slower	 growth	 in	 normoxia	 and	 hypoxia.	 MinA_3	 grew	
significantly	 slower	 in	 normoxia,	 in	 hypoxia	 no	 significant	 difference	 could	 be	 observed	
(Figure	54	A	and	B).	
	
	
Figure	 54:	 Growth	 assay	 for	 MINA53	 and	 NO66	 knockout	 cell	 lines;	 growth	 was	 performed	 in	 three	
independent	 experiments,	 values	 and	 standard	 error	 bars	 represent	 the	mean	 of	 three	 replicates	 of	 one	
experiment;	knockout	 cell	 lines	MINA53#3	and	#4,	NO66#3	and	#4,	and	wild	 type	Hek293	were	 seeded	at	
approximatly	 the	 same	 amounts	 and	 harvested	 and	 counted	 for	 5	 days;	 A)	 and	 C)	 cells	were	 kept	 under	
normal	oxygen	conditions	(approx.	21	%);	B)	and	D)	cells	were	kept	under	hypoxic	conditions	(0.1	%)	
NO66	knockout	cells	proliferate	like	wild	type	in	normoxic	conditions	(Figure	54	C).	Knockout	
cell	proliferation	in	hypoxia	seemed	to	be	elevated,	but	not	in	a	significant	range	(Figure	54	
D).	
	
Analysis	of	ribosomes	isolated	from	MINA53	and	NO66	knockout	strains	
Ribosomes	 of	 knockout	 cell	 lines	 Hek293	 KO-MINA53#4	 and	 Hek293	 KO-NO66#3	 were	
isolated	 and	 analyzed	 in	 two	 different	 assays.	 Firstly,	 ribosome	 profiles	 after	 sucrose	
gradients	were	determined.	Secondly,	isolated	ribosomes	were	subjected	to	LC-MS/MS	and	
analyzed	for	altered	modifications	on	ribosomal	proteins.	
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Isolated	ribosomes	were	analyzed	by	analytical	sucrose	gradients	(Appendix	6.1.2,	Figure	74	
C	 and	 D).	 MINA53-KO#4	 and	 NO66-KO#3	 ribosomes	 showed	 no	 obvious	 differences	
compared	to	wild	type	(Appendix	6.1.2,	Figure	74	A).	Major	ribosome	assembly	defects	can	
be	excluded	(personal	communication	with	Dr.	Sarah	Matheisl,	Prof.	Dr.	Roland	Beckmanns	
Laboratory,	Gene	Center	Munich,	LMU).	
	
To	 analyze	 the	 ribosomes	 with	 regard	 to	 differences	 in	 protein	 modifications,	 2	 pmol	 of	
crude	ribosomes	were	analyzed	by	label-free	LC	MS/MS	(Ignasi	Forné,	Axel	Imhof	laboratory,	
Biomedical	Center	Munich,	LMU).	Three	biological	replicates	of	Hek293	(WT)	ribosomes,	and	
two	 replicates	 of	MINA53-KO,	NO66-KO	and	OGFOD1-D2	 ribosomes	were	 analyzed	by	 LC-
MS/MS.	
The	proteins	 identified	 in	all	samples	were	analyzed	by	GO	term	analysis	(Figure	55).	Most	
proteins	were	related	to	translation	and	peptide	biosynthesis.	 In	fact,	all	human	ribosomal	
proteins	 were	 found	 in	 the	 samples	 confirming	 isolation	 of	 ribosomes	 and	 the	 ribo-
interactome.	Further	analyses	of	alterations	in	protein	contents	in	individual	samples	will	be	
undertaken.	
	
	
Figure	 55:	 Panther	 gene	 ontology	 (GO)	 term	 analysis	 for	 proteins	 of	 isolated	 ribosomes	 identified	 by	 LC-
MS/MS,	displayed	are	the	fold	enrichment	of	certain	GO	terms	and	P-values	of	the	enrichment 
MINA53,	 NO66,	 and	 OGFOD1	 are	 reported	 to	 modify	 certain	 amino	 acids	 in	 different	
ribosomal	 proteins.	 MINA53	 hydroxylates	 His39	 in	 RPL27a,	 NO66	 His216	 in	 RPL8	 and	
OGFOD1	 Pro62	 in	 RPS235,6.	 Having	 a	 deeper	 look	 into	 those	 proteins	 and	 corresponding	
peptides	revealed	that	those	peptides	of	interest	could	be	detected	in	LC-MS/MS	(Table	3).	
RPL27a	 peptides	were	 identified	with	 hydroxylated	 His	 (His	 OH)	 in	 all	 samples	 but	 not	 in	
MINA53-KO	replicates	 (Table	3),	here	only	unmodified	RPL27a	peptide	was	found.	Also	for	
RPL8	and	NO66	 in	the	knockout	sample,	only	unmodified	peptide	could	be	detected,	 in	all	
other	 samples	 hydroxylation	of	His216	 takes	 place.	 In	OGFOD1	D2	 ribosomes,	 only	 RPS23	
peptides	with	hydroxylated	Pro62	were	found,	in	accordance	with	OGFOD1	D2	cell	line	still	
exhibiting	comparable	OGFOD1	protein	levels	as	wild	type	cells	(see	Chapter	2.2.4.3).	
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Table	3:	Peptides	of	 interest	 in	 ribosome	preparations	 from	different	knockout	 cell	 lines,	 identified	by	 LC-
MS/MS	and	described	by	intensities	
With	 the	 fragmentation	 spectra,	 the	16	Dalton	mass	 shift	 corresponding	most	 likely	 to	 an	
oxidation	 can	 be	 pinpointed	 to	 one	 particular	 amino	 acid	 (Figure	 56	 E).	 For	 MINA53	
substrate	RPL27a	as	example,	the	fragmented	ion	spectra	assigned	His39	to	be	hydroxylated	
in	wild	type	and	NO66	KO	(Figure	56	A	and	B),	but	not	in	both	MINA53	KO	samples	(Figure	
56	C	and	D).	
	
	
Figure	56:	Fragmentation	assignments	 for	RPL27a	peptide	 in	different	samples;	hydroxylated	peptide	 in	A)	
Hek293	(WT)	sample	2	and	B)	Hek293	KO-NO66#3	sample	2,	unmodified	peptide	in	C)	Hek293	KO-MINA53#4	
sample	 1	 and	D)	 sample	 2,	 E)	 y4-	 ion	 corresponding	 to	modified	H	with	 16	Da	 shift	 in	Hek293	WT_2	 and	
unmodified	in	Hek293	KO-MINA53#4_1		
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With	this	data	set,	novel	PTMs	on	ribosomal	proteins	could	also	be	identified.	For	example,	
another	so	far	not	reported	modification	was	found	in	the	RPL8	peptide.	Pro206	is	suggested	
to	be	hydroxylated	(Table	3).	
	
The	 analysis	 of	 ribosomes	 isolated	 from	 the	 different	 generated	 cell	 lines	 showed	 no	
intriguing	 differences	 in	 the	 ribosome	 profiles.	 Mass	 spectrometry	 based	 experiments	
confirmed	Hek293	KO-MINA53#4	and	Hek293	KO-NO66#3	being	knockout	cell	lines.	Also	the	
reported	substrates	could	be	identified	and	were	dependent	on	MINA53	or	NO66.	OGFOD1	
D2	 cell	 line	 on	 the	 other	 hand	 showed	 no	 detectable	 differences	 to	 wild	 type	 cells	 with	
regards	to	ribosome	assembly	or	hydroxylated	RPS23	Pro62.	
	
2.3.2.3 Generation	of	reconstituted	cell	lines	for	MINA53	and	NO66	
To	 characterize	 MINA53	 and	 NO66	 in	 regards	 to	 their	 enyzmatic	 activity	 and	 the	
dimerization	ability,	knockout	strains	were	reconstituted	by	viral	transduction	with	different	
variants	of	MINA53	or	NO66.		
	
MINA53/NO66	wild	 type	protein,	 the	 iron	binding	AxA	 (MINA53	H179A,	D181A	and	NO66	
H340A,	 D342A)	 mutant	 or	 the	 Triple	 mutant	 (MINA53	 W264A,	 F267A,	 L308A	 and	 NO66	
W428A,	 F431A,	 L436A)	 disrupted	 in	 dimerization	 were	 brought	 back	 into	 MINA53/NO66	
knockout	cell	lines.		
	
	
Figure	57:	Lentiviral	transduction	to	reconstitute	MINA53	knockout	cell	line	#4;	A)	MINA53,	NO66,	and	Actin	
protein	amounts	determined	by	Western	blot	with	 indicated	antibodies;	B)	Quantification	of	Western	blot	
signals;	C)	flow	cytometric	analysis	of	CD2	positive	cells	(in	the	right	upper	quarter)	after	viral	transduction.	
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Successful	stable	expression	of	proteins	was	tested	in	western	blot	(Figure	57	A	and	Figure	
58	 A)	 and	 by	 flow	 cytometry.	 The	MINA53/NO66	 variants	were	 cloned	 into	 a	 vector	 that	
encodes	 the	 CD2	 marker.	 Cloned	 insert	 and	 CD2	 marker	 sequence	 are	 separated	 by	 the	
„self-cleaving“	2A	peptide	(T2A	site)	which	causes	the	ribosome	to	skip	at	this	sequence	and	
to	 start	 translation	 again	 at	 the	 next	 C-terminal	 start	 codon125.	 In	 case	 of	 reconstitution,	
marker	 protein	 CD2	 gets	 coexpressed	 but	 is	 not	 fused	 to	 the	 different	 MINA53/NO66	
variants.		
CD2	could	be	detected	in	the	virus	transduced	cells	with	percentages	ranging	from	99.3	to	
100%	of	cells	being	positive	(Figure	57	C	and	Figure	58	C).	
	
Quantification	 of	 western	 blot	 signals	 for	 MINA53	 and	 NO66	 in	 the	 different	 cell	 lines	
revealed	 a	 high	 level	 of	 reconstituted	 protein	 expressed	 in	 each	 cell	 line.	 Endogenous	
MINA53/NO66	levels	seemed	to	be	unchanged	(Figure	57	B	and	Figure	58	B).	
	
	
Figure	58:	 Lentiviral	 transduction	 to	 reconstitute	NO66	knockout	cell	 line	#3;	A)	NO66,	MINA53,	and	Actin	
protein	amounts	determined	by	Western	blot	with	 indicated	antibodies;	B)	Quantification	of	Western	blot	
signals;	C)	flow	cytometric	analysis	of	CD2	positive	cells	(in	the	right	upper	quarter)	after	viral	transduction.	
	
The	reconstituted	cell	lines	were	further	tested	in	a	proliferation	assay	to	determine	growth	
phenotypes.	 In	 addition	 to	 reconstituted	 knockout	 cell	 lines,	 Hek293	wild	 type	 cells	 have	
been	transduced	to	generate	MINA53	or	NO66	overexpression	cell	lines	(MINA53	WT	OE	or	
NO66	WT	OE).	
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Figure	59:	Growth	assay	for	MINA53	and	NO66	knockout	cell	lines	and	lentiviral	transduced	rescue	cell	lines;	
1.1*103	 cells	 were	 seeded	 in	 six	 biological	 replicates	 and	 measured	 for	 5	 days	 for	 cell	 viability	 using	
AquaBluer	 (alamar	 blue);	mean	 values	 of	 the	 six	 replicates	 are	 shown,	 error	 bars	 represent	 the	 standard	
deviations	A)	MINA53	KO,	MINA53	overexpressing	(OE),	and	„rescue“	cells	were	kept	under	normal	oxygen	
conditions	(approx.	21	%)	and	B)	under	hypoxic	conditions	(0.1	%);	NO66	KO,	NO66	overexpressing	(OE),	and	
„rescue“	cells	were	kept	in	normoxia	(C)	and	hypoxia	(D).	
The	different	MINA53	cell	lines	were	tested	under	normoxic	and	hypoxic	conditions	(Figure	
59).	In	normoxia,	MINA53-KO#4	displayed	a	reduced	growth	in	comparison	to	Hek293	(wild	
type)	 cells,	 the	MINA53	 overexpressing	 cell	 line	 (MINA53	WT	 OE)	 showed	 an	 even	more	
reduced	growth	(Figure	59	A).	In	hypoxia,	those	effects	could	not	be	detected	in	a	significant	
range	 (Figure	 59	 B).	 Reconstitution	 of	 the	 knockout	 cell	 line	 with	 wild	 type	 MINA53	
(MINA53-KO#4-WT),	 iron	 binding	 defective	 mutant	 MINA53-AxA	 (MINA53-KO#4-AxA)	 or	
dimerization	 triple	 mutant	 ((MINA53-KO#4-Triple)	 resulted	 in	 no	 major	 differences	
compared	to	the	knockout	or	wild	type	in	normoxic	or	hypoxic	conditions	(Figure	59	A,	B).	
	
Growth	 of	 NO66	 cell	 lines	 showed	 a	 quite	 similar	 picture	 as	 MINA53	 cell	 lines.	
Overexpression	of	NO66	 in	normoxic	conditions	seemed	to	slow	down	growth	significantly	
(Figure	59,	C,	NO66	WT	OE)	 (Figure	59	C).	NO66	knockout	cells	 (NO66-KO#3)	grew	slightly	
better	 than	wild	 type.	 Reconstitution	 of	 the	 knockout	 with	 NO66	wild	 type	 (NO66-KO#3-
WT),	 AxA	 cell	 line	 (NO66-KO#3-AxA),	 and	 triple	mutant	 (NO66-KO#3-Triple)	 resulted	 in	 no	
significant	differences	compared	to	the	knockout	or	wild	type	in	normoxic	conditions	(Figure	
59	 C).	 However,	 again	 the	 high	 error	 bars	 allow	 no	 significant	 conclusions.	 In	 hypoxic	
conditions,	all	cell	lines	behave	comparable	(Figure	59	D).	
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2.3.3 Phylogenetic	and	genomic	studies	of	MINA53	and	NO66	
Hydroxylation	 of	 ribosomal	 proteins	 is	 conserved	 from	 bacteria	 to	 human.	 Ribosomal	
hydroxylases	MINA53	and	NO66	as	well	as	bacterial	ancestor	ycfD	have	a	conserved	domain	
structure	and	dimerize	via	proposed	dimerization	domains6	(Figure	6	in	Introduction).	
	
2.3.3.1 Conservation	of	MINA53	and	NO66	proteins	
	
Figure	 60:	 Clustal	 omega	 alignment	 of	 MINA53	 protein	 sequences	 from	 H.sapiens	 (Uniprot	 :	 Q8IUF8),	
M.musculus	 (Q8CD15),	D.rerio	 (F1R7K2),	X.laevis	 (A0A1L8HCP3),	 and	H.vulgaris.	 The	protein	domains	 JmjC	
(blue),	dimerization	(yellow),	winged-helix	(green)	as	well	as	the	prospective	iron-binding	motif	HxD…H	(red)	
are	indicated	based	on	the	human	sequence6.	
	
H.sapiens
M.musculus
D.rerio
X.laevis
H.vulgaris
JmjC domain
dimerization domain
winged helix domain
H  D
H
H.sapiens       MPKKAKPTG----SGK------------E-EGPAPCKQMK-LEA-AGGPSALNFDSPSSLFESLISPIKTETFFKEFWEQ
M.musculus      MPKKVQPTG----DEN------------E-EASVPCKRVK-EEL-PETLSVLNFDSPSSFFESLISPIKVETFFKEFWEQ
D.rerio         MPKISRRAARRSGQEERLQRVSSASSPATQRSGSPQEIEQ-EERLQRVSTLSSSGSPQEFFQSLIRPLDLQEFFQRFWER
X.laevis        MPRRGRKEQ----EPE----------------HSEPKLAK-RDE-ADSKSPLDFSTPEKLFESLISPVTSDAFFRDYWET
H.vulgaris      MVK---RKGS-------------SSDDVA--KNVTKKVKKVSDVNEQKESKLNYTSCESVMSSLLQPISVKTFFEEFWEK
                * :                                 :  :  :      :  .  : ... :.**: *:  . **. :** 
H.sapiens       KPLLIQRDDPALATYYGSLFKLTDLKSL-CSRGMYYGRDVNVCRCVNGKKKVLNKDGKAHFLQLRKDFDQKRATIQFHQP
M.musculus      KPLLIQRDDPVLAKYYQSLFSLSDLKRL-CKKGVYYGRDVNVCRSISGKKKVLNKDGRAHFLQLRKDFDQKRATIQFHQP
D.rerio         QPLVLHRSDAALAGYYGSLFPLSGLRRL-CARGLQYGTDINTCRCVRGQKRLLNRAGAVDFCLLERDFLEKKATIQFHQP
X.laevis        KVLLLQGRDPAFTDYFQTLFRLSDLKHI-AGGGIYYERDVNVFKCRDGKKIALPRHGKATYLHLLKDFGSGKATIQFHQP
H.vulgaris      KPLYIKREN---SGYYGDLFSLSSMKEILAAHELEFETDVNVCRYVDNEKELLNEDGCLTVDKFDKLMNDKHATFQLHQP
               : * ::  :   : *:  ** *:.:: : .   : :  *: *. :   .:*  * . *      : : : . :**:*:***
H.sapiens       QRFKDELWRIQEKLECYFGSLVGSNVYITPAGSQGLPPHYDDVEVFILQLEGEKHWRLYHPTVPLAREYSVE-AEERIGR
M.musculus      QRYKDELWRIQEKLECYFGSLVGSNVYMTPAGSQGLPPHYDDVEVFILQLEGTKHWRLYSPTVPLAHEYSVE-SEDRIGT
D.rerio         QRFQDELWRIQERLECFFGCLVGSNVYITPAGAQGLPPHYDDVEVLILQLEGQKHWRLYEPTVPLAREYSLE-PEGRIGA
X.laevis        QRFNDALWHIMEKLECFFGALVGSNVYITPQDSQGLPAHYDDVEVFILQLEGEKRWRLYNPVVPLARDYSVV-PEDQIGS
H.vulgaris      QRYGTVLWQLMEKMETYFGCLVGSNVYITPKESQGLAPHCDDVEVFILQLEGTKHWKLYKPMVELSRDYTQDLSQDSIGE
                **:   **:: *::* :**.*******:**  :***  * *****:****** *:*:** * * *:::*:    :  ** 
                    
H.sapiens       PVHEFMLKPGDLLYFPRGTIHQADTPAGLAHSTHVTISTYQN---------------------------------NSWGD
M.musculus      PTHDFLLKPGDLLYFPRGTIHQAETPSGLAYSIHLTISTYQN---------------------------------NSWGD
D.rerio         PTHDFILQAGDLLYFPRGTIHQADTPAGAGHSTHLTLSTYQNMCVCAVHNVTHTHTHTLQNVLVLHSFIVCVRACRSWGD
X.laevis        PTHDFVLKPGDLLYFPRGVIHQAQALPGSSHSTHVTISTYQN---------------------------------NSWSD
H.vulgaris      PIMELTLEPGDLLYFPRGTIHQARS-VGESYSTHITLSTYQN---------------------------------NTLGD
                *  :: *: *********.**** :  * .:* *:*:*****                                 .: .*
H.sapiens       FLLDTISGLVFDTAKEDVELRTGIPRQLLLQVESTTVATRRL------------------S----GFLRTLADRLEGT-K
M.musculus      CLLDSISGFVFDIAKEDVALRSGMPRRMLLNVETPADVTRKL------------------S----GFLRTLADQLEGR-E
D.rerio         LLLDLMPGCVFDRMKTDCELRTGLPRGLLTTPSISPAVSHQL------------------S----VFLQRLADVVDHQGQ
X.laevis        YLQDLLPGILFDAAKANIDLRRGIPRQQILSLDTPGVI-QQI------------------S----SLLNTVAKGLESH-R
H.vulgaris      FMSIAVSQAIESALENDVNFRRGLPINYLSYLGTAKNFSKYFDEDGKESKLSSNENNEKVKKFKDSVKKHLSKLIDHIDV
                 :   :   : .  : :  :* *:*   :          : :                  .     . . ::. ::    
H.sapiens       ELLSSDMKKDFIMHRLPPYSAGDGAELSTPGGKLPRLDSVVRLQFKDHIVLTVLPD------------------------
M.musculus      ELLSSDMKKDFVKHRLPPFFEGNGTETMDPGKQLPRLDNIIRLQFKDHIVLTVGPD------------------------
D.rerio         TLRSSSMRRDFISHRLPPFVQDPQ--LLQPVGGAPALQDTVSLRFKDHLLLTVEPS------------------------
X.laevis        HIRSFEMLRDFMASRLPPFLDNKE--PGQTSGMPPKLNSTVQLLYRDYSFFTVDHV------------------------
H.vulgaris      NTAADMMSYDFMASRLPPFGHVVKEEQLN-EFKSPTLDSKIKLRYPEHVRPVYYDQEETDEADNTVGDDDSEDEEEETVK
                   :  *  **:  ****:               * *:. : * : ::   .                            
H.sapiens       ----------------------------------------QDQSDEAQEKMVYIYHSLKNSRETHMMGN------E-EET
M.musculus      ----------------------------------------KNPFDEAQQKVVYIYHSLKNVRQMHMIGE------E-EES
D.rerio         ----------------------------------------PDHTDEATELLVYVLHSLRNRRDTHMMMGASDEDEDDEES
X.laevis        ----------------------------------------AEESNAAAEQVVYVYHSLKNTRETHMMAM------QEEDR
H.vulgaris      KDEDEKNEEKDEKSPKSNKKSSDKKDTSMEGNEDEEDEDDDDASVHDDEPCIKIVHSLNNNRETHMSGH-------DLSR
                                                         :      :  : : ***.* *: **            . 
H.sapiens       EFHGLRFPLSHLDALKQIWNS-PAISVKDLKLTTDEEKESLVLSLWTECLIQVV-------
M.musculus      EIFGLRFPLSHVDALKQIWCG-SPIRVKDLKLDTDEEKENLALSLWSESLIQVL-------
D.rerio         QVGGLRFPLSHLEALQQLLVS-DRVPVEDLQLQQ-EDKLNLLLALWSEGLLRVTGALENHH
X.laevis        PVTGLRFPLPYANALKRIWES-ESVSVGKLPLDRDEDKENLALSLWTEGLLAIVP------
H.vulgaris      DVFSLKLPIHFAQAITSVMNSNDFICVRDLPLDDDEDKLQLATSLYSDDLIEIK-------
                 . .*::*: . :*:  :  .   : * .* *   *:* .*  :*::: *: :        
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M.musculus
D.rerio
X.laevis
H.vulgaris
H.sapiens
M.musculus
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X.laevis
H.vulgaris
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M.musculus
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X.laevis
H.vulgaris
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D.rerio
X.laevis
H.vulgaris
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To	 investigate	 the	 evolution	 of	MinA53	 and	 NO66,	multiple	 protein	 sequence	 alignments	
were	 conducted.	 Both	 proteins	 have	 a	 conserved	 domain	 structure	 consisting	 of	 a	 JmjC	
domain,	followed	by	a	dimerization	and	a	winged	helix	domain	(Figure	60	and	for	NO66	in	
Appendix	6.1.3	Figure	75).		
	
However,	several	amino	acid	 insertions	 longer	than	10	amino	acids	can	be	observed	in	the	
MINA53	protein	alignment	(Figure	60),	 like	in	D.rerio	 in	the	N-terminus	of	the	dimerization	
domain	or	 in	H.vulgaris	 in	 the	winged	helix	 domain	 (Figure	 60).	 The	 iron	binding	HxD...	H	
motif	is	conserved	in	all	species	(in	red,	Figure	60).	
	
2.3.3.2 Characterization	of	Hydra	vulgaris	MINA53	and	NO66	
Database	 searches	 in	 the	 basal	 pre-bilaterian	 cnidarian	 Hydra	 vulgaris	 genome126,127	
predicted	 two	 sequences	 encoding	 for	 Hydra	 MINA53	 (HvMINA53)	 and	 Hydra	 NO66	
(HvNO66).	Based	on	those	sequences,	both	genes	could	be	amplified	and	cloned	from	Hydra	
vulgaris	cDNA.	The	sequences	were	thereby	confirmed.		
Alignment	of	Hydra	proteins	with	the	human	homologues	revealed	that	the	sequences	are	
conserved	and	exhibited	of	the	same	domain	architecture.	The	Fe(II)	binding	motif	HxD/E…H	
as	 well	 as	 the	 2OG	 coordinating	 amino	 acid	 were	 conserved	 for	 both	 hvMINA53	 and	
hvNO66.	However,	whereas	NO66	protein	sequence	is	quite	conserved,	several	amino	acid	
insertions	 with	 more	 than	 10	 aa	 in	 MINA53	 were	 detected	 (Figure	 60	 and	 for	 NO66	 in	
Appendix	6.1.3	Figure	75).		
	
	
Figure	61:	Expression	of	Hydra	vulgaris	(hv)	GFP-tagged	MINA53	in	Hydra	animals;	A-C’’’	shows	hvMINA53-
GFP	positive	cells	in	fixed	Hydra	vulgaris	animals,	DNA	was	counterstained	with	DAPI	
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To	 examine	 conservation	 of	 both	 proteins,	 subcellular	 localization	 of	 HvMINA53	 and	
HvNO66	was	 analyzed.	 Expression	 of	 GFP-tagged	 proteins	 in	Hydra	 animals	 was	 analyzed	
upon	 transfection	 with	 a	 particle	 gun128.	 Confocal	 imaging	 of	 ectopically	 expressed	 GFP-
tagged	 HvMINA53	 revealed	 nuclear	 localization,	 but	 in	 contrast	 to	 the	 human	 MINA53,	
HvMINA53	lacks	accumulation	in	the	nucleoli	(Figure	61).	
	
	
Figure	62:	Expression	of	Hydra	vulgaris	 (hv)	GFP-tagged	NO66	 in	Hydra	animals;	A-C’’’	 shows	hvNO66-GFP	
positive	cells	in	fixed	Hydra	vulgaris	animals,	DNA	was	counterstained	with	DAPI.	
HvNO66	 showed	 nuclear	 localization	 with	 a	 prominent	 accumulation	 in	 nucleoli	 for	 the	
Hydra	protein	(Figure	62)	as	described	for	human	NO66.		
	
2.3.3.3 Genomic	analysis	of	MINA53	and	NO66	across	the	animal	kingdom	
Despite	high	conservation	of	protein	sequences,	MINA53	and	NO66	genes	show	differences	
on	genomic	level.	Whereas	human	MINA53	consists	of	9	exons	separated	by	introns,	human	
NO66	 is	 a	 so-called	 single	 exon	 gene	 (SEG),	 lacking	 introns.	 To	 investigate	 evolution	 of	
MINA53	and	NO66	genes	and	transcripts,	phylogenetic	studies	were	conducted.	
	
In	2017,	MINA53	and	NO66	were	renamed	to	RIOX2	 (MINA53)	and	RIOX1	 (NO66).	For	 the	
following	section,	RIOX1	and	RIOX2	were	used	for	the	transcript	names.	
Analyses	of	the	human	MINA53	and	NO66	genes	using	the	Ensembl	genome	browser	portal	
revealed	10	exons	for	human	MINA53	(RIOX2).	The	gene	encodes	9	different	transcripts	and	
comprises	9	coding	exons	and	alternatively	used	non-coding	5’-UTR	and	3’-UTR	exons.	The	
largest	 transcript,	 RIOX2-002	 (ENST00000333396.11),	 encodes	 a	 protein	 of	 465	 aa	 and	
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encompasses	a	locus	of	30639	base	pairs	(bp)	on	the	human	chromosome	3.	Surprisingly,	in	
contrast	 the	 human	 NO66	 (RIOX1)	 gene	 encodes	 one	 transcript	 RIOX1-003	
(ENST00000304061.7)	and	is	an	intronless	gene,	spanning	2428	bp	with	5’-	and	3’-UTRs	on	
chromosome	14.	
Initial	 analyses	 of	MINA53	 and	NO66	 in	 different	 organisms	 revealed,	 that	 not	 all	 encode	
both	proteins	(Figure	63).	In	Protostomia,	like	Drosophila	melanogaster	and	C.elegans,	only	
NO66	could	be	found.	
	
	
Figure	63:	Genomic	encoded	MINA53	and	NO66	in	different	organisms	
To	gain	further	 insights	 into	the	evolution	of	MINA53	and	NO66	genes,	more	species	 from	
the	animal	kingdom	were	included.	Amino	acid	sequences	of	MINA53	and	NO66	orthologues	
were	 identified	 in	 the	 Ensembl	 and	 EnsemblMetazoa	 genomic	 resources	 using	 the	human	
MINA53	 and	 NO66	 protein	 reference	 sequences	 in	 Protein	 BLAST	 (blastp)	 search	 (in	
collaboration	with	Andreas	Lengeling,	The	Roslin	Institute,	University	of	Edinburgh).		
In	Trichoplax	adhaerens	as	very	basic	metazoan	organism,	same	JmjC	protein	sequence	was	
found	 using	 MINA53	 or	 NO66	 sequences.	 This	 sequence	 consists	 -	 probably	 due	 to	 low	
quality	 of	 the	 published	 genome	 -	 of	 only	 the	 JmjC	 domain,	 lacking	 C-	 and	 N-termini.	
Therefore	 the	sequence	could	not	be	cleary	classified	 for	MINA53	or	NO66.	However,	 this	
sequence	was	used	and	acts	as	outgroup	to	root	the	phylogenetic	tree	(Figure	64). 
Comprehensive	 searches	 for	 MINA53	 and	 NO66	 sequence	 revealed	 for	 some	 of	 those	
species	 no	 MINA53	 (Figure	 64,	 in	 gray	 boxes).	 Model	 organisms	 Caenorhabditis	 elegans	
(C.elegans)	 and	Drosophila	melanogaster	 (D.melanogaster)	 only	 encode	NO66	 (Figure	 63),	
the	same	is	true	for	additional	 invertebrate	species	from	arthropoda,	mullosca,	nematoda,	
and	 annelida.	 Whereas	 Clonorchis	 sinensis	 and	 the	 two	 organisms	 of	 the	 Caenorhabditis	
genus	 have	 only	 NO66,	 two	 other	 organisms	 of	 the	 platyhelminthes	 phylum	 Ciona	
intestinales	and	Ciona	savingyi	contain	MINA53	and	NO66.	The	fresh-water	polyp	Hydra	as	
ClassPhylum NO66 MINA53
Homo sapiens (hs) Chordata Mammalia + +
Mus musculus (mm) (mouse) Chordata Mammalia + +
Gallus gallus (gg) (chicken) Chordata Aves + +
Danio rerio (dr) ( ) Chordata Actinopterygii + +
Rattus norvegicus (rn) (brown rat) Chordata Mammalia + +
Biomphalaria glabrata (bg) (freshwater snail) Mollusca Gastropoda + -
Strongylocentrotus purpuratus (sp) (purple sea urchin) Echinodermata Echinoidea + +
Xenopus laevis (xl) (african clawed frog) Chordata Amphibia + +
Monodelphis domestica (md) (gray short-tailed opposum) Chordata Mammalia + +
Tribolium castaneum (tc) ( ) Arthropoda Insecta + -
Latimeria chalumnae (lc) (west indian ocean coelacanth) Chordata Sarcopterygii + +
Capitella teleta (ct) Annelida Polychaeta + -
Clonorchis sinensis (cs) ( ) Platyhelminthes Trematoda + -
Ciona intestinalis (ci) (sea squirt) Chordata Tunicata + +
Drosophila melanogaster (dm) ( ) Arthropoda Insecta + -
Caenorhabditis elegans (ce) Nematoda Chromadorea + -
Hydra vulgaris (hv) Hydrozoa(freshwater polyp) Cnidaria + +
Protostom
ia
zebra fish
fruit fly
red flour beetle
chinese liver fluke
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early	 metazoan	 animal	 of	 the	 phylum	 Cnidaria	 also	 posseses	 both	 MINA53	 and	 NO66	
sequences	(Figure	63	and	Figure	64).		
	
	
Figure	 64:	 Phylogenetic	 tree	 for	 MINA53	 and	 NO66	 JmjC	 domains	 in	 different	 organisms;	 maximum	
likelihood	tree	was	generated	using	ClustalW-MAFFT-Alignment,	ML-IQTree	by	Evi	Lengeling-Wollscheid	(The	
Roslin	Institute,	University	of	Edinburgh),	support	values	are	written	on	the	branches	and	are	reliable	from	
80%	 for	 the	 first	 and	 95%	of	 the	 second	 value;	 highlighted	 in	 blue	MINA53	 containing	 organisms,	 in	 light	
green	single	exon	genes	in	mammalia	and	aves,	in	gray	organisms	encoding	only	NO66.	
MinA53 or NO66 
Trixoplax adhaerens
52.5/65
88.8/72
84.1/61
66/22
88.5/63
99.9/100
86.2/91
82.7/98
99.9/100
99.9/100
93.6/100
89/98 NO66- Xenopus laevis
NO66- Latimeria chalumnae
81/91 NO66- Danio rerio
NO66- Petromyzon marinus
NO66- Helobdella robusta
NO66- Priapulus caudatus
92.5/51
86.2/36
NO66- Strongylocentrotus purpuratus
74.7/54
70.8/73
89.3/86
9.3/23
89.4/89
100/100
98.8/100
NO66- Tribolium castaneum
NO66- Lepeophtheirus salmonis
63.7/41
80.9/84 NO66- Hydra vulgaris
NO66- Clonorchis sinensis
91.5/82
100/99
99.9/100 NO66- Caenorhabditis elegans
NO66- Caenorhabditis briggsae
NO66- Loa loa
100/97
8.9/52
79.9/61
92.5/95
98.2/100
94.2/52
90.7/52
MINA53- Homo sapiens
85.3/51
86.5/100 MINA53- Mus musculus
MINA53- Rattus norvegicus
MINA53- Danio rerio
72.8/56
MINA53- Monodelphis domestica
92.4/59 MINA53- Gallus gallus
MINA53- Latimera chalumnae
MINA53- Xenopus laevis
MINA53- Petromyzon marinus
60.7/88
MINA53- Strongylocentrotus purpuratus
100/100 MINA53- Ciona intestinales
MINA53- Ciona savingyi
MINA53- Priapulus caudatus
23.9/48 MINA53- Hydra vulgaris
YcfD- Escherichia coli
92.6/98
92.5/99
81.9/99 NO66- Biomphalaria glabrata
NO66- Crassostrea gigas
NO66- Lottia gigantea
69.6/90 NO66- Lingula anatina
NO66- Capitella teleta
99.9/100 NO66- Ciona intestinales
NO66- Ciona savingyi
1.01
NO66- Amphinedon queenslandica
18
14
12
18
14
12
10
11
NO66- Aedes aegypti
NO66- Drosophila melanogaster
NO66- Bombyx mori
NO66- Heliconius melpomene
NO66- Atta cephalotes
NO66- Apis mellifera
NO66- Gallus gallus
NO66- Mus musculus
NO66- Rattus norvegicus
NO66- Monodelphis domestica
NO66- Homo sapiens
   Exon number   
1
1
1
1
1
13
15
13
13
17
11
18
2
1
3
2
6
6
3
7
15
12
5
5
16
Mammalia
Aves
Arthro-
poda
MINA53
Chordata
Annelida
Platyhelminthes
Nematoda
Mollusca
Poriphera
Annelida
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In	addition	to	the	observation,	that	MINA53	is	not	present	in	some	species,	further	genomic	
analysis	revealed,	that	NO66	exists	as	single	exon	gene	(intron-less	gene)	in	some,	but	not	all	
species	(Figure	64).	In	the	phylogenetic	tree	of	the	JmjC	domains	of	MINA53,	NO66,	and	YcfD	
also	exon	numbers	are	provided	for	NO66.	In	the	examinated	Chordata,	the	mammals	with	
Homo	 sapiens,	Mus	 musculus,	 Rattus	 norvegicus,	 and	Monodephis	 domestica	 as	 well	 as	
Gallus	gallus	as	member	of	the	avian	lineage,	NO66	consists	as	single	exon	gene.	The	insecta	
have	 NO66	 encoded	 as	 a	 gene	 with	 one	 to	 six	 exons.	 Other	 clades	 like	 for	 example	 the	
mollusca	 -	 represented	 here	 by	 Biomphalaria	 glabrata,	 Crassostrea	 gigas,	 and	 Lottia	
gigantea	 -	 exhibit	 NO66	 as	multi-exon	 gene	 (more	 than	 10	 exons).	 Fish,	 amphibians	 and	
other	chordates	all	possess	NO66	genes	with	up	to	15	exons	(Latimeria	chalumnae).	
MINA53	JmjC	domains	cluster	in	one	branch	and	can	be	clearly	separated	from	NO66	(Figure	
64).	 JmjC	 domain	 from	 the	 bacterial	 ancestor	 YcfD	 being	 in	 one	 branching	 node	 with	
HvMINA53	suggests	an	early	invention	of	MINA53.	
	
Strong	support	for	NO66	Jmjc	domains	relatedness	is	given	for	closely	related	taxa	(D.rerio	+	
O.latipes,	B.mori	+	H.melpomene)	or	higher	taxa	ranks	(e.g.	Mammalia,	Chordata,	Mollusca).	
Low	node	 support	 (e.g.	H.robusta	 +	Chordata,	S.purpuratus	 +	L.salmonis/Insecta)	 indicates	
that	 additional	 research	 is	 needed	 to	 fully	 understand	 the	 evolution	 of	 this	 gene	 and	 its	
functional	diversification.		
	
These	analyses	rise	the	question	of	the	advantage	of	human	NO66	to	be	a	single	exon	gene.	
If	 MINA53	 or	 NO66	 is	 the	 evolutionary	 more	 conserved	 protein,	 can	 not	 be	 cleary	
determined	and	needs	further	examination.	
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3 Discussion	
3.1 Ribosomal	oxygenase	OGFOD1	
CCNA2	as	novel	interactor	of	OGFOD1	
With	 different	 assays,	 interaction	 of	 CCNA2	 and	 OGFOD1	 could	 be	 confirmed.	 The	 N-
terminal	 DSBH	 of	 OGFOD1	 was	 found	 to	 be	 crucial	 for	 binding.	 The	 N-terminal	 domain	
harbours	the	motif	for	iron	binding	and	displays	the	catalytically	active	domain.	However,	as	
also	the	iron	binding	defective	AxA	mutant	was	able	to	bind,	the	catalytic	activity	of	OGFOD1	
is	 not	 determining	 interaction	 capability.	 In	 CCNA2	 the	 interacting	 domain	 could	 not	 be	
determined,	in	vivo	and	in	vitro	assays	led	to	contrary	results.	
	
Cyclin	A	is	one	of	the	major	regulators	of	the	cell	cycle.	The	mainly	nuclear	cyclin	A	(CCNA2)	
protein	 can	 be	 detected	 from	 S-phase	 until	 mitosis,	 where	 it	 is	 rapidly	 degraded	 in	
prometaphase109,129,130.	In	S	phase,	CCNA2	is	bound	to	cyclin	dependent	kinase	2	(CDK2)	and	
involved	 in	 initiation	and	termination	of	DNA	replication.	During	G2/M	transition	CCNA2	 is	
associated	with	CDK1	and	needed	 for	 the	activation	of	 the	other	main	cell	 cycle	 regulator	
Cyclin	B,	probably	by	regulating	its	translocation	to	the	nucleus131,132.	 In	prometaphase	the	
sudden	degradation	of	CCNA2	 is	crucial	 for	 the	stabilization	of	kinetochore-microtubuli	 for	
the	 correct	 chromosome	 segregation133,	 ectopical	 overexpression	 can	 even	 lead	 to	
chromosomal	 double	 strand	 breaks134.	 Missregulated	 CCNA2	 causes	 major	 defects	 in	 cell	
cycle	progression133-136.	
The	exact	 functions	of	CCNA2	and	 the	 regulation	by	and	 throughout	 the	cell	 cycle	are	still	
ongoing	 research.	 Mechanisms	 regulating	 CCNA2	 were	 identified,	 like	 post-translational	
modifications	of	CCNA2.	Acetylations	of	CCNA2	affect	its	stability,	as	acetylated	CCNA2	gets	
ubiquitinylated	 by	 the	 anaphase-promoting	 complex	 (APC/C)	 and	 subsequently	
degraded137,138.	
In	 mass	 spectromtry	 (MS),	 several	 prolines	 in	 CCNA2	 with	 potential	 hydroxylation	 were	
identified.	 However,	 in	 three	 different	 experiments	 with	 recombinant,	 endogenous,	 and	
Flag-tagged	 CCNA2,	 each	 time	 different	 prolines	 were	 suggested	 to	 be	 hydroxylated.	 A	
limiting	factor	was	also	protein	coverage	of	CCNA2.	In	the	best	case,	62	%	of	CCNA2	protein	
sequence	was	detected,	therefore	several	prolines	could	not	be	analyzed	(Figure	65	A).	Still,	
three	candidate	peptides	were	chosen	based	on	mass	spectrometry	(Figure	65	B	and	C)	for	a	
peptide	hydroxylation	assay.		
	
High	 conservation	 scores	 of	 P114	 in	 peptide	 2	 (Figure	 65	D)	 and	 P137	 in	 peptide	 3	made	
them	 good	 candidates	 for	 hydroxylation	 by	 OGFOD1	 which	 might	 even	 be	 conserved	
through	 evolution.	 Due	 to	 high	 conservation,	 P402	 would	 also	 be	 interesting	 for	 further	
analysis.		
	
Attempts	 to	 identify	 hydroxylation	 of	 those	 peptides	 by	 OGFOD1	 were	 performed	 by	
cooperation	partner	Cyrille	Thinnes	(C.	Schofield	laboratory,	Chemistry	Research	Laboratory,	
Oxford)	 using	 a	MALDI-TOF	 based	 assay.	Whereas	 the	 established	 positive	 control	 with	 a	
RPS23	peptide5	proved	the	activity	of	recombinant	OGFOD1	in	such	an	assay,	the	CCNA2	20-
mer	peptides	did	not	show	any	hydroxylation	associated	mass	shift.	
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Figure	 65:	 Schematic	 overview	 of	 domains	 of	 CCNA2;	 A)	 coverage	 of	 CCNA2,	 dashed	 boxes	 indicate	 not	
covered	sequences;	B)	identified	potential	hydroxy	prolines	by	LC-MS/MS;	C)	selected	peptides	being	tested	
using	 petide	 hydroxylation	 assay	 based	 on	 MALDI-TOF,	 D)	 conservation	 of	 potential	 hydroxy	 prolines;	
alignments	were	generated	with	ClustalOmega,	conservation	graphes	by	JalView.	
Different	peptide	lengths	or	additional	protein	domains	of	CCNA2	might	be	needed	for	this	
in	 vitro	 approach.	 Limitations	 of	 this	 assay	 were	 already	 reported	 in	 2009139.	 Lysine	
hydroxylation	 in	 U2AF65	 by	 JMJD6	 could	 be	 detected	 with	 LC-MS/MS,	 but	 testing	 the	
corresponding	peptides	with	MALDI-TOF	showed	no	enzyme	activity	of	JMJD6	towards	the	
distinct	 lysines139.	 Therefore,	 in	 addition	 to	 the	 local	 hydroxylation	 site,	 other	 domains	 in	
CCNA2	 may	 be	 important	 for	 the	 binding	 and	 the	 catalytic	 activity	 of	 OGFOD1.	 Further,	
structural	factors	supporting	the	interaction	might	be	needed.	Using	full	length	CCNA2	from	
cell	 extracts	 in	 the	 in	 vivo	 CCNA2	 IPs	 analyzed	by	 LC-MS/MS,	 instead	of	pure	peptide	and	
recombinant	OGFOD1	could	supply	the	reaction	with	potential	helping	factors.	
To	define	CCNA2	as	substrate	of	OGFOD1	and	identify	hydroxylated	prolines,	other	methods	
should	 be	 used	 like	 a	 more	 sensitive	 mass	 spectrometry	 approach	 or	 MALDI-TOF	 with	
peptides	of	variable	length	or	full	length	CCNA2.	
	
	
OGFOD1	influencing	the	cell	cycle?	
OGFOD1	 expression	 did	 not	 change	 throughout	 the	 cell	 cycle,	 also	 the	 interaction	 with	
CCNA2	showed	no	cell	 cycle	dependency.	Direct	binding	of	OGFOD1	to	CCNA2,	which	was	
not	 in	 complex	 with	 CDK2,	 could	 point	 towards	 a	 CDK-independent	 function	 of	 CCNA2	
beyond	 the	 cell	 cycle.	 A	 recent	 report	 assigned	 CCNA2	 a	 CDK-independent	 role	 as	 RNA	
binding	protein	 specifically	binding	Mre11	mRNA	and	 thereby	promoting	 its	 translation140.	
More	 experiments	 concerning	 the	 nature	 of	 CCNA2-OGFOD1	 with	 regards	 to	 potential	
additional	interaction	factors	or	to	cell	cycle	timing	should	be	conducted.	
	
However,	 OGFOD1	 was	 found	 to	 directly	 influence	 the	 cell	 cycle.	 IP	 of	 CCNA2	 with	
concurrent	overexpression	of	OGFOD1	led	to	a	change	of	the	CCNA2	interactome.	Proteins	
like	Replication	protein	A	70	kDa	DNA-binding	subunit	(RPA1)	and	Replication	protein	A	32	
kDa	subunit	(RPA2)	were	enriched	in	OGFOD1	overexpressing	samples.	RPA1	and	RPA2	are	
D-Box Cyclin box 1 432Cyclin box 21CCNA2 coverage 
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components	of	the	heterotrimeric	replication	protein	A	complex	(RPA).	The	complex	 is	the	
major	single-stranded	DNA	binding	protein	in	eukaryotic	cells.	It	binds	and	thereby	stabilizes	
single-stranded	DNA	intermediates	that	occur	during	DNA	replication	or	as	response	to	DNA	
damage141,142.	 Additionally,	 the	 complex	 binds	 proteins	 involved	 in	 DNA	 replication,	 DNA	
repair,	 and	 recombination143.	 In	 1996,	 the	 interaction	 of	 CCNA2	 and	 RPA2	 and	 RPA2	
phosphorylation	mediated	 by	 the	 CDK2-CCNA2	 complex	was	 shown	 by	 in	 vitro	 data144.	 In	
order	to	confirm	interaction	of	CCNA2	with	RPA1	and	RPA2	in	cells	we	immunoprecipitated	
endogenous	CCNA2	from	293T	cells	and	identified	CCNA2	binding	proteins	with	LC-MS.	We	
were	able	to	co-precipitate	well-known	CCNA2	interactors	like	CDC20145,	CDK1	and	CDK2146,	
but	 also	 RPA1	 and	 RPA2	 specifically	 when	 compared	 with	 control	 IP	 experiment.	 In	 an	
overexpression	system	with	Flag-CCNA2	and	untagged	OGFOD1	and	OGFOD1	AxA,	RPA2	was	
highly	enriched	 in	 the	Flag-CCNA2	 IP	 sample	 in	 comparison	 to	a	 control.	 This	would	 imply	
that	 enzymatic	 activity	 of	 OGFOD1	 is	 not	 involved	 in	 the	 regulation	 of	 the	 CCNA2	
interactome.	 Initial	experiments	determining	the	progression	of	synchronized	cells	through	
the	 cell	 cycle	 revealed	 some	 delay	 for	 GFP-OGFOD1	 expressing	 cells.	 Cell	 overexpressing	
NLS-GFP	 proceeded	 with	 no	 observable	 time	 lag,	 indicating	 an	 effect	 of	 OGOFD1	
overexpression	on	the	cell	cycle.		
	
In	a	 recent	 report,	a	 role	of	OGFOD1	 in	cell	proliferation	was	shown	 in	breast	cancer	cells	
and	chronic	 lymphocytic	 leukemia,	where	OGFOD1	displayed	a	high	expression91,92.	On	the	
other	 hand,	 knockdown	 in	 breast	 cancer	 cells	 led	 to	 the	 accumulation	 of	 cells	 in	G1-	 and	
G2/M	phase.	 Following	 this,	 the	 authors	 assigned	OGFOD1	 a	 role	 in	 cell	 proliferation	 and	
tumorigenesis	 and	 propose	 a	 translation-independent	 role	 for	 OGFOD1	 in	 cell	 cycle	
regulation92.	 Recently,	 using	 a	 whole	 cell	 proteomics	 approach	 these	 findings	 were	
corroborated.	In	this	setting,	siRNA	induced	OGFOD1	knockdown	led	to	a	strong	reduction	of	
cells	in	S-phase93.	
	
	
Interaction	of	OGFOD1	with	the	translation	regulator	eEF2K	
Recently,	 proline	 98	 of	 eukaryotic	 elongation	 factor-2	 kinase	 (eEF2K)	 was	 found	 to	 be	
hydroxylated.	This	post-translational	modification	(PTM)	of	eEF2K	restrained	its	activity	and	
might	in	turn	regulate	translation	via	eukaryotic	elongation	factor	2	(eEF2)118.	As	not	many	
proline	 hydroxylases	 were	 identified	 yet,	 we	 were	 interested	 if	 OGFOD1	 is	 the	 so	 far	
unknown	enzyme	modifying	eEF2K.	In	intitial	IP	experiments,	eEF2K	could	be	co-precipitated	
with	OGFOD1.		
	
Translation	 is	 regulated	 and	 repressed	 during	 distinct	 phases	 of	 the	 cell	 cycle	 and	 during	
stress119,147.	eEF2K	seems	to	provide	one	mechanisms	to	stall	translation	by	phosphorylating	
eEF2.	This	 inhibiting	phosphorylation	of	eEF2	threonin	56	 (T56)	prevents	 its	binding	to	 the	
ribosome	 and	 thereby	 impairs	 translation	 elongation148.	 EEF2K	 is	 regulated	 by	 different	
pathways	like	mTOR	signaling,	nutrient	starvation,	or	oxidative	stress	via	phosphorylation	by	
the	 AMP	 kinase149.	 Recently,	 a	 serine	 phosphorylation	 (S595)	 of	 eEF2	 carried	 out	 by	 the	
CCNA2-CDK2	complex	was	 identified	and	contributes	to	eEF2’s	regulation149.	This	cell	cycle	
dependent	phosphorylation	seems	to	 facilitate	 the	 following	 inhibitory	phosphorylation	by	
eEF2K.	 In	 mitosis,	 S595	 and	 T56	 phosphorylations	 are	 increased,	 probably	 resulting	 in	
repressed	translation	as	it	is	known	for	M	phase14	(Figure	66).		
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Figure	66:	Schematic	overview	of	eEF2K	and	eEF2	regulation	
The	 CCNA2-CDK2	 dependent	 modificiation	 might	 be	 one	 mechanism	 to	 couple	 cell	 cycle	
progression	 with	 translation149.	 This	 cell	 cycle	 regulated	 translation	 inhibition	 might	 be	
mediated	 by	 OGFOD1-catalyzed	 eEF2K	 hydroxylation.	With	 the	 F2H	 assay	 this	 interaction	
could	not	be	confirmed.	In	this	experiment,	Flag-tagged	eEF2K	was	used.	This	tag	might	not	
be	 ideal	 for	 this	 assay,	 therefore,	 the	 experimental	 set-up	 could	 be	 further	 adjusted	 to	
confirm	 this	 interaction.	 Following,	mass	 spectrometry	based	experiments	and	MALDI-TOF	
peptide	screening	with	the	reported	hydroxylated	proline	could	be	performed	to	determine	
OGFOD1	as	responsible	prolyl	hydroxylase.	
	
	
OGFOD1	correlation	with	stress	granules	(SGs)	
To	unravel	 the	 function	of	OGFOD1	 in	SGs,	 first	 the	 formation	of	SGs	was	monitored	over	
time.	SGs	could	be	detected	by	TIA-1	recruitment	15	min	after	stress	induction.	Endogenous	
OGFOD1	was	recruited	 to	SGs	after	30	min.	Overexpressed	OGFOD1	 independently	of	 size	
and	location	of	the	tag	was	not	recruited	to	stress	granules,	even	though	TIA-1	role	 in	SGs	
could	 be	 studied	with	 GFP-tag150.	 Tagged	OGFOD1	might	 be	 disturbed	 in	 interaction	with	
proteins	needed	for	its	recruitment	towards	SGs.	
	
Translocation	of	the	nuclear	protein	OGFOD1	towards	cytoplasmic	stress	granules	(SGs)	was	
already	 reported5,89.	 Interacting	 proteins	 comprised	 some	 stress	 granule	 proteins,	 the	
eIF2alpha	 kinase	 heme-regualted	 inhibitor	 (HRI),	 and	 eIF2alpha	 itself.	 Overexpression	 of	
OGFOD1	 resulted	 in	decreased	polysome	 levels	and	 increased	amounts	of	phosphorylated	
eIF2alpha	 during	 recovery	 from	 stress89.	 Knockdown	 on	 the	 other	 hand	 led	 to	 enhanced	
recovery	of	translation	by	enhanced	polysome	formation	during	the	recovery	from	stress89.	
	
To	further	explore	function	and	relevance	of	OGFOD1	in	stress	granules,	isolation	of	SGs	and	
analysis	of	the	composition	could	be	performed.	To	study	OGFOD1	domains	needed	for	the	
translocation,	reported	interactors	related	with	stress	granules	could	be	further	examined.		
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Attempts	to	generate	OGFOD1	knockout	cell	lines	
Generation	 of	 OGFOD1	 knockout	 cell	 lines	 in	 Hek293	 cells	 was	 not	 possible,	 only	 one	
heterozygous	 knockout	 clone	 could	 be	 generated.	 In	 contrast,	 generation	 of	MINA53	 and	
NO66	knockouts	in	Hek293	cells	was	successful.	Judging	from	protein	levels	of	wild	type	and	
OGFOD1	 D2	 +/-	 cells,	 protein	 levels	 seemed	 even	 to	 be	 compensated	 by	 the	 remaining	
OGFOD1	 gene	 copy.	 Considering	 the	 unchanged	 protein	 amount	 and	 a	 growth	 behaviour	
comparable	 to	wild	 type	 cells,	 also	 the	 ribosomal	profile	of	 the	heterozygous	OGFOD1	D2	
cells	 did	 not	 differ	 from	 wild	 type.	 Analysis	 of	 the	 ribosomes	 by	 MS	 confirmed	 the	
compensation	 of	 OGFOD1	 protein	 levels,	 as	 the	 RPS23	 P62	 was	 only	 identified	 in	 the	
hydroxylated	status	in	OGFOD1	D2	cells.		
A	 second	 attempt	 to	 generate	 homozygous	 knockout	 cells	 starting	with	 the	 heterozygous	
clone	did	not	succeed	and	resulted	 in	no	surviving	cells.	This	 led	us	to	the	conclusion,	that	
OGFOD1	knockout	 in	Hek293	cell	 is	 lethal.	These	findings	support	a	role	of	OGFOD1	in	cell	
cycle	progression.	
	
However,	OGFOD1	does	not	seem	to	be	essential	in	all	cell	lines	or	organisms.	In	S.cerevisiae	
knockout	of	the	homologue	Tpa1	did	cause	only	minor	defects20.	On	the	contrary,	depletion	
of	 OGFOD1	 homologue	 Sud-1	 in	 D.	 melanogaster	 caused	 lethality	 in	 early	 embryonic	
development44.	In	mammalian	cell	culture	,	siRNAs	targeting	OGFOD1	caused	marked	effects	
on	 proliferation	 in	 HCT116,	 Hek293,	 and	 other	 cell	 lines.	 In	 HeLa,	 despite	 efficient	 knock	
down,	no	effect	was	observable5.	Saito	and	colleagues	were	even	able	to	generate	OGFOD1	
knockouts	in	Nalm-6	cells,	a	human	pre-B	acute	lymphoblastic	leukemia	cell	line90.	
With	regard	to	this	dependency	on	the	cellular	background,	another	cell	line	could	be	used	
for	generation	of	knockout	cell	lines.	Rescue	of	the	knockout	with	different	OGFOD1	variants	
could	then	be	used	for	the	characterization	of	OGFDO1’s	function	with	regards	to	ribosome	
regulation,	cell	cycle	involvment,	and	the	function	in	stress	granules.	
	
	
3.2 Bacterial	oxygenase	ycfD	
Whereas	 knockout	 of	 OGFOD1	was	 not	 possible,	 generation	 of	 bacterial	 knockout	 strains	
lacking	 ycfD	 seemed	 to	 have	 no	 negative	 effect	 on	 bacteria.	 Earlier	 studies	 showed	 that	
overexpression	 of	 His-tagged	 ycfD	 led	 to	 tremendous	 growth	 defects,	 the	 comercially	
available	 Keio	 ycfD	 knockout	 strain	 JW1114-2103	 was	 viable4,46.	 However,	 under	 stress	
conditions	 like	 growth	 in	 minimal	 medium,	 growth	 defects	 of	 the	 knockout	 strain	 were	
observed4.	
YcfD	 knockout	 strains	 generated	 in	 this	 work	 are	 slightly	 different,	 as	 Keio	 collection	
knockouts	are	 full	 genomic	knockouts.	 In	 this	work,	 the	 first	 and	 last	50	basepairs	of	 ycfD	
were	used	for	the	recombination	event,	therefore	the	knockout	strain	might	still	express	the	
first	amino	acids	of	ycfD	followed	by	the	counter	selection	cassette.	However,	the	enzymatic	
JmjC	domain	is	completely	lost,	leading	us	to	the	assumption	of	the	loss	of	catalytic	activity	
of	ycfD.		
With	 the	 strains	 generated	 in	 this	 work,	 the	 observed	 growth	 defects	 could	 not	 be	
recapitulated.	 Also	 the	 ycfD-AxA	 strain	 lacking	 catalytic	 activity	 displayed	 normal	 growth	
behaviour.	 Consistently,	 ribosome	profiles	of	 knockout	 and	AxA	mutant	 strain	obtained	 in	
this	 work	 did	 not	 display	 obvious	 effects,	 suggesting	 normal	 ribosomal	 assembly	 and	
translation	activity.	However,	 the	 reported	growth	phenotype	with	 JW1114	could	also	not	
be	 resumed,	 ribosome	 profiles	 of	 this	 strain	 were	 comparable	 to	 wild	 type	 profiles.	 For	
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future	experiments,	the	genomic	surrounding	of	ycfD	in	JW1114	should	be	further	evaluated	
to	exclude	residual	ycfD	expression.	
	
YcfD	catalyzed	hydroxylation	of	arginine	81	in	RPL16	occurs	at	a	prominent	localization	in	the	
ribosome,	in	closest	proximity	to	the	peptidyl	transferase	center	(PTC)	in	the	ribosome.	L16	
itself	 is	 needed	 for	 formation	 of	 the	 70S	 initiation	 complex47,	 for	 the	 peptidyl	 transferase	
activity48,	 and	 to	 coordinate	 and	 stabilize	 the	 binding	 of	 A-site	 tRNAs49.	 Despite	 the	
important	functions	of	RPL16	in	the	ribosomal	context,	the	hydroxylation	by	ycfD	seems	not	
to	be	essential	in	bacteria.	
Also	 monooxygenase	 yfcM	 knockout	 in	 Salmonella	 grows	 phenotypically	 normal151.	 YfcM	
hydroxylates	 lysinylated	Lys	34	of	the	conserved	translation	elongation	factor	P	(EF-P),	this	
modification	 is	 the	 final	 step	 in	 maturation	 of	 EF-P152.	 EF-P	 is	 needed	 for	 translation	
elongation	and	stimulates	peptide	bond	formation	at	the	P	site151.	EF-P	is	also	reported	to	be	
critial	for	rapid	translation	of	polyproline	stretches,	which	cause	translational	pausing.	Still,	
knockout	of	EF-P	causes	only	a	minor	growth	rate	reduction153,154.	Loss	of	hydroxylation	 in	
EF-P	seems	to	be	as	harmless	to	bacteria	as	loss	of	hydroxylation	of	R81	in	RPL16.	This	might	
suggest,	 that	even	 if	universal,	 certain	modifications	only	 fine-tune	 translation	but	are	not	
essential.	
	
	
3.3 Histidine	hydroxylases	MINA53	and	NO66	
Characterization	of	knockout	strains	
Knockout	 of	 human	MINA53	 and	 NO66	 in	 Hek293	 using	 CRISPR/Cas9	 showed	 only	minor	
growth	defects	and	ribosome	profiles	also	 revealed	no	differences	compared	to	wild	 type.	
The	 reconstituted	 cell	 lines	 did	 also	 not	 show	 drastic	 effects	 on	 the	 proliferation,	 even	
though	 reconstituted	 protein	 expression	 was	 much	 higher	 than	 endogenous	 MINA53	 or	
NO66	expression.	Despite	these	observations,	both	proteins	are	described	to	be	involved	in	
cancer	 cell	 growth.	MINA5355-70	was	 reported	 to	be	upregulated	 in	different	 cancer	 types,	
NO66	plays	a	role	in	osteoblast	differentiation79	and	bone	formation	in	mice81,82.	
Their	 similarities	 concerning	 protein	 domain	 structure	 and	 crystal	 structure,	 ribosomal	
substrates,	 and	 subcellular	 localization	 might	 suggest	 a	 redundancy	 of	 both	 proteins.	
Therefore,	 a	 double	 knockout	 of	 MINA53	 and	 NO66	 could	 be	 an	 option	 to	 examine	 this	
hypothesis.	
	
	
Phylogenetic	and	genomic	studies	for	MINA53	and	NO66	
The	 special	 genomic	 situation	 of	 NO66	 and	 the	 question	 of	 redundancy	 of	 MINA53	 and	
NO66	led	us	to	a	genomic	and	phylogenetic	approach.		
Searching	 for	MINA53	and	NO66	 sequences	 in	different	organisms	 revealed,	 that	 some	of	
those	species	did	not	exhibit	MINA53	sequences.	Model	organisms	Caenorhabditis	elegans	
(C.elegans)	and	Drosophila	melanogaster	 (D.melanogaster)	only	encode	NO66,	the	same	 is	
true	 for	 other	 invertebrate	 species	 from	 arthropoda,	 mullosca,	 nematoda,	 and	 annelida.	
Suprisingly,	 the	 fresh-water	polyp	Hydra	 as	early	metazoan	animal	of	 the	phylum	Cnidaria	
posseses	both	MINA53	and	NO66	sequences.		
Expression	 of	 both	 Hydra	 NO66	 with	 GFP-tag	 in	 Hydra	 vulgaris	 showed	 a	 comparable	
subcellular	 distribution	 for	NO66.	Human	 as	well	 as	HvNO66	 are	 localized	 in	 the	 nucleoli.	
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Hydra	MINA53	in	contrast	to	human	protein,	is	localized	to	the	nucleus,	but	not	the	nucleoli	
in	Hydra	 vulgaris.	 This	might	be	 a	hint	 towards	 an	 adapted	or	 slighly	 changed	 function	of	
MINA53	 through	 out	 the	 evolution,	 whereas	 NO66	 might	 have	 kept	 the	 same	 function.	
However,	 this	 hypothesis	 needs	 further	 experiments.	 NO66	 function	 in	 C.elegans	 or	
D.melanogaster	 could	 be	 examined,	 also	 organisms	 harboring	 both	 proteins	 sequences	
could	be	analyzed	for	MINA53	and	NO66	protein	functions.	
	
Whereas	MINA53	 –	 as	 91%	 of	 eukaryotic	 genes155	 -	 consists	 of	 introns	 and	 exons,	 NO66	
consists	of	only	one	exon	and	 is	therefore	 intronless	(single	exon	gene,	SEG).	Whereas	the	
mammalia	and	chicken	as	representative	of	 the	aves	possess	NO66	with	only	one	exon,	 in	
protostomia	NO66	gene	consists	of	a	high	exon	number	up	to	18	exons	separated	by	introns.	
The	arthropoda	harbour	one	exon	(D.melanogaster)	up	to	seven	exons.	Neither	did	the	exon	
number	decrease	consistently	over	evolution,	nor	consists	NO66	as	single	exon	gene	only	in	
organisms	harboring	both	MINA53	and	NO66	gene.	
Intronless	 genes	 are	 a	 characteristic	 feature	of	 prokaryotes,	 but	 still	 ca.	 9%	of	 the	human	
encoding	genes	consist	of	only	one	exon155.	All	histons,	around	50%	of	the	G-protein	coupled	
receptors	 (GPCRs)	 and	 several	 proteins	 involved	 in	 transcription	 and	 translation,	 are	
encoded	 by	 intronless	 genes156.	 Advantages	 of	 SEGs	 might	 be	 of	 economical	 nature.	
Generating	 mRNAs	 with	 introns	 would	 need	 more	 time	 and	 energy,	 splicing	 requires	
additional	 factors.	 On	 the	 other	 hand,	 intron	 containing	 genes	 would	 allow	 diversity	 in	
protein	products	by	alternative	splicing155-157.	
NO66	 might	 be	 a	 single	 exon	 gene	 to	 allow	 the	 cell	 to	 react	 quickly	 to	 changing	
environmental	or	stress	conditions.	This	might	change	the	hydroxylation	status	of	ribosomal	
protein	 RPL8,	 which	 could	 fine-tune	 translation	 in	 response	 to	 different	 stimuli.	
Nevertheless,	 the	research	about	SEGs	 is	 just	at	 the	beginning	to	unravel	 the	function	and	
the	importance	of	being	intronless.	However,	NO66	is	the	only	human	2OG	oxygenase	with	
no	introns.	
	
In	 addition,	 the	 phylogenetic	 analysis	 implies	 that	 MINA53	 could	 be	 the	 earlier	 invented	
protein	due	to	the	branching	of	ycfD	and	MINA53.	The	consistency	of	NO66	being	present	in	
all	studied	organisms	might	contradict	 this.	Others	suggest	ycfD	to	be	evolved	 into	NO666.	
However,	 they	used	not	 only	MINA53	 and	NO66	but	 also	other	 2OG	oxygenases	 for	 their	
phylogenetic	analyses.	
	
	
Studies	concerning	the	connection	of	dimerization	and	catalytic	activity	
A	 few	2OG	oxygenases	are	 reported	 to	 form	homo-dimers	or	 -multimers,	but	not	much	 is	
known	about	the	function	of	oligomerization.	
MINA53	 and	 NO66	 as	 well	 as	 bacterial	 ancestor	 ycfD	 have	 a	 very	 conserved	 domain	
structure	and	dimerize	 via	proposed	dimerization	domains6.	 For	MINA53	and	NO66,	 three	
amino	 acids	 in	 the	 dimerization	 domain	 could	 be	 identified	 which	 –	 if	 mutated	 -	 led	 to	
disruption	of	 the	homo-oligomerization.	 For	NO66	and	 substrate	RPL8,	 inhibition	of	NO66	
dimerization	also	disrupted	substrate	binding.	MINA53	triple	mutant	could	not	be	examined	
in	 substrate	 binding,	 but	 the	 cellular	 localization	 changed	 from	 nucleolar	 to	 an	 evenly	
distribution	 over	 the	 cell	 nucleus	 (data	 not	 shown).	 Therefore,	 for	 MINA53	 and	 NO66,	
dimerization	 seems	 to	 be	 essential	 for	 substrate	 binding,	 localization,	 and	 maybe	 for	
enzymatic	 activity.	 A	 change	 in	 localization	 controlled	 by	 homo-oligomerization	 has	 been	
described	 for	 another	 2OG	 oxygenase.	 JMJD6	 has	 been	 shown	 to	 shuttle	 between	
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nucleoplasm	and	nucleoli	upon	homo-oligomerization158.	Another	example	describing	homo-
oligomerization	as	 factor	determining	activity	 is	 the	oxygenase	 FIH,	 is	 reported	 to	be	only	
catalytically	active	in	the	form	of	a	dimer159.	Also	in	the	hypoxic	pathway,	prolyl	hydroxylase	
domain	 protein	 2	 (PHD2)	 displays	 the	 opposite	 catalytic	 function	 of	 dimerization.	
Dimerization	 in	 response	 to	 oxidative	 stress	 leads	 to	 the	 inactivation	 of	 the	 protein	 and	
thereby	the	hypoxic	response	pathway	is	activated160.	
	
OGFOD1	 as	 third	 human	 oxygenase	 modifying	 the	 ribosome	 directly	 is	 not	 reported	 to	
dimerize.	 The	 crystal	 structure	and	 the	domain	architecture	 is	different	 from	MINA53	and	
NO66.	However,	not	forming	homo-oligomers,	OGFOD1	protein	itself	consists	of	two	DSBH	
folds88.	This	might	mimic	a	dimerization	and	could	play	a	role	 in	substrate	recognition	and	
protein	activity.	Another	ROX,	the	tRNA	modifying	TYW5	seems	to	dimerize	via	C-terminal	α-
helices2.	
	
In	view	of	the	involvment	of	MINA53	and	NO66	in	cell	proliferation	and	cancer,	disruption	of	
the	dimerization	might	offer	a	new	therapeutic	approach.	General	2OG	oxygenase	inhibitors	
are	 dimethyloxalglycine	 (DMOG)	 or	 N-oxalylglycine	 (NOG)161.	 Both	 are	 unreactive	 2OG	
analogues,	 which	 are	 not	 released	 from	 the	 catalytic	 side	 of	 2OG	 oxygenases	 after	 the	
reaction	 and	 thereby	 inhibiting	 further	 catalytic	 activity.	 This	 way	 of	 inhibition	 is	 very	
unspecific	 as	 it	 targets	 nearly	 all	 2OG	 oxygenases,	 specific	 inhibitiors	 for	 single	 2OG	
oxygenase	 are	 rare161.	 As	 some	 2OG	 oxygenases	 form	 homo-oligomers	 with	 a	 functional	
significance,	it	might	be	promising	to	search	for	specific	inhibitors	targeting	oligomerization.	
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4 Material	
4.1 Chemicals	and	consumables	
Chemical	 Producer/Manufacturer	
4',6-Diamidino-2-phenylindole	dihydrochloride	(DAPI)	 Sigma	
Acetic	acid	 VWR	
Agarose	 Biozym	
Albumin	from	bovine	serum/BSA	 Sigma	
Ammonium	persulfate	(APS)	 Sigma	
Ampicillin	sodium	salt	 Roth	
AquaBluerTM		 MultiTarget	Pharmaceuticals,	LLC	
Bacto	Agar	 Th.	Geyer	
Calcium	chloride	 Sigma	
Cell	extraction	buffer	 Life	Technologies	
Chloramphenicol	 Roth	
D-(+)-Glucose	 Roth	
Direct	PCR	lysis	reagent		 Peqlab	
Dithiothreitol	(DTT)	 Life	Technologies	
DNA	Loading	Dye	(6x)	 Thermo	Fisher	Scientific	
Dulbecco's	Modified	Eagle	Medium	(DMEM)	(1x),	liquid	
(High	Glucose)	
Life	Technologies	
ECL	Western	blotting	detection	reagents	and	analysis	
system	kit	
GE	Healthcare	
Ethanol	 Merk	
3X	FLAG®	Peptide	 Sigma	
FCS	(fetal	calf	serum)	 Biochrom	
Glycerol	 Roth	
Glycine	 Roth	
HD	Green	plus	 Intas	
HEPES	Buffer	salt	 Roth	
Hoechst33342	 Molecular	Probes	
Hydrochloric	acid	32%	(Hcl)	 Roth	
Isopropanol	 Th.	Geyer	
Isopropyl	β-D-1-thiogalactopyranoside	(IPTG)	 Roth	
Kanamycin	sulphate	 Roth	
L-Arabinose	 Sigma	
Laemmli	Sample	Buffer	(4x)	 Biorad	
LB	Broth	 Roth	
Lipofectamine	2000	Reagent	 Life	Technologies	
Magnesium	chloride	 Roth	
Magnesium	sulfate	heptahydrate	 Sigma	
2-Mercaptoethanol	 Sigma	
Nitrocellulose	membran	(Amersham	Protran	Premium	
0.45	NC)	
GE	Healthcare	
Nonidet	P40	substitute	 Sigma	
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NUCLEAR-ID®	Red	DNA	stain	 Enzo	Life	Sciences	
Paraformaldehyde	solution	4%	 Santa	Cruz	
PBS	Dulbeco's	phophate	buffered	saline	 Life	Technologies	
PEI	Polyethylenimine,	branched	 Sigma	
Penicillin-Streptomycin	(10,000	U/mL)	 Life	Technologies	
Phosphatase	inhibitor	cocktail	2	 Sigma	
Phosphatase	inhibitor	cocktail	2	 Sigma	
Ponceau	S	Solution	0,1	%	Ponceau	S	 Sigma	
Potassium	chloride	(KOH)	 Roth	
Powdered	milk	 Roth	
Protease	inhibitor	cocktail		 Sigma	
Protease	inhibitor	cocktail,	Complete	mini,	EDTA-free	 Roche	
Proteinase	K,	20	mg/ml	 Peqlab	
Rotiphorese®	Gel	30	(37.5:1	Acrylamide/Bisacrylamide)	 Roth	
Sodium	acetate	 AppliChem	
Sodium	arsenite	 Sigma	
Sodium	chloride	 Roth	
Sodium	dodecyl	sulfate	(SDS)	 Roth	
Sodium	hydroxide	 Sigma	
Sucrose	 Roth	
Tetracyclin	hydrochloride	 Roth	
Tetramethylethylendiamine	(TEMED)	 Roth	
Thymidine	(cell	culture	grade)	 Sigma	
Tris	base	 Roth	
Triton	X-100	 AppliChem	
Trypsin/EDTA	 Biochrom	
Tween-20	 Roth	
Ultrapure	water	 Biochrom	
Vectashield	 Biozol	
Vitamin	B1	(Thiamine)	 Roth	
	
4.2 Instruments	and	Equipment	
Name	 Company	
LRSII	flow	cytometer	 BD	Biosiences	
Attune	acoustic	Focusing	Cytometer	 AB,	applied	biosystems	
Vi-CELL	XR	2.04	 Beckman	Coulter	
2104	EnVision®	Multilabel	Plate	Readers	 PerkinElmer	
Invivo	300	Hypoxic	Workstation	 Baker	Ruskinn	
	
Microscope	type	 Microscope	name	
Confocal	laser-scanning	 Leica	TCS	SP5	II	
Fluorescence	 Carl	Zeiss	LSM	510	META	
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4.3 Cell	lines	
Cell	line	 Description	 Source	
HeLa	 Human	cervix	carcinoma	cells	 ATCC	
Hek293	 Human	embryonic	kidney	cells	 ATCC	
Hek293T	 Derivative	of	human	embryonic	kidney	293	cells	
containing	the	SV40	T-antigen	
ATCC	
BHK	 Baby	Hamster	Kidney	cells	 AG	Leonhardt,	
LMU	München	
HeLa-Cell	Cycle	
Chromobody®-TagRFP	
HeLa	cell	line	stably	expressing	Cell	Cycle	
Chromobody®	fused	to	the	red	fluorescent	
protein	TagRFP	
ChromoTek	
GmbH	
Hek293_KO-MINA53	
cell	line	#1	-#4	
CRISPR/Cas9	generated	MINA53	knockout	cell	
lines	
This	work	
Hek293_KO-NO66	cell	
line	#3,	4,	6,	and	7	
CRISPR/Cas9	generated	NO66	knockout	cell	
lines	
This	work	
Hek293_+/-_O1D2	 CRISPR/Cas9	generated	cell	line	with	
heterozygous	knock	of	OGFOD1	
This	work	
Hek293_NO66KO#3+N
O66-WT	
NO66	knockout	cell	line	#3	lentiviral	stable	
reconstituted	with	NO66	wild	type	protein	
This	work	
Hek293_NO66KO#3+N
O66-AxA	
(H340A,D342A)	
NO66	knockout	cell	line	#3	lentiviral	stable	
reconstituted	with	NO66	active	site	mutated	
protein	
This	work	
Hek293_NO66KO#3+N
O66-Triple	
(W428A,F431A,L436A)	
NO66	knockout	cell	line	#3	lentiviral	stable	
reconstituted	with	NO66	protein	mutated	in	
three	residues	in	the	dimerization	domain	
This	work	
Hek293_MINA53KO#4
+MINA53-WT	
MINA53	knockout	cell	line	#4	lentiviral	stable	
reconstituted	with	MINA53	wild	type	protein	
This	work	
Hek293_MINA53KO#4
+MINA53-AxA	(H179A,	
D181A)	
MINA53	knockout	cell	line	#4	lentiviral	stable	
reconstituted	with	MINA53	active	site	mutated	
protein	
This	work	
Hek293_MINA53KO#4
+MINA53-Triple	
(W264A,	F267A,	
L308A)	
MINA53	knockout	cell	line	#4	lentiviral	stable	
reconstituted	with	MINA53	protein	mutated	in	
three	residues	in	the	dimerization	domain	
This	work	
	
4.4 Bacterial	strains	
Bacterial	
strain	
Description	 Source	
BL21	 Sex:	F-	Chromosomal	Markers:	lon-11,	Δ(ompT-nfrA)885,	
Δ(galM-ybhJ)884,	λDE3	[lacI,	lacUV5-T7	gene	1,	ind1,	
sam7,	nin5],	Δ46,	[mal+]K-12(λS),	hsdS10	
AG	Hadian,	
HelmholtzZentru
m	München	
TOP10	 Sex:	F-,	Chromosomal	Markers:	mcrA	Δ(	mrr-hsdRMS-
mcrBC)	Φ80lacZΔM15	Δ	lacX74	recA1	araD139	Δ(	
araleu)7697	galU	galK	rpsL	(StrR)	endA1	nupG	
AG	Hadian,	
HelmholtzZentru
m	München	
BW25113	 parent	strain	for	the	Keio	Collection	of	single	gene	 CGSC	Strain#:	
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knockouts,	Sex:	F-,	Chromosomal	Markers:	Δ(araD-
araB)567,	ΔlacZ4787(::rrnB-3),	λ-,	rph-1,	Δ(rhaD-
rhaB)568,	hsdR514	
7636	
JW1114	 Keio	Collection	of	single-gene	knockout	for	ycfD,	Sex:	F-	
Chromosomal	Markers:	Δ(araD-araB)567,	
ΔlacZ4787(::rrnB-3),	λ-,	ΔycfD788::kan,	rph-1,	Δ(rhaD-
rhaB)568,	hsdR514	
CGSC	Strain#:	
9045	
BW25113	
(rpsL150)	
BW25113	modified,	rpsL	was	exchanged	by	rpsL150,	Sex:	
F-,	Chromosomal	Markers:	Δ(araD-araB)567,	
ΔlacZ4787(::rrnB-3),	λ-,	rph-1,	Δ(rhaD-rhaB)568,	
hsdR514,	rpsL	(StrR)	
This	work	
BW25113	
(rpsL150,	
ycfD-rpsL-
neo-
cassette)	
BW25113	(rpsL150)	modified,	nucleotides	51-1071	of	
ycfD	were	exchanged	by	counter	selection	cassette,	Sex:	
F-,	Chromosomal	Markers:	Δ(araD-araB)567,	
ΔlacZ4787(::rrnB-3),	λ-,	rph-1,	Δ(rhaD-rhaB)568,	hsdR514	
This	work	
BW25113	
(rpsL150,	
ycfD-
neo/kan-
cassette)	
BW25113	(rpsL150)	modified,	nucleotides	51-1071	of	
ycfD	were	exchanged	by	counter	selection	cassette,	Sex:	
F-,	Chromosomal	Markers:	Δ(araD-araB)567,	
ΔlacZ4787(::rrnB-3),	λ-,	rph-1,	Δ(rhaD-rhaB)568,	
hsdR514,	rpsL	(StrR)	
This	work	
BW25113	
(rpsL150,	
ycfD-AxA)	
BW25113	(rpsL150)	modified,	ycfD	wild	type	gene	is	
replaced	by	ycfD	sequence	encoding	base	pair	excange	
resulting	in	H125A	and	D127A,	Sex:	F-,	Chromosomal	
Markers:	Δ(araD-araB)567,	ΔlacZ4787(::rrnB-3),	λ-,	rph-1,	
Δ(rhaD-rhaB)568,	hsdR514,	rpsL	(StrR)	
This	work	
	
4.5 Primary	and	secondary	antibodies	
Antibody	target	 Catalog	
number	
Source	 Species	 Dilution	
IF	
Dilution	
WB	
actin-HRP	 sc-1616	HRP	 Santa	Cruz	 goat	 	 1:500	
CCNA2	(Cyclin	A),	clone	CY-A1	 C4710-.2ML	 Sigma	 mouse	 1:200		 1:500	
Cyclin	A	(H-432)	 sc-751	 Santa	Cruz	 rabbit	 1:100,	
1:200	
1:100,	
1:200		
Cyclin	B1	(H-433)	 sc-752	 Santa	Cruz	 rabbit	 1:100,	
1:200	
1:100,	
1:200		
CDK1/Cdc2	p34	(17)		 sc-54	 Santa	Cruz	 mouse	 	 1:100	
Cdk2	(D-12)	 sc-6248	 Santa	Cruz	 mouse	 1:100,	
1:200	
1:100	
GFP	 11	814	460	
001	
Roche	 mouse	 	 1:500	
HA	Tag	 sc-Y11	 Santa	Cruz	 rabbit	 1:100	 	
M2	anti-FLAG	 F1804-200ul	 Sigma	 mouse	 	 1:500		
MINA53	 ab169154	 Abcam	 mouse	 	 1:300		
NO66/C14orf169	 ab113975	 Abcam	 rabbit	 	 1:1000		
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NO66/C14orf169	 ab192861-
10ul	
Abcam	 rabbit	 	 1:1200	
OGFOD1	 HPA003215		 Sigma	 rabbit	 1:500	 1:500	
RPS23	 ab57644	 Abcam	 mouse	 	 1:50	
TIA1	 sc-1751	 Santa	Cruz	 goat	 1:50,	
1:100		
	
UBF	(H-300)	 sc-9131	 Santa	Cruz	 rabbit	 1:200	 	
Isotype	control	for	Cyclin	A	(H-
432)	
sc-2027	x	 Santa	Cruz	 rabbit	 	 	
Table	4:	Primary	antibodies	
	
Antibody	target	 Catalog	
number	
Source	 Species	 Coupled	to	 Dilution	
Peroxidase-conjugated	
Donkey	anti-Rabbit	IgG	
711-035-
152	
Dianova	 Donkey	 Peroxidase	 1:1000	
Peroxidase-conjugated	
Donkey	anti-Goat	IgG	
705-035-
147	
Dianova	 Donkey	 Peroxidase	 1:1000	
Peroxidase-conjugated	
Donkey	anti-Mouse	IgG	
715-035-
150	
Dianova	 Donkey	 Peroxidase	 1:1000	
Maus	IgG	anti-
Kaninchen	IgG	(L)	
211-032-
171	
Dianova	 Mouse	 Peroxidase	 1:1000	
Anti-Maus	IgG	(L)-
HRPO	
115-035-
174	
Dianova	 Goat	 Peroxidase	 1:1000	
Alexa	Fluor(R)	488	
donkey	anti-goat	IgG	
A11055	 Life	
Technologies	
Donkey	 Alexa	Fluor	488	 1:1000	
Alexa	Fluor	®	594	
rabbit	anti-mouse	IgG	
A11062	 Life	
Technologies	
Chicken	 Alexa	Fluor	594	 1:1000	
Alexa	Fluor	®	594	
chicken	anti-goat	IgG	
A21468	 Life	
Technologies	
Rabbit	 Alexa	Fluor	594	 1:1000	
Alexa	Fluor	®	488	
donkey	anti-rabbit	IgG	
A21206	 Life	
Technologies	
Donkey	 Alexa	Fluor	488	 1:1000	
Alexa	Fluor	®	594	
donkey	anti-rabbit	IgG	
A21207	 Life	
Technologies	
Donkey	 Alexa	Fluor	594	 1:1000	
Alexa	Fluor(R)	488	
chicken	anti-mouse	IgG	
A21200	 Life	
Technologies	
Chicken	 Alexa	Fluor	488	 1:1000	
Table	5:	Secondary	antibodies	
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4.6 Plasmid/Clones	
Insert	 Plasmid	 Restric-
tion	
sites	
Established	
by	
Expression	
in	
Information	
CCNA2	
(human)	
pmCherry-
N1	
KpnI/		
BamHI	
This	work	 Mammalian	
cell	culture	
Full	length	CCNA2	with	
a	C-terminal	mCherry-
tag	
CCNA2	
(human)	
pRSet5D-
GFP	
BstEII/		
EcoRI	
This	work	 Bacteria	 Full-length	CCNA2	with	
N-terminal	GFP-tag	
CCNA2	
(human)	
pGex-4T-2	 BamHI/		
XhoI	
This	work	 Bacteria	 CCNA2	full	length	in	
with	N-terminal	GST-
tag	
CCNA2	
(human)	
p3xFlag-
CMV-9-10	
KpnI/		
BamHI	
Alex	Wolf	 Mammalian	
cell	culture	
full	length	CyclinA2	
with	N-terminal	
3xFLAG-tag	
CCNA2	
(human)	aa1-
180	
p3xFlag-
CMV-9-10	
KpnI/		
BamHI	
This	work	 Mammalian	
cell	culture	
aa1-180	of	CyclinA2	
with	N-terminal	
3xFLAG-tag	
CCNA2	
(human)	aa1-
180		
pRSet5D-
GFP	
BstEII/	
EcoRI		
Olga	
Swolski	
Bacteria	 aa1-180	of	CyclinA2	
with	N-terminal	GFP-
tag	
CCNA2	
(human)	aa1-
46	+	181-432	
p3xFlag-
CMV-9-10	
KpnI/		
BamHI	
This	work	 Mammalian	
cell	culture	
aa1-46	und	181-342	of	
CyclinA2	with	N-
terminal	3xFLAG-tag	
CCNA2	
(human)	aa1-
46	+	181-432	
pRSet5D-
GFP	
BstEII/	
EcoRI		
Olga	
Swolski	
Bacteria	 aa1-46	und	181-342	of	
CyclinA2	with	N-
terminal	GFP-tag	
CCNA2	
(human)	
aa181-432	
p3xFlag-
CMV-9-10	
KpnI/		
BamHI	
This	work	 Mammalian	
cell	culture	
aa181-432	of	CyclinA2	
with	N-terminal	
3xFLAG-tag	
CCNA2	
(human)	
aa181-432		
pRSet5D-
GFP	
BstEII/	
EcoRI		
Olga	
Swolski	
Bacteria	 aa181-432	of	CyclinA2	
with	N-terminal	GFP-
tag	
CDK2	(human)	
isoform1	
pET28a	 BamHI/		
HindIII	
This	work	 Bacteria	 Full	length	CDK2	
isoform1	with	N-
terminal	His-tag.	
eEF2K	
(human)	
p3xFlag-
CMV-9-10	
KpnI/		
BamHI	
This	work	 Mammalian	
cell	culture	
Full	length	eEF2K	with	
N-terminal	3xFLAG-tag	
hSpCas9-2A-
Puro	
PX459	 		 Addgene	 Mammalian	
cell	culture	
Addgene	#48139	
MINA53	
(human)	
pEGFP-C1	 XhoI/		
KpnI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	MINA53	
with	N-terminal	GFP-
tag		
MINA53	
(human)	
pEGFP-N1	 XhoI/		
AgeI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	MINA53	
with	C-terminal	GFP-
tag		
MINA53	 pLVTHM- PmeI/	 This	work	 Lentiviral	 Full	length	MINA53	
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(human)	 T2A-CD2	 SpeI	 vector	 with	with	T2A-CD2-tag		
MINA53	
(human)	
H179A,	D181A	
pEGFP-C1	 XhoI/		
KpnI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	MINA53	
H179A,	D181A	with	N-
terminal	GFP-tag	
MINA53	
(human)	
H179A,	D181A	
pLVTHM-
T2A-CD2	
PmeI/	
SpeI	
This	work	 Lentiviral	
vector	
Full	length	MINA53	
H179A,	D181A	with	
T2A-CD2-tag	
MINA53	
(human)	
W264A,	
F267A,	L308A	
pEGFP-C1	 XhoI/		
KpnI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	MINA53	
W264A	&	F267A	&	
L308A	with	N-terminal	
GFP-tag	
MINA53	
(human)	
W264A,	
F267A,	L308A	
pLVTHM-
T2A-CD2	
PmeI/	
SpeI	
This	work	 Lentiviral	
vector	
Full	length	MINA53	
W264A	&	F267A	&	
L308A	with	with	T2A-
CD2-tag	
MINA53	
(Hydra	
vulgaris)	
pHotG	 NheI/	
XmaI	
This	work	 Hydra	
vulgaris	
Full	length	MINA53	
with	C-terminal	GFP-
tag	
NLS	 pEGFP-C1	 -	 Leonhardt	
group	
Mammalian	
cell	culture	
GFP	fused	to	a	NLS	
sequence	
NO66	
(human)	
pEGFP-C1	 EcoRI/		
KpnI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	NO66	with	
N-terminal	GFP-tag	
NO66	
(human)	
pLVTHM-
T2A-CD2	
PmeI/	
SpeI	
This	work	 Lentiviral	
vector	
Full	length	NO66	with	
N-terminal	GFP-tag	
NO66	
(human)	
H340A,	D342A	
pEGFP-C1	 EcoRI/		
KpnI	
This	work	 Mammalian	
cell	culture	
Full	length	NO66	
H340A	&	D342A	with	
N-terminal	GFP-tag	
NO66	
(human)	
H340A,	D342A	
pLVTHM-
T2A-CD2	
PmeI/	
SpeI	
This	work	 Lentiviral	
vector	
Full	length	NO66	
H340A	&	D342A	with	
T2A-CD2-tag	
NO66	
(human)	
W428A,	
F431A,	L436A	
pEGFP-C1	 EcoRI/		
KpnI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	NO66	
W428A	&	F431A	&	
L436A	with	N-terminal	
GFP-tag	
NO66	
(human)	
W428A,	
F431A,	L436A	
pLVTHM-
T2A-CD2	
PmeI/	
SpeI	
This	work	 Lentiviral	
vector	
Full	length	NO66	
W428A	&	F431A	&	
L436A	with	T2A-CD2-
tag	
NO66	(Hydra	
vulgaris)	
pHotG	 NheI/	
XmaI	
This	work	 Hydra	
vulgaris	
Full	length	NO66	with	
C-terminal	GFP-tag	
OGFOD1	
(human)	
pET24	 	 Emily	
Flashman	
Bacteria	 Untagged	full-length	
OGFOD1	
OGFOD1	
(human)	
pET28a	 NheI/		
XhoI	
Alex	Wolf	 Bacteria	 Full-length	OGFOD1	
with	N-terminal	His-tag	
OGFOD1	
(human)	
pEGFP-N1	 XhoI/		
BamHI	
Alex	Wolf	 Mammalian	
cell	culture	
Full	length	OGFOD1	
with	C-terminal	GFP-
tag	
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OGFOD1	
(human)	
pEGFP-C1	 XhoI/		
BamHI	
Alex	Wolf	 Mammalian	
cell	culture	
Full	length	OGFOD1	
with	N-terminal	GFP-
tag		
OGFOD1	
(human)	
pHA	 Not1/		
Not1	
Alex	Wolf	 Mammalian	
cell	culture	
Full	length	OGFOD1	
with	C-terminal	HA-tag		
OGFOD1	
(human)	
pcDNA3	 BamHI/		
XhoI	
Alex	Wolf	 Mammalian	
cell	culture	
Untagged	full	length	
OGFOD1	
OGFOD1	
(human)	aa1-
238	
pEGFP-N1	 Xho1/	
BamH1		
Olga	
Swolski	
Mammalian	
cell	culture	
aa1-238	of	OGFOD1	
with	C-terminal	GFP-
tag	
OGFOD1	
(human)	aa1-
260	
pEGFP-N1	 XhoI/		
BamHI	
Alex	Wolf	 Mammalian	
cell	culture	
aa1-260	of	human	
Ogfod	with	C-terminal	
GFP-tag	
OGFOD1	
(human)	aa1-
30	+	aa261-
542	
pEGFP-N1	 XhoI/		
BamHI	
Alex	Wolf	 Mammalian	
cell	culture	
aa1-30	and	aa261-542	
of	OGFOD1	ORF	in	
frame	separated	by	4	
aminoacids	(PRAM)	
with	C-terminal	GFP-
tag	
OGFOD1	
(human)	
aa21-542	
pEGFP-N1	 XhoI/		
BamHI	
Alex	Wolf	 Mammalian	
cell	culture	
OGFOD1	lacking	aa1-
20	with	C-terminal	
GFP-tag	
OGFOD1	
(human)	
aa31-542	
pEGFP-N1	 XhoI/		
BamHI	
This	work	 Mammalian	
cell	culture	
OGFOD1	lacking	aa1-
30	with	C-terminal	
GFP-tag.	
OGFOD1	
(human)	
H155A+D157A	
pEGFP-N1	 XhoI/		
BamHI	
Alex	Wolf	 Mammalian	
cell	culture	
Full	length	OGFOD1	
H155A+D157A	with	C-
terminal	GFP-tag	
OGFOD1	
(human)	
H155A+D157A	
pET28a	 NheI/		
XhoI	
This	work	 Bacteria	 Full-length	OGFOD1	
H155A+	D157A	with	N-
terminal	His-Tag	
OGFOD1	
(human)	
H155A+D157A	
pcDNA3	 BamHI/		
XhoI	
This	work	 Mammalian	
cell	culture	
Untagged	full	length	
OGFOD1	
H155A&D157A		
OGFOD1	
(human)	
R519A+L521A	
pEGFP-N1	 Xho1/	
BamH1		
Olga	
Swolski	
Mammalian	
cell	culture	
Full	length	OGFOD1	
R519A	+	L521A	with	C-
terminal	GFP-tag	
OGFOD1	
internal	HA	
pCDNA3	 BamHI/		
XhoI	
This	work	 Mammalian	
cell	culture	
OGFOD1	linker	
(nucleotides	745-769)	
replaced	by	HA-tag	
OGFOD2	Iso1	
(human)	
pCDNA3	 KpnI/	
XbaI	
Justė	
Wesche	
Mammalian	
cell	culture	
Untagged	full	length	
OGFOD2I1	
RPL27A	
(human)	
pcDNA5-
FRT-TO-
3xFLAG	5´	
HindIII/		
XhoI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	Rpl27a	with	
N-terminal	Flag-tag,	
additional	6	amino	
acids	(LESRGPV*)	at	C-
terminus	
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RPL8	(human)	 pcDNA5-
FRT-TO-
3xFLAG	5´	
HindIII/		
XhoI	
Kevin	
Brockers	
Mammalian	
cell	culture	
Full	length	RPL8	with	
N-terminal	Flag-tag	
RPS23	
(human)	
pmCherry-
N1	
KpnI/		
BamHI	
This	work	 Mammalian	
cell	culture	
Full	length	RPS23	with	
C-terminal	mCherry-
tag	
--	 pRSet5D-
GFP	
	 Leonhardt	
group	
Bacteria	 Empty	vector	
expressing	GFP-His	
--	 pMD2.G		 	 Krappmann	
group	
	 Lentiviral	envelope	
plasmid	(Addgene	ID	
12259)	
--	 psPAX2		 	 Krappmann	
group	
	 Lentiviral	packaging	
plasmid	(Addgene	ID	
12260)	
	
	
4.7 	Primer	
Primer	 Sequence	(5’-3’)	 Used	for	
rpsL_up1	 CTTGACACCTTTTCGGCATCGC	 Amplification	of	
rpsL150	(StrR)	rpsL_down1	 CGTTGTTAATTCAGGATTGTCC	
rpsL-neo-ycfD_F	
ATGGAATACCAACTCACTCTTAACTGGCCCGAT
TTTCTTGAACGTCACTGGGCCTGGTGATGATGG
CGGGATCG		
Generation	of	bacterial	
ycfD	mutant	rpsL-neo-ycfD_R	
TTACCCTTCGAAGAACCAATACCCGCTATTGAC
CAGCGCCGCGAGCATCGTCAGAAGAACTCGTC
AAGAAGGCG	
ycfD_F1	
ATGGAATACCAACTCACTCTTAACTGGCCCGAT
TTTCTTGAACGTCACTG	
ycfD_R1	
TTACCCTTCGAAGAACCAATACCCGCTATTGAC
CAGCGCCGCGAGCATCG	
O1-AxAmuta_F	 GCCCTGCTGTGCGCTGATGCTGAGCTGGAAGG
GC	
Mutagenesis	of	
OGFOD1	to	H155A	and	
D157A,	iron	binding	
motif	
O1-AxAmuta_R	 GCCCTTCCAGCTCAGCATCAGCGCACAGCAGG
GC	
O1R519AL521Amu
tF	
GCATATTAACCACGCAAGCGCGGAACAAAAGA
AAACC	
Mutagenesis	of	
OGFOD1	to	R519A	and	
L521A,	potential	cyclin	
binding	motif	
O1R519AL521Amu
tR	
GGTTTTCTTTTGTTCCGCGCTTGCGTGGTTAATA
TGC	
intHA-O1_intF	 CAGATTACGCTCACATCCCACAAGATCATGAG	 Generation	of	OGFOD1	
with	internal	HA-tag	intHA-O1_intR	 GAACATCGTATGGGTAGTTGGGAGGCCG	
intHA-
O1_overlapF	 CTACCCATACGATGTTCCAGATTACGCTCAC	
CCNA2insR	 GGTATGTGTGAATATCGGTCCGCGGTTGTTGG	
Generation	of	CCNA2	
deletion	mutants	
CCNA2insF	 CCAACAACCGCGGACCGATATTCACACATACC	
CCNA2outBamHIR	 CGGGATCCTTACAGATTTAGTGTCTCTGGTGGG	
CCNA2outKpnIF2	 CGGGTACCAATGTTGGGCAACTCTGCG	
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CCNA2aa1-
180BamHR2	
GCGGATCCCTACTCATGGTAGTCTGGTACTTCA
TTAAC	
CCNA2aa181-
432KpnIF	
CGGGTACCGATATTCACACATACCTTAGGGAAA
TGG	
O1_31-end_XhoIF	
GCCTCGAGATGACGGAAGAAACCTTGAAAAAG
C	
Generation	of	OGFOD1	
lacking	aa	1-30	
O1_31-
end_BamHIR	
CGGGATCCCGTTCATAATAGATGAATGAAAAGT
CCCAG	
O1-AA1_XhoIF	 GGCTCGAGATGAATGGGAAGCGGCC	 Generation	of	OGFOD1	
lacking	aa	238-542	O1-AA1-
238_BamHR	 CCGGATCCCCATGAAACCAGCCACTTATAG	
CDK2_CBPN1Hind
3F	 CCAAGCTTTTATGGAGAACTTCCAAAAGGTGG	
Amplification	of	CDK2	
from	cDNA	and	cloning	
CDK2_CBPN1Bam
HIR	 GTGGATCCAAGAGTCGAAGATGGGGTACTGG	
CDK2_CBPC1Bam
HIR	 GTGGATCCTCAGAGTCGAAGATGGGG	
hydraNO66_NheF	 CAGGCTAGCATGAATAACAACAAAGTATCAGC	 Amplification	of	Hydra	
vulgaris	NO66	from	
cDNA	and	cloning	hydraNO66_XmaR	 GACCCGGGTGTATGGACCAATGGAACC	
hydraMinA_NheF	 CAGGCTAGCATGGTGAAACGCAAAGGTTC	 Amplification	of	Hydra	
vulgaris	NO66	from	
cDNA	and	cloning	hydraMinA_XmaR	 GGCCCGGGTTTGATTTCAATCAAATCATCAC	
Table	6:	Cloning	primers	for	different	projects	
	
	
Targeted	
gene	
Name	of	primer	 Sequence	of	primer	(5’-3’)	
OGFOD1	 O1KO_guide1upF	 CACCG	ATTAGCTCTGCTATGTTACT	
O1KO_guide1upR	 AAAC	AGTAACATAGCAGAGCTAATC	
O1KO_guide2backF	 CACC	GCCACATTAACTCTTCCAGC	
O1KO_guide2backR	 AAAC	GCTGGAAGAGTTAATGTGGC	
MINA53	 MinAEx1_upGuideF	 CACC	CTGCACTGGCCACATACTAT	
MinAEx1_upGuideR	 AAAC	ATAGTATGTGGCCAGTGCAG	
MinAEx1_downGuideF	 CACCG	AATGTCTGCCGGTGTGTCAA	
MinAEx1_downGuideR	 AAAC	TTGACACACCGGCAGACATT	C	
NO66	 NO66_upGuide22F	 CACC	CGTATCTTCCTGGACCTCAA	
NO66_upGuide22R	 AAAC	TTGAGGTCCAGGAAGATACG	
NO66_downGuide15F	 CACC	CACCGGGTAGCGCGTCCCCC	
NO66_downGuide15R	 AAAC	GGGGGACGCGCTACCCGGTG		
Table	7:	Designed	primers	for	guideRNAs	
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Primer/	
Oligonucleotide	
Sequence	(5’-3’)	 Used	for	
Screen_O1ex2F	 GTGCTACCCAAAGTTTGAGGG		 Amplification	of	CRISPR/Cas9	
targeted	OGFOD1	locus	Screen_O1ex2R	 GGAAGACATTATCACTCTCTCCATCC	
ScreenMinAEx1F	 GGTAGGTTTGCATTTCCTTACTGC	 Amplification	 of	 CRISPR/Cas9	
targeted	MINA53	locus	ScreenMinAEx1R	 CACCCTTGAGCTGATATGTGGC	
NO66_screen2F	 CTCCAGGCCAGTGCAGG	 Amplification	 of	 CRISPR/Cas9	
targeted	NO66	locus	NO66_screen2R	 GGTAAAAGTGATCTGGCGGC	
Table	8:	Primers	for	screening	of	potential	CRISPR/Cas9	knockout	cell	lines	
	
4.8 Beads	for	immunoprecipitation	
Name	 Source	
GFP-Trap®	covalently	coupled	to	the	surface	
of	agarose	beads	
Chromotek	
Anti-Flag	M2	Affinity	Agarose	Gel	 Sigma-Aldrich	
Protein	G	Sepharose	4	Fast	Flow	 GE	Healthcare	
Glutathione	Sepharose	4B	 GE	Healthcare	
	
4.9 Marker	and	enzymes	
Marker	 Source	
Precision	Plus	Protein	Dual	color	standard	 Biorad	
GeneRuler	DNA	ladder	mix	1kb	 Thermo	Fisher	Scientific	
GeneRuler	100	bp	Plus	DNA	ladder	 Thermo	Fisher	Scientific	
	
Enzyme	 Source	
Restriction	enzymes	 New	England	Biolabs	
MyTaq™	DNA	Polymerase	 Bioline	
Phusion	Flash	High-Fidelity	PCR	Master	Mix	 Biozym	
MyTaq™	DNA	Polymerase	 Bioline	
T4	DNA	ligase	 New	England	Biolabs	
Calf	intestinal	alkaline	phosphatase	 New	England	Biolabs	
Lysozym		 AppliChem	
DNAse	 ThermoFisher	
	
4.10 	Transfection	reagents	
Transfection	reagent	 Source	
Polyethylenimine	pH	7,	branched	(PEI)	 Sigma	
X-tremeGENE	HP	DNA	Transf.	Reag.	1.0	ml	 Roche	
LIPOFECTAMINE	2000	REAGENT	1,5ml	 Thermo	Fisher	Scientific	
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4.11 	Kits	
Kit	 Company	
NucleoSpin	Gel	and	PCR	Clean-up	 Macherey-Nagel	
QIAprep	Spin	Miniprep	Kit	 Qiagen	
QiaFilter	Plasmid	Maxi	Kit	 Qiagen	
QuikChange	Site-directed	mutagenesis	kit	 Agilent	
Counter-Selection	BAC	Modification	Kit	 Gene	Bridges	
	
4.12 	Buffers	and	Solutions	
4.12.1 	Cell	lysis	buffer	
Mammalian	cell	lysis	buffer	 	
NaCl	 150	mM	
Tris-HCl	pH	8	 10	mM	
NP40	 0.5	%		
Phosphatase	inhibitor	cocktail	2	 10	µl/ml		
Phosphatase	inhibitor	cocktail	3	 10	µl/ml	
Protease	inhibitor	 10	µl/ml	
	
Bacteria	lysis	buffer	 	
Tris-HCl	pH	7.5	 50	mM	
Lysozym	 0.5	mg/ml	
Protease	inhibitor	EDTA	free	(Roche)	 10	pill/	10	ml	
DNAse	 1	U/ml	
	
4.12.2 	Gel	electrophoresis	(DNA)	
TAE	Buffer		 	
Tris	 40	mM	(pH	7.6)	
Acetic	acid	 0.57	%	(V/V)	
EDTA	solution	(pH	8,0)	 1	mM	
	
1%	Agarose	gel	 	
Agarose	 1%	(W/V)	
HDGreen®	Plus	Safe	DNA	Dye	 0.3%	(V/V)	
TAE	Buffer	 	
	
4.12.3 	SDS-PAGE	and	Western	blot	
0.5	M	Tris-	buffer	pH	6,8	 	
Tris-HCl	 0.5	M	
SDS	 0.4%	(W/V)	
adjust	pH	6,8	 	
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1.5	M	Tris-	buffer	pH	8,8	 	
Tris-HCl	 1.5	M	
SDS	 0.4%	(W/V)	
Adjust	pH	8,8	 	
	
3	%	Stacking	gel	 	
30	%	Acrylamide/Bisacrylamide	 3%	(V/V)	
0.5	M	Tris-HCl-buffer	pH	6.8	 0.125	M	
SDS	 0.1%	(W/V)	
APS	 0.1%	(W/V)	
Temed	 0.01%	(V/V)	
	
12.5	%	Separating	gel	 	
30	%	Acrylamide/Bisacrylamide	 12.5%	(V/V)	
1.5	M	Tris-HCl-buffer	pH	8.8	 0.375	M	
SDS	 0.1%	(W/V)	
APS	 0.1%	(W/V)	
Temed	 0.01%	(V/V)	
	
Electrophoresis	buffer	(SDS-PAGE)	 	
Tris	 25	mM	
Glycin	 190	mM	
SDS	 0.1%	(W/V)	
check	and	adjust	to	pH	8.3	 	
	
Blot	Buffer	 	
Tris	 25	mM	
Glycin	 190	mM	
check	and	adjust	to	pH	8.3	 	
	
4.12.4 	Immunological	protein	detection	
TBS	 	
Tris	 20	mM	
NaCl	 140	mM	
KCl	 2.7	mM	
adjust	pH	7.4	 	
	
TBST	 	
Tris	 20	mM	
NaCl	 140	mM	
Tween	20	 0.1%	(V/V)	
adjust	pH	7.4	 	
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4.12.5 	Immunofluorescence	experiments	
Permeabilization	solution	 	
Triton	X-100	 1	%	(V/V)	
	 In	PBS	
	
Blocking	solution	 	
FCS	 10	%	(V/V)	
Tween-20	 0.2	%	(V/V)	
	 In	PBS	
	
Wash	solution	 	
BSA	 1	%	(W/V)	
Tween-20	 0.2	%	(V/V)	
	 In	PBS	
	
4.12.6 	Immunoprecipitation	experiments	
Wash	buffer	1	 	
NaCl	 150	mM	
Tris-HCl	pH	8	 10	mM	
	
Wash	buffer	2	 	
NaCl	 300	mM	
Tris-HCl	pH	8	 10	mM	
	
4.12.7 	Cloning	
Annealing	buffer	 	
KAc	 100	mM	
HEPES	(pH	7.4)	 30	mM	
Mg(Ac)2	 2	mM	
	
4.12.8 	Hydra	medium	
Hydra	culture	medium	 	
KCl	 0.1	mM	
NaCl	 1	mM	
MgSO4	 0.1	mM	
Tris	 1	mM	
CaCl2	 1	mM	
	
4.12.9 	Bacterial	growth	
LB	medium	 	
LB	Broth,	Powder	(Lennox)		 20	mg/L	
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LB	agar	 	
LB	Broth,	Powder	(Lennox)		 20	mg/L	
Agar	 15	mg/L	
	
Minimal	medium	(M9)	 	
Na2HPO4	 42	mM	
KH2PO4	 22	mM	
NH4Cl	 18	mM	
NaCl	 8	mM	
CaCl2	 2	µM	
MgSO4	 0.05	mM	
Glucose	 0.2	%	(W/V)	
Thiamine	 2.5	µM	
	
4.12.10 	Ribosome	isolation	
4.12.10.1 Isolation	of	bacterial	ribosomes	
Bacterial	ribosome	lysis	buffer	 	
Hepes	pH	7.8	 10	mM	
MgCl2	 30	mM	
NH4Cl	 150	mM	
β-mercaptoethanol	 6	mM	
Lysozym	 0.5	mg/ml	
	
Sucrose	buffer	for	sucrose	
gradients	
	
Hepes	pH	7.8	 10	mM	
MgCl2	 30	mM	
NH4Cl	 150	mM	
β-mercaptoethanol	 6	mM	
Sucrose	 10	or	40	%	(W/V)	
	
4.12.10.2 Isolation	of	human	ribosomes	for	LC-MS/MS	analysis	
Mammalian	ribosome	lysis	buffer	 	
Hepes/KOH	pH	7.0	 50	mM	
KOAc	 100	mM	
NP40	 0.5	%	
Mg(OAc)2	 25	mM	
DTT	 1	mM	
Protease	inhibitor	EDTA	free	(Roche)	 1	pill/	10	ml	
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Sucrose	buffer	for	sucrose	cushion	 	
Hepes/KOH	pH	7.0	 50	mM	
KOAc	 500	mM	
Mg(OAc)2	 25	mM	
β-mercaptoethanol	 5	mM	
Nikkol	 0.1	%	
Protease	inhibitor	EDTA	free	(Roche)	 10	pill/	10	ml	
Sucrose	 750	mM	
	
Mammalian	ribosome	storage	buffer	 	
Hepes/KOH	pH	7.0	 50	mM	
KOAc	 500	mM	
Mg(OAc)2	 6	mM	
DTT	 1	mM	
RNasin	Plus	RNase	Inhibitor	 0.2	U/µl	
	
4.12.10.3 Isolation	for	ribosome	profiles	for	mammalian	cells	
Mammalian	ribosome	lysis	buffer	 	
Hepes/KOH	pH	7.0	 50	mM	
NaCl	 300	mM	
NP40	 0.5	%	
MgCl2	 6	mM	
RNasin	Plus	RNase	Inhibitor	 0.2	U/µl	
	
Sucrose	buffer	for	sucrose	cushion	 	
Hepes/KOH	pH	7.6	 50	mM	
NaCl	 300	mM	
MgCl2	 6	mM	
RNasin	Plus	RNase	Inhibitor	 0.2	U/µl	
Sucrose	 30	%	(W/V)	
	
Mammalian	ribosome	storage	buffer	 	
Hepes/KOH	pH	7.6	 20	mM	
KCl	 150	mM	
Mg(OAc)2	 6	mM	
DTT	 1	mM	
Sucrose	 6.8	%	(W/V)	
RNasin	Plus	RNase	Inhibitor	 0.2	U/µl	
	
Sucrose	buffer	for	sucrose	gradients	 	
Hepes	pH	7.0	 50	mM	
KOAc	 150	mM	
Mg(OAc)2	 6	mM	
DTT	 1	mM	
Protease	inhibitor	EDTA	free	(Roche)	 10	pill/	10	ml	
Sucrose	 10	or	40	%	(W/V)	
5	Methods	
95	
5 Methods	
5.1 Bacteria	
5.1.1 Transformation	
Chemically	competent	cells	were	transformed	by	a	45	sec	heatshock	at	42	°C	after	30	min	
incubation	 of	 the	 bacteria	with	 the	 plasmid	 DNA.	 Following	 the	 heatshock,	 bacteria	were	
incubated	for	2	min	on	ice.		
Competent	 cells	 for	 electroporation	 were	 transformed	 following	 the	 instructor	 manual	
(BioRad).		
Independet	 of	 transformation	methode,	 bacteria	 were	 allowed	 to	 recover	 at	 37	 °C	 in	 LB	
medium	 (see	 4.12.9)	 and	 spread	 onto	 LB-Agar	 plates	 (see	 4.12.9)	 with	 the	 appropriate	
antibiotic.	
Bacteria	transformed	with	a	plasmid	were	stored	in	20	%	glycerol	stocks	at	-80	°C.	
	
5.1.2 Bacterial	growth	
Bacteria	were	grown	in	LB	medium	with	the	appropriate	antibiotics	at	37	°C	or	temperatures	
examined	to	be	the	best	for	following	application.	
	
5.1.2.1 Expression	trail	
To	 find	 the	 best	 conditions	 for	 expression	 of	 the	 protein,	 several	 growth	 conditions	were	
tested.	A	culture	of	bacteria	carrying	the	plasmid	of	interest	were	inoculated	and	incubated	
at	37°C	over	night	(O/N).	Per	condition,	100	ml	cultures	are	inoculated	from	the	O/N	culture	
and	 incubated	 at	 37	 °C	 until	 they	 reach	 OD600	 from	 0.6-0.8.	 Subsequently,	 cultures	 were	
shifted	to	temperatures	of	37	°C,	30	°C	and	18-20	°C	and	if	needed	bacterial	expression	was	
induced	with	1	mM	IPTG.	Cultures	at	37	°C	and	30	°C	were	incubated	for	4	h,	18	°C	cultures	
over	night	(O/N).	
	
5.1.2.2 Harvesting	and	lysis	of	bacteria	
Bacteria	were	harvested	by	centrifugation	for	30	min	at	4000	rpm	at	room	temperature	(RT).	
1	 g	 bacterial	 pellet	 was	 resuspended	 in	 5	 ml	 50	 mM	 Tris-HCl	 pH	 7.5	 and	 lysed	 by	 three	
repeated	freeze-	(-80	°C)	and	thaw-	(37	°C)	cycles.	Lysates	were	centrifuged	at	13.000	rpm	
for	20	min	at	4	 °C	 to	obtain	soluble	protein.	The	resulting	pellet	was	resuspend	 in	50	mM	
Tris-HCl	(pH	7.5).	20	µg	of	protein	were	analyzed	with	the	soluble	protein	on	an	SDS	PAGE	by	
Coomassie	staining.	
For	 immunoprecipitation	 experiments,	 bacteria	 pellets	 were	 lysed	 in	 bacteria	 lysis	 buffer	
(4.12.1).	
	
5.1.2.3 Growth	assay	for	bacteria	
Bacterial	growth	assay	was	performed	in	the	2104	EnVision®	Multilabel	Plate	Reader	(Perkin	
Elmer).	Per	strain,	150	µl	of	bacteria	with	same	starting	OD600	of	0.05	were	seeded	into	96	
well	flat	bottom	plates	in	triplicates.	Cultures	were	grown	using	2	mm	orbital	shaking	at	250	
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rounds	per	minute	(RPM)	at	37	°C.	OD600	was	determined	by	the	plate	reader	every	15	min	
for	at	least	20	h.	
	
5.1.3 Generation	of	bacterial	knockout	strains	
Bacterial	 knockout	 strains	were	 generated	 using	 the	 „Counter-Selection	 BAC	Modification	
Kit“	from	Gene	Bridges	which	is	based	on	Red/ET	recombination.	
The	kit	provides	the	pRed/ET	plasmid,	which	carries	the	λ	phage	red	gba	operon	expressed	
under	 the	 control	 of	 the	 arabinose-inducible	 pBAD	 promoter	 conferring	 tetracycline	
resistance	(tet).	The	origin	of	replication	is	temperature	sensitive	and	restricts	replication	at	
37	°C.	Therefore,	bacteria	carrying	the	plasmid	were	kept	at	30	°C,	expression	of	the	red	gba	
genes	is	induced	by	addition	of	L-Arabinose	at	37	°C.	
Streptomycin	 resistance	 is	 a	 prerequisite,	 therefore	 in	 BW25113,	wild	 type	 rpsL	 gene	was	
replaced	by	the	rpsL150	gene	which	leads	to	a	streptomycin	resistance	due	to	a	K43R	amino	
acid	 substitution.	RpsL150	 gene	was	 PCR	 amplified	 from	 TOP10	 bacteria	 and	 recombined	
into	BW25113	carrying	the	plasmid	pRED/ET	(tet).	Following	the	kit	 instructions,	BW25113	
strain	 was	 transformed	 with	 the	 pRed/ET	 plamid	 carrying	 a	 ampicillin	 (ampR)	 resistance.	
After	 selection	 for	 ampicillin,	 bacteria	 were	 transformed	 with	 the	 linear	 PCR-amplified	
rpsL150	flanked	by	50	nucleotides	(nts)	homology	arms	to	target	the	rpsL	locus.	Subsequent	
activation	 of	 Red/ET	 recombination	 led	 to	 insertion	 of	 the	 rpsL150	 gene.	 Schematic	
procedure	 for	 strain	 generation	 is	 depicted	 for	 ycfD	 catalytically	 inactive	 mutant	 strain	
(BW25113	(rpsL150,	ycfD-H125A,	D127A)	(Figure	67).	BW25113	(rpsL150)	was	transformed	
with	 pRed/ET	 and	 used	 for	 generation	 of	 different	 bacterial	 genomic	 modifyed	 strains	
following	the	manufacturers	instruction.		
Electroporation	 was	 performed	 with	 MicroPulser	 Electroporator	 from	 Biorad.	 PCR	
amplification	was	achived	by	Phusion	High-Fidelity	PCR	master	mix	(Thermo	Fisher).		
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Figure	 67:	 Principle	 of	 introducing	 ycfD	mutations	 into	 the	 bacterial	 chromosome	 using	 Red/ET	mediated	
recombination	and	rpsL-based	counter-selection	 	 (Gene	Bridges	“Counter-Selection	BAC	Modification	Kit”);	
A)	 Engineered	 streptomycin-resistant	 strain	 is	 transformed	with	 the	 pRed/ET	 plamid	 carrying	 a	 ampicillin	
(ampR)	resistance,	B)	Bacteria	are	transformed	with	a	linear,	PCR-amplified	rpsL-neo/kan	cassette	flanked	by	
50	 nucleotides	 (nts)	 homology	 arms,	 in	 this	 case	 first	 and	 last	 50	 nts	 of	 ycfD,	 C)	 Activation	 of	 Red/ET	
recombination	 leads	 to	 insertion	 of	 the	 cassette	 replacing	 ycfD	 gene	 leading	 to	 a	 neomycin(neoR)	 and	
kanamycin	 (kanR)	 resistance,	 the	 additional	 copy	 of	 the	 dominant	 wild	 type	 rpsL	 gene	 leads	 to	 strep	
sensitivity,	D)	With	a	second	transformation,	PCR	amplified	linear	DNA	of	ycfD	with	the	desired	mutation,	in	
this	case	the	 iron	binding	sites	H125	and	D127	are	mutated	to	Ala,	 is	 inserted	 into	the	bacteria,	E)	Red/ET	
directed	recombination	exchanges	the	rpsL-neo/kan	counter	selection	cassette	with	mutated	ycfD	resulting	
in	BW25113	(rpsL150,	ycfD	AxA)	strain,	which	is	resistant	to	streptomycin	(strepR).	
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5.2 Human	Cell	culture	
5.2.1 General	culturing	conditions	
BHK,	HeLa,	HEK293	and	HEK293T	cells	were	cultured	in	DMEM	(Dulbecco's	modified	Eagle's	
medium)	 supplemented	 with	 10%	 FBS,	 penicillin	 (100	 units/ml)	 and	 streptomycin	 (100	
μg/ml)	at	37	°C	with	5%	CO2.		
HeLa-Cell	Cycle	Chromobody®-TagRFP	were	cultured	additionally	with	50	µg/ml	Gentamycin.	
	
5.2.2 Cell	treatment	methods	
Hypoxic	 culture	 growth	 was	 performed	 in	 an	 Invivo	 300	 Hypoxic	 Workstation	 (Baker	
Ruskinn)	at	37	°C,	attached	to	the	Ruskinn	gas	mixer	module	Q.	Conditions	of	0.1	%	oxygen	
and	5	%	CO2	were	used.	
	
For	stress	inductions,	cells	were	incubated	with	1	mM	sodium	arsenite	added	directly	to	the	
medium	for	1	h	or	as	indicated.	
	
5.2.3 Transfection	
Cells	were	transfected	with	expression	plasmids	using	Lipofectamine®	2000	according	to	the	
manufacturer´s	instructions	or	PEI	pH	7.	Cell	medium	was	changed	3	h	post-transfection.	
Transfection	reagent	PEI	pH	7	was	prepared	as	described	in	Ehrhardt	et	al162.	
Amounts	used	for	both	transfection	reagents	are	listed	in	Table	9.	
	
Flask	size	 Transfection	 mix	 for	 Lipofectamine®	
2000	
Transfection	mix	for	PEI	pH	7	
12well	 1	µg	DNA	+	50	µl	DMEM;	2µl	
Lipofectamine®	2000	+	50	µl	DMEM	
	
6well	 2.5	µg	DNA	+	62.5	µl	DMEM;	2.5	µl	
Lipofectamine®	2000	+	62.5	µl	DMEM	
2.5	µg	DNA	+	5	µl	PEI	pH	7	+	50	µl	
DMEM	
T25	 10	µg	DNA	+	250	µl	DMEM;	10µl	
Lipofectamine®	2000	+	250	µl	DMEM	
10	µg	DNA	+	20µl	PEI	pH	7	+	200	µl	
DMEM	
T75	 	 20	µg	DNA	+	40µl	PEI	pH7	+	400	µl	
DMEM	
p100	 22	µg	DNA	+	750	µl	DMEM;	22	µl	
Lipofectamine®	2000	+	250	µl	DMEM	
22	µg	DNA	+	44	µl	PEI	pH	7	+	440	µl	
DMEM	
Table	9:	Amounts	of	transfection	reagents	used	for	transfections	
	
5.2.4 Harvesting	of	cells	
Cells	were	harvested	by	scraping	in	an	appropiate	amount	of	1x	PBS	or	by	trypsinizing	and	
following	centrifugation	at	800	g	for	5	min	at	room	temperature.	
	
5.2.5 Cell	lysis	
Harvested	 cells	 were	 lysed	 in	 Lysis	 buffer	 (see	 4.12.1	 or	 cell	 extraction	 buffer	 (Life	
technologies).	Both	buffers	were	supplemented	with	10	µl/ml	protease	inhibitor	and	each	10	
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µl/ml	phosphatase	inhibitor	cocktail	2	and	3.	Lysis	was	carried	out	for	10-30	min	rocking	at	8	
°C.	 Supernatant	 achieved	 from	 centrifugation	 at	 14000	 g	 for	 10	min	 at	 4	 °C	was	 used	 for	
further	experiments.	
	
5.2.6 Growth	assay	
Two	methods	were	used	to	monitor	cell	proliferation.		
1)	0.1x	106	cells	were	seeded	in	the	appropriate	amount	of	6	well	plates.	To	monitor	growth,	
every	 day	 cells	 from	 one	 6	 well	 plate	 were	 trypsinated	 and	 counted	 by	 the	 cell	 viability	
analyzer	Vi-CELL	XR	2.04.	Each	cell	line	was	seeded	and	counted	in	triplicates.	
2)	On	day	0	(T0),	103	cells	were	seeded	into	96	well	plates	in	6	replicates.	To	monitor	growth,	
media	was	removed	and	AquaBluerTM	diluted	1:100	 in	growth	medium	was	added	to	each	
well	and	incubated	at	37	°C,	5	%	CO2	for	5	h.	Fluorecence	intensity	at	540	nm	extinction	and	
590	nm	emmission	was	read	in	the	2104	EnVision®	Multilabel	Plate	Reader	(Perkin	Elmer).	
	
5.2.7 	Synchronization	
For	 synchronization,	 cells	 at	 30-50	 %	 confluency	 were	 grown	 with	 growth	 medium	
containing	 2	 mM	 thymidine.	 After	 17/18	 h	 incubation	 at	 37	 °C	 and	 5	 %	 CO2,	 cells	 were	
released	from	the	first	thymidine	block	by	removing	the	thymidine-containing	medium	and	
rinsing	 the	 cells	 two	 times	with	 growth	medium.	 Subsequently,	 cells	were	 trypsinized	and	
seeded	to	appropriate	cell	culture	dishes.		
6	 h	 after	 seeding,	 cells	 could	 be	 transfected	 using	 the	 appropriate	 amount	 of	 DNA	 and	
Lipofectamine®	2000.	The	second	thymidine	block	was	applied	after	10/9	h	by	addition	of	2	
mM	 thymidine	 to	 the	 growth	 medium.	 In	 case	 of	 transfection,	 cell	 growth	 medium	 was	
exchanged	 with	 medium	 containing	 2	 mM	 thymidine.	 Release	 of	 the	 second	 block	 after	
15/17	h	was	initiated	as	mentioned	above.		
	
Progression	 through	 cell	 cycle	was	monitored	 by	 flow	 cytomerty.	 For	 living	 cells,	 5	 µg/ml	
Hoechst33342	DNA	stain	(Gift	from	W.	Beisker,	HelmholtzZentrum	München)	was	added	to	
the	cells	in	growth	medium	and	incubated	for	at	least	30	min.	For	longer	storage,	cells	were	
fixed	in	70	%	EtOH	at	4	°C	for	at	least	30	min.	After	two	times	washing	with	1x	PBS,	DNA	was	
stained	with	NUCLEAR-ID®	Red	DNA	stain	diluted	1:500	in	1x	PBS.	
Subsequently,	cells	were	analyzed	using	flow	cytometry.	At	 least	1x104	cells	were	analyzed	
using	LRSII	flow	cytometer	(BD	Biosiences),	data	was	collected	using	FACSDiva	software	(BD	
Biosciences)	and	analyzed	using	FlowJo	software.	
	
Samples	 for	Western	 blot	were	 harvested	 by	 trypsination	 (see	 5.2.4).	 Protein	 levels	were	
analyzed	directly	by	SDS	PAGE	with	subsequent	Western	blot	or	after	immunoprecipitation	
of	OGFOD1	and/or	CCNA2.	
	
5.2.8 	Immunofluorecence	
5.2.8.1 Preparation	of	samples	
HeLa	 cells	 grown	 to	 50–70	 %	 confluence	 on	 18	 mm	 diameter	 glass	 coverslips	 were	
transfected	 with	 expression	 constructs	 using	 Lipofectamin®	 2000	 according	 to	 the	
manufacturer's	 instructions.	 24	 h	 post-transfection,	 cells	 were	 fixed	 with	 4%	
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paraformaldehyde	for	10	min	at	RT.	If	no	antibody	staining	was	needed,	the	cells	slides	were	
directly	stained	with	1	µg/ml	DAPI,	mounted	in	Vectashield	and	sealed	with	nail	polish.	
For	immunostaining	with	antibodies,	the	cells	were	permeabilized	with	1	%	Triton	X-100	in	
PBS.	After	blocking	in	blocking	solution	for	1	h,	primary	antibodies	were	diluted	in	blocking	
solution	and	applied	to	the	slides	for	1	hour	at	RT.	Subsequently,	same	procedure	was	used	
with	 the	 secondary	antibodies,	 incubation	was	 carried	out	 in	 the	dark.	Between	and	after	
antibody	incubations,	slides	were	washed	three	times	for	10	min	with	wash	solution.	After	
staining	with	1	µg/ml	DAPI,	slides	were	mounted	in	Vectashield	and	sealed	with	nail	polish.	
Buffers	and	solutions	are	listed	in	4.12.5.		
Slides	were	stored	at	4	°C	in	the	dark	and	analyzed	by	fluorescence	microscopy.	
	
5.2.8.2 Imaging	using	confocal	microscopy	
Light	 optical	 sections	 were	 acquired	 with	 a	 Leica	 TCS	 SP5-2	 confocal	 laser-scanning	
microscope	(Böttger	Lab,	Biocenter	LMU).	Fluorochromes	were	visualised	with	the	405	laser	
with	 an	 excitation	wavelength	of	 405nm	and	emission	 filters	 413	 to	 443nm	 for	DAPI.	 The	
argon	 laser	 with	 excitation	wavelength	 of	 488nm	 and	 emission	 filters	 496	 to	 537nm	was	
used	for	GFP.	To	obtain	an	improved	signal-to-noise	ratio,	each	section	image	was	averaged	
from	three	successive	scans.		
	
5.2.8.3 Imaging	using	fluorescence	microscopy	
Classic	fluorescence	microscopy	was	carried	out	using	Carl	Zeiss	LSM	510	META	(Dr.	Annette	
Feuchtinger,	 Andreas	 Voss,	 Abteilung	 Analytische	 Pathologie,	 Helmholtz	 Zentrum	
Neuherberg). 
	
5.3 Immunoprecipitation	assays	(IP)	
5.3.1 Immunoprecipitation	with	overexpressed	proteins	
All	 steps	 of	 the	 procedure	were	 carried	 out	 on	 ice.	 Transfected	 cells	were	 harvested	 and	
lysed	in	lysis	buffer	(see	4.12.1).	Lysed	cells	were	centrifuged	at	14000	g	for	10	min	at	4	°C	
and	 the	 resulting	 supernatant	 diluted	 with	 wash	 buffer	 1	 (see	 4.12.6).	 For	 subsequent	
analysis,	around	10	%	of	the	 input	were	spared	(Input	fraction,	„I“).	Proteins	not	bound	to	
beads	were	saved	for	subsequent	analysis	(„Flow	through	fraction“	or	„F“).	Elution	of	protein	
complexes	 („Beads	 fraction“,	 „B“	 or	 „Elution	 fraction“,	 „E“)	 was	 achieved	 dependent	 on	
precipitation	methode,	 see	 following	 subitems.	 Samples	 were	 analyzed	 by	 SDS	 PAGE	 and	
Western	blot.	
	
5.3.1.1 GFP	IP	
GFP	 immunoprecipitation	 in	 mammalian	 cells	 was	 performed	 using	 GFP-Trap®	 following	
manufacture’s	instructions.	Protein	complexes	were	eluted	from	the	beads	by	incubation	of	
beads	with	1x	Laemmli	buffer	at	95	°C	for	5	min.	
	
For	 recombinant	 IP,	 bacteria	were	 transformed	with	 appropriate	plasmids	 and	grown.	 For	
GFP-immunoprecipitation,	 in	total	2500	µg	crude	bacterial	 lysate	was	mixed	and	incubated	
for	2h	before	GFP-IP	was	performed	following	GFP-Trap®	instructions.	
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5.3.1.2 Flag	IP	
For	 IP	 of	 Flag-tagged	 protein,	 ANTI-FLAG®	 M2	 Affinity	 Gel	 was	 used	 following	 the	
instructions.	Elution	of	protein	complexes	was	achived	by	incubation	of	the	beads		with	100	
µg/ml	3X	FLAG®	Peptide	for	30	min	at	4	°C.	
	
5.3.1.3 GST	IP	
For	 recombinant	 IP,	 bacteria	were	 transformed	with	 appropriate	plasmids	 and	grown.	 For	
GST-immunoprecipitation,	 in	total	2500	µg	crude	bacterial	 lysate	was	mixed	and	incubated	
for	 2h	 before	 GST-IP	 was	 performed	 using	 Glutathione	 Sepharose	 4B	 (GE	 Healthcare)	
following	manufacture’s	instructions.	
	
5.3.2 Immunoprecipitation	with	endogenous	proteins	
1.5x	108	cells	were	harvested	and	 lysed	 (5.2.4	and	5.2.5).	To	capture	endogenous	proteins	
with	 the	 appropriate	 antibody,	 3	 µg	 antibody	was	 coupled	 to	 Protein	G	 Sepharose	 4	 Fast	
Flow	 (GE	 Healthcare)	 for	 2	 h.	 For	 immunoprecipitations	 after	 synchronization,	 1.5	 µg	
antibody	 was	 used	 for	 8x	 106	 cells.	 Subsequently,	 immunoprecipitation	 was	 carried	 out	
following	manufacture’s	 instructions.	 Protein	 complexes	were	 eluted	 by	 incubation	 of	 the	
beads	with	1x	Laemmli	buffer	at	95	°C	for	5	min.	Samples	were	analyzed	by	SDS	PAGE	and	
Western	blot.	
	
5.4 Analysis	of	samples	by	LC-MS/MS		
5.4.1 Analysis	of	IP	samples	
IP	 samples	 were	 analyzed	 by	 label-free	 LC–MS/MS	 (Juliane	Merl-Pham,	 Stephanie	 Hauck,	
HelmholtzZentrum	München).	
	
5.4.2 Analysis	of	isolated	ribosomes	
Isolated	ribosomal	fractions	(see	5.10.2)	were	analyzed	by	label-free	LC	MS/MS	(Axel	Imhof	
laboratory,	Ignasi	Forné,	Biomedical	Center	Munich,	LMU).	
	
5.5 F2H®	Assay	(ChromoTek)	
Fluorescence-2-hydrid	 assay	 (Chromotek)	 experiments	 were	 carried	 out	 following	 the	
manufacture’s	 protocol.	Differing	 from	 the	protocol,	 1.2	µg	GFP-bait	 and	1.2	µg	mCherry-
prey	DNA	with	 1.6	µg	platform	 reagent	were	 co-transfected	using	 Lipofectime	2000.	 Cells	
were	 fixed	with	 4	%	 paraformaldehyde	 (10	min	 at	 room	 temperature)	 and	 stained	with	 1	
µg/ml	DAPI.	Slides	were	mounted	in	Vectashield,	sealed	with	nail	polish,	and	stored	at	4	°C	in	
the	dark	until	analysis	by	fluorescence	microscopy.	
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5.6 	Molecular	cloning	
5.6.1 	Classic	cloning	
For	 classic	 cloning,	 the	 insert	 was	 amplified	 by	 PCR	 using	 primer	 which	 introduced	 the	
required	restriction	sites.	The	PCR	product	was	seperated	by	size	in	gel	electrophoresis.	PCR	
products	or	DNA	were	mixed	with	6x	DNA	gel	loading	dye	and	loaded	for	analysis	on	a	1	%	
agarose	gel	in	1x	TAE	buffer	(see	4.12.2)	supplemented	with	3	µl	HDGreen	(Intas)	for	50	ml	
of	gel.	Electrophoresis	was	carried	out	at	90	V.	Gel	elution	of	the	corresponding	DNA	band	
was	 carried	 out	 with	 the	 Macherey-Nagel	 „NucleoSpin	 Gel	 and	 PCR	 Clean-up“	 kit.	 PCR	
product	 and	 1	 µg	 of	 the	 cloning	 vector	 were	 digested.	 Afterwards,	 the	 vector	 was	
dephosphorylated	using	Calf	intestine	alkine	phosphatase	(New	England	Biolabs).	Ligation	of	
around	50	ng	gel-eluted	insert	and	10	ng	vector	was	carried	out	with	T4	ligase	(New	England	
Biolabs)	 for	 10	min-1	 h	 at	 RT.	 Ligated	 product	was	 transformed	 to	 heat	 shock	 competent	
TOP10	(see	5.1.1).	Positive	clones	were	identified	by	colony	PCR.	DNA	from	positive	clones	
was	 isolated	from	bacteria	culture	using	„QIAprep	Spin	Miniprep	kit“	 (Qiagen)	and	verified	
by	sequencing.	
	
5.6.2 	Cloning	by	alignment	
For	 cloning	 of	 gRNAs	 to	 the	 Cas9	 containing	 vector,	 sense	 and	 antisense	 gRNAs	 were	
purchased	from	Eurofins.	Aligned	gRNAs	(in	buffer	4.12.7)	formed	overhangs	mimiking	BbsI	
restriction.	The	vector	was	digested	with	BbsI.	Subsequent	procedure	as	described	in	5.6.1.	
	
5.6.3 	Mutagenesis	
Mutagenesis	 was	 carried	 out	 following	 the	 manufacture’s	 instructions	 (QuikChange	 Site-
directed	mutagenesis	kit,	Agilent).	
	
5.7 Generation	of	knockout	cell	using	CRISPR/Cas9	system	
Based	on	the	protocol	of	Ran	and	colleagues121,	knockout	cell	lines	were	generated	using	the	
genome	editing	method	CRISPR/Cas9.		
	
5.7.1 Generation	of	knockout	constructs	
Using	the	online	CRISPR	Design	tool	(http://crispr.mit.edu/),	guide	RNAs	were	designed	for	
OGFOD1,	NO66	and	MINA53	(see	Table	7)	according	to	the	nature	protocol	of	Ran	et	al121.	
Guide	 RNAs	 (gRNAs)	 were	 cloned	 into	 the	 pSpCas9(BB)-2A-Puro	 (Addgene	 plasmid	 ID:	
PX459;	 gift	 from	 Krappmann	 Lab,	 Helmholtz	 Zentrum	 München)	 plasmid	 as	 described	 in	
5.6.2.	
	
5.7.2 Transfection		
pSpCas9(BB)-2A-Puro	plasmids	with	inserted	gRNAs	were	transfected	into	Hek293	cells	using	
Lipofectamine	2000.	24	h	post	 transfection,	cells	carrying	 the	plasmids	were	selected	by	3	
µg/ml	puromycin	for	72	h.		
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5.7.3 Validation	of	knockout	on	genomic	level	
Isolation	 of	 clonal	 cell	 lines	was	 achieved	 by	 serial	 dilution	 into	 96	well	 plates.	 Single	 cell	
clones	were	 allowed	 to	 expand	 and	 later	 screened	 for	 successful	 genome	 editing	 by	 PCR	
amplification	of	the	corresponding	DNA	loci.	
For	isolation	of	genomic	DNA,	0.1x	106	cells	were	used.	Cell	were	harvested	by	trypsination	
and	 following	centrifugation	at	1000	g	at	 room	temperature	 for	4	min.	The	cell	pellet	was	
washed	twice	with	1x	PBS	and	resuspended	in	100	µl	Peqlab	DirectPCR	lysis	reagent,	1	µl	of	
proteinase	K	and	incubated	over	night	at	56°C.	Inactivation	of	Proteinase	K	was	achieved	by	
incubation	at	95	°C	for	30	min.	Supernatant	after	centrifugation	at	16000	g	at	4	°C	for	20	min	
was	transfered	to	a	new	tube	and	1-2	µl	used	for	PCR.		
Primers	used	for	amplification	of	engineered	genomic	loci	see	in	4.7,	Table	8.	PCR	program	
consisted	of	a	initial	denaturation	of	5	min	of	95	°C,	50	cycles	of	95	°C	for	30	sec,	57	°C	for	30	
sec	and	elongation	at	72	°C	for	1	min.	Additional	elongation	was	allowed	after	the	cycles	for	
1	min	at	72	°C.	PCR	products	were	analyzed	on	a	1	%	agarose	gel.	
	
5.7.4 Confirmation	of	knockout	on	protein	level	
Validation	 of	 knock-out	 on	 protein	 level	 was	 achieved	 by	 SDS	 PAGE	 with	 subsequent	
Western	Blot	analysis	and	immuno-staining	with	appropriate	antibodies	(see	5.9).	
	
5.8 	Reconstitution	of	cells	by	lentiviral	infection	
To	 insert	 DNA	 randomly	 into	 the	 genome,	 cells	were	 infected	with	 lentivirus	 carrying	 the	
construct	of	 interest	 in	 the	pLVTHM-T2A-CD2	vector	 (gift	 from	Krappmann	Lab,	Helmholtz	
Zentrum	München).	Lentivirus	was	produced	by	transfecting	2x	106	Hek293T	cells	with	1	µg	
pMD2.G,	 1.5	µg	pPAX	 (gift	 from	Krappmann	 Lab,	Helmholtz	 Zentrum	München),	 and	2	µg	
pLVTHM-T2A-CD2	with	insert	using	XtremeGene.	After	72	h,	virus	was	collected,	filtered	and	
target	Hek293	cells	were	 infected	 in	 the	presence	of	10	µg/ml	polybrene	by	spin	 infection	
for	 1.5	 h.	 Following	 centrifugation,	 the	 virus	 containing	 medium	 was	 removed	 and	 cells	
expanded.	
Positive	reconsitution	was	validated	by	SDS	PAGE	with	subsequent	Western	Blot	analysis	and	
immuno-staining	 with	 appropriate	 antibodies.	 Additionally,	 cells	 were	 analyzed	 for	 CD2-
positive	 cells	 by	 flow	 cytometry	 using	 Attune	 Acoustic	 Focusing	 Cytometer	 (AB,	 applied	
biosystems)	and	FlowJo	software.	
	
5.9 SDS	PAGE	and	Western	blot	
Polyacrylamid	 gels	 were	 casted	 following	 manufacture’s	 instructions	 (Biorad).	 Buffers	 are	
listed	in	4.12.3.	Samples	were	mixed	with	4x	Laemmli	buffer	and	incubated	for	5	min	at	95	
°C.	SDS	gels	were	run	at	80	V	for	20	min,	then	at	160	V	in	electrophoresis	buffer.	
Following	SDS	PAGE,	protein	are	blotted	onto	a	nitrocellulose	membran	at	200	mA	for	2	h	in	
blot	buffer.	Ponceau	S	Solution	was	used	to	visualize	the	protein	 loading.	Membrans	were	
block	in	5	%	milk	powder	in	TBST	for	1	h	at	RT	or	O/N	in	8	°C.	
After	blotting	proteins	on	a	nitrocellulose	membran,	the	membran	was	incubated	in	5	%	milk	
powder	in	TBST	for	at	least	one	hour	to	reduce	unspecific	antibody	binding.		
Immunodetection	was	carried	out	by	incubation	of	the	membrane	with	antibodies	diluted	in	
5	%	milk	powder	 in	TBST.	After	 incubation	with	 the	primary	antibody	and	 the	appropriate	
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secondary	HRP-coupled	antibody	for	1h	at	room	temperature,	protein	detection	was	carried	
out	with	chemiluminescent	solution	ECL	western	blotting	detection	reagents.		
	
5.10 	Ribosome	isolation	
5.10.1 	Isolation	of	ribosomes	for	bacteria	
Bacteria	were	harvested	in	late	log	phase	of	growth	by	centrifugation	for	10	min	at	3500	rpm	
at	 4	 °C.	 The	 pellets	 were	 lysed	 in	 bacteria	 cell	 lysis	 buffer	 and	 frozen	 immediately	 with	
DNaseI	in	liquid	nitrogen	and	transferred	to	-80	°C	for	at	least	30	min.	Following,	the	lysates	
were	incubated	for	10	min	on	ice	and	centrifugated	at	13200	rpm	for	30	min	at	4	°C.	Around	
4	mg	of	the	supernatant	was	loaded	on	top	of	a	10-40	%	(w/v)	linear	gradient	prepared	with	
BioComp	PGFip	(Piston	Gradient	Fractionator).	The	gradient	was	ultracentrifugated	for	3	h,	
35000	rpm	at	4	°C	(SW41	rotor,	Beckman	Coulter).	
Fractions	 were	 collected	 from	 top	 to	 bottom	 (Gradient	 Station	 ip,	 BioComp)	 while	
continuously	recording	the	absorption	profile	at	λ	=	254	nm	(Econo	UV	Monitor,	BIO-RAD).	
Buffers	are	listed	in	4.12.10.1	
This	experiment	was	performed	in	Dr.	Daniel	Wilson's	Laboratory,	Gene	Center	Munich,	with	
the	help	of	Dr.	Agata	Starosta.	
	
5.10.2 	Isolation	of	ribosomes	for	LC-MS/MS	analysis	
1.4x	107	cells	were	lysed	in	300	µl	freshly	prepared	lysis	buffer.	After	30	min	lysis	by	inverting	
at	4	°C,	the	lysate	was	centrifuged	at	14.000	rpm	for	15	min	at	4	°C	to	remove	debris,	nuclei	
and	mitochondria.	The	supernatant	was	loaded	onto	650	µl	of	sucrose	cushion	solution	and	
centrifuged	 for	 45	 min	 at	 100000	 rpm	 (TLA120.2	 rotor,	 Beckman	 Coulter).	 After	
centrifugation,	 supernatant	was	 removed	 immediately.	 The	 ribosomal	 pellet	was	 carefully	
resuspended	in	storage	buffer	on	ice	to	homogeneity.	Buffers	are	listed	in	4.12.10.2.	
The	resulting	supernatant	are	the	solved	ribosomes	and	was	measured	for	OD260	absorption.	
1	 unit	 OD260	 corresponds	 to	 20	 pmol/ml	 ribosomes.	 2	 pmol	 ribosomes	were	 used	 for	 LC-
MS/MS	analysis.	
	
5.10.3 	Isolation	for	ribosome	profiles	for	mammalian	cells	
6x	108	cells	were	lysed	in	600	µl	freshly	prepared	lysis	buffer.	After	1	h	10	min	incubation	on	
ice,	 the	 lysate	 was	 centrifuged	 at	 12.000	 g	 for	 10	 min	 for	 4	 °C	 to	 remove	 debris.	 The	
supernatant	was	loaded	onto	500	µl	of	30	%	sucrose	cushion	solution	and	centrifuged	for	16	
h	 at	 26000	 rpm	 (TLA120.2	 rotor,	 Beckman	Coulter).	 After	 centrifugation,	 supernatant	was	
removed	 immediately.	 The	 ribosomal	 pellet	 was	 carefully	 resuspended	 on	 ice	 in	 storage	
buffer	until	homogeneity.	To	remove	non-suspended	particles,	the	solution	was	centrifuged	
for	1	min	at	12000	g	at	4	°C.	The	resulting	supernatant	contained	the	solved	ribosomes	and	
was	measured	for	A260	absorption	and	frozen	in	liquid	nitrogen.	
To	analyze	the	mono-	and	polysome	fractions	 in	the	ribosome	preparation	of	different	cell	
lines,	2.6	units	OD260	were	directly	loaded	onto	a	10	-	40	%	sucrose	gradient.	Gradients	were	
generated	with	BioComp	PGFip	(Piston	Gradient	Fractionator)	with	10	%	and	40	%	sucrose	
buffer.	 Gradients	were	 centrifuged	 for	 19	 h	 at	 16500	 rpm	 at	 4	 °C	 (SW40	 rotor,	 Beckman	
Coulter).	Buffers	are	listed	in	4.12.10.3.	Procedure	is	depicted	in	Figure	68.	
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Figure	68:	Sucrose	gradient	A260	absorbance	ribosome	profiles.	Cell	lysates	were	layered	onto	a	30%	sucrose	
cushion.	Crude	ribosome	pellets	achieved	from	centrifugation	were	resuspended	and	loaded	onto	a	10-40%	
sucrose	gradient.	 Following	ultracentrifugation,	 the	gradients	were	 fractionated	 from	top	 to	bottom	while	
continuously	recording	the	absorption	profile	at	λ	=	254	nm.	
	
Fractions	 were	 collected	 from	 top	 to	 bottom	 (Gradient	 Station	 ip,	 BioComp)	 while	
continuously	recording	the	absorption	profile	at	λ	=	254	nm	(Econo	UV	Monitor,	BIO-RAD).	
The	 protocol	 was	 adapted	 by	 Sarah	 Matheisl	 from	 Khatter	 and	 colleagues	 163.	 This	
experiment	was	performed	in	Prof.	Dr.	Roland	Beckmanns	Laboratory,	Gene	Center	Munich,	
LMU,	with	the	help	of	Dr.	Sarah	Matheisl.	
	
5.11 	Hydra	culture	
Hydra	 experiments	 were	 carried	 out	 with	 the	 help	 of	 Jasmin	Moneer	 in	 the	 Böttger	 Lab,	
Biocenter	LMU.	Hydra	vulgaris	 strain	Basel	was	held	 in	mass	culture	 in	hydra	medium	at	a	
constant	temperature	of	18	°C	and	were	fed	regularly	with	freshly	hatched	Artemia	nauplii.		
	
5.11.1 	Transfection	of	Hydra	cells	
2.4	 mg	 Gold	 particles	 (1.0	 µm	 diameter,	 BioRad)	 were	 coated	 with	 10	 µg	 plasmid	 DNA	
according	to	 instructions	of	manufacturer.	DNA	was	 introduced	 into	the	hydra	cells	with	a	
Helios	gene	gun	system	(BioRad)	as	described	before	128.	
	
5.11.2 	Fixation	and	mounting	of	Hydra	
Animals	 were	 relaxed	 in	 2	 %	 urethane	 in	 hydra	 medium	 and	 fixed	 with	 4	 %	
paraformaldehyde	at	 room	 temperature	 for	 1	hour.	After	 three	washes	with	PBS,	 animals	
were	counterstained	with	1	µg/ml	DAPI	and	mounted	on	slides	in	Vectashield.	
	
5.12 	Phylogenetic	analyses	
5.12.1 	Ensemble	database	searches	
Sequences	 were	 obtained	 in	 collaboration	 with	 Andreas	 Lengeling	 (The	 Roslin	 Institute,	
University	 of	 Edinburgh).	 Orthologes	 of	 NO66	 (RIOX1)	 and	 MINA53	 (RIOX2)	 genes	 were	
identified	 using	 Ensembl	 (http://www.ensembl.org/info/about/species.html)	 and	
EnsemblMetazoa	 (http://metazoa.ensembl.org/species.html)	 portals	 by	 employing	 pblast	
searches.	 The	 genome	 of	 each	 selected	 species	 was	 queried	 with	 the	 human	 or	 Hydra	
vulgaris	 RIOX1/Riox1	 (Q9H6W3	 and	 XP_002157896.3)	 and	 ROX2/Riox2	 (Q8IUF8	 and	
XP_002167270)	 protein	 reference	 sequences.	 For	 phylogenetic	 analyses	 of	 orthologues	
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proteins	only	sequences	were	included	in	which	both,	the	human	and	hydra	pblast	queries,	
matched	 to	 a	 single	 locus	of	 the	 selected	 species	 and	 the	 identified	protein	displayed	 the	
characteristic	 domain	 architecture	 of	 Riox1	 and	 Riox2	 proteins.	 Species	 were	 selected	
throughout	the	animal	kingdom	to	represent	main	taxonomic	classes,	where	available	with	
at	 least	 to	species	per	class	depending	on	genome	sequence	coverage	and	quality	of	gene	
structure	annotations.	Hydra	vulgaris	protein	sequences	and	gene	annotations	for	Riox1	and	
Riox2	were	obtained	from	https://metazome.jgi.doe.gov/pz/portal.html.	
	
5.12.2 	Multiple-sequence	alignments	and	construction	of	phylogenetic	trees	
Dr.	 Evi	 Lengeling-Wollscheid	 (The	 Roslin	 Institute,	 University	 of	 Edinburgh)	 performed	 the	
sequence	 alignments	 and	 generated	 the	 phylogenetic	 tree.	 Therefore,	 JmjC	 domain	
sequences	of	MINA53	and	NO66	from	49	species	and	of	YcfD	(ecycfD),	the	ROX	protein	from	
Escherichia	 coli	 were	 subjected	 to	 a	 maximum	 likelihood	 analysis	 using	 the	 online	
phylogenetic	 tool	W-IQ-TREE	 (Version	1.5.4	at	http://iqtree.cibiv.univie.ac.at,	 Trifinopoulos	
et	al.,	NAR	2016;	PMID:	27084950).	 In	the	 IQ-Tree	webserver	the	 ‘Substitution	model’	and	
the	 default	 ‘Auto’	 settings	 were	 selected	 to	 determine	 the	 best-fit	 substitution	 model	
followed	by	tree	construction.	Within	the	‘Branch	Support	Analysis’	the	default	settings	of	an	
ultrafast	 bootstrap	 analysis	 with	 1000	 replicates	 was	 used,	 with	 maximum	 number	 of	
iterations	 set	 at	 1000	 and	 a	 minimum	 correlation	 coefficient	 of	 0.99	 and	 for	 the	 ‘Single	
branch	tests’	the	SH-aLRT	branch	test	with	1000	replicates	was	selected164.	
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6 Appendix	
6.1 Additional	data	
6.1.1 CCNA2	and	OGFOD1	interaction	
	
Figure	69:	Influence	of	GFP-tagged	OGFOD1	on	cell	cycle	progression;	Hek293T	cells	were	synchronized	with	
a	double	 thymidine	block.	Between	 the	 first	 and	 second	block,	 cells	were	 transfected	with	 indicated	GFP-
tagged	 proteins	 using	 Lipofectamine.	 Samples	 were	 taken	 after	 indicated	 hours	 after	 release.	 Cell	 cycle	
profiles	were	obtained	by	flow	cytometry	after	NUCLEAR-ID®	Red	DNA	stain	(ENZO	life	sicence,	ENZ-52406)	
staining	 of	 DNA.	 In	 A)	 untransfected	 cells	 B)-D)	 overexpression	 of	 GFP-tagged	 proteins	 as	 indicated,	 cell	
numbers	are	listed	under	the	graphs.	
	
	
	
Count
Specimen 0h O1axa.fcs GFP-positive 48525
Specimen 2h O1axa.fcs GFP-positive 31005
Specimen 4h o1axa.fcs GFP-positive 50568
Specimen 6h o1 axa.fcs GFP-positive 27852
Specimen 7h o1axa.fcs GFP-positive 53982
Specimen 9h o1axa.fcs GFP-positive 50248
Sample Name Subset NameCount
Specimen 0h.fcs GFP-negative 2895
Specimen 2h.fcs GFP-negative 2580
Specimen 4h.fcs GFP-negative 13352
Specimen 6h.fcs GFP-negative 12851
Specimen 7h.fcs GFP-negative 22288
Specimen 9h.fcs GFP-negative 15874
Sample Name Subset Name
Not transfected cells 
DNA content
2n  4n
DNA content
0h
2h
6h
9h
2n   4n
4h
7h
DNA content
0h
2h
6h
9h
2n   4n
4h
7h
Overexpression
OGFOD1 (H155A, 
D157A)-GFP
Overexpression 
OGFOD1-GFP
Overexpression 
NLS-GFP
DNA content
0h
2h
6h
9h
2n   4n
4h
7h
Count
Specimen 0h nls.fcs GFP-positive 27857
Specimen 2h nls.fcs GFP-positive 15670
Specimen 4h nls.fcs GFP-positive 19868
Specimen 6h nls.fcs GFP-positive 35312
Specimen 7h nls.fcs GFP-positive 37452
Specimen 9h nls.fcs GFP-positive 70167
Sample Name Subset Name Count
Specimen 0h O1.fcs GFP-positive 41771
Specimen 2h o1.fcs GFP-positive 29504
Specimen 4h o1.fcs GFP-positive 41997
Specimen 6h o1.fcs GFP-positive 41716
Specimen 7h o1.fcs GFP-positive 54308
Specimen 9h o1.fcs GFP-positive 62084
Sample Name Subset Name
A B DC
0h
2h
6h
9h
4h
7h
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Figure	70:	Proteins	identified	in	CCNA2	IP	sample	using	LC-MS/MS	with	enrichment	higher	than	two	fold.	
Accession
Unique	
peptides
Confidence	
score Name Description ratio	CCNA2-IP/control
P67870 2 54 CSNK2B Casein	kinase	II	subunit	beta Infinity
Q9HD26 2 55 GOPC Golgi-associated	PDZ	and	coiled-coil	motif-containing	protein Infinity
Q12834 2 67 CDC20 Cell	division	cycle	protein	20	homolog Infinity
P33552 3 82 CKS2 Cyclin-dependent	kinases	regulatory	subunit	2 1104.3
P01857 2 32 IGHG1 Ig	gamma-1	chain	C	region 407.7
Q13309 6 199 SKP2 S-phase	kinase-associated	protein	2 168.7
P20248 14 649 CCNA2 Cyclin-A2 106.2
P61024 3 101 CKS1B Cyclin-dependent	kinases	regulatory	subunit	1 76.7
A5YKK6 6 159 CNOT1 CCR4-NOT	transcription	complex	subunit	1 72.8
Q15369 2 32 TCEB1 Transcription	elongation	factor	B	polypeptide	1 63.7
O60343 5 159 TBC1D4 TBC1	domain	family	member	4 58.5
P61962 2 60 DCAF7 DDB1-	and	CUL4-associated	factor	7 42.7
P28749 12 440 RBL1 Retinoblastoma-like	protein	1 37.8
P63208 5 168 SKP1 S-phase	kinase-associated	protein	1 36.9
P30291 9 304 WEE1 Wee1-like	protein	kinase 35.1
Q9H211 3 94 CDT1 DNA	replication	factor	Cdt1 33.7
Q9BY12 6 174 SCAPER S	phase	cyclin	A-associated	protein	in	the	endoplasmic	reticulum 26.3
P24941 9 363 CDK2 Cyclin-dependent	kinase	2 26.0
Q92793 8 254 CREBBP CREB-binding	protein 23.4
P19474 7 211 TRIM21 E3	ubiquitin-protein	ligase	TRIM21 17.6
O75496 3 86 GMNN Geminin 15.5
P55209 2 46 NAP1L1 Nucleosome	assembly	protein	1-like	1 15.2
Q9H0U4 2 89 RAB1B Ras-related	protein	Rab-1B 14.6
Q09472 2 79 EP300 Histone	acetyltransferase	p300 14.4
P46782 3 125 RPS5 40S	ribosomal	protein	S5 13.7
Q6PJG2 5 170 ELMSAN1 ELM2	and	SANT	domain-containing	protein	1 12.7
P06493 7 310 CDK1 Cyclin-dependent	kinase	1 10.4
P61254 2 39 RPL26 60S	ribosomal	protein	L26 8.4
Q9Y3Z3 13 423 SAMHD1 Deoxynucleoside	triphosphate	triphosphohydrolase	SAMHD1 8.4
Q7Z2Z1 7 195 TICRR Treslin 8.2
Q04917 2 70 YWHAH 14-3-3	protein	eta 7.6
P13674 2 47 P4HA1 Prolyl	4-hydroxylase	subunit	alpha-1 5.8
P12268 4 130 IMPDH2 Inosine-5'-monophosphate	dehydrogenase	2 5.7
Q4VCS5 7 251 AMOT Angiomotin 5.6
Q15459 2 55 SF3A1 Splicing	factor	3A	subunit	1 4.7
Q14974 3 108 KPNB1 Importin	subunit	beta-1 4.4
P15927 2 72 RPA2 Replication	protein	A	32	kDa	subunit 4.2
P31946 2 47 YWHAB 14-3-3	protein	beta/alpha 4.0
Q9UJZ1 2 65 STOML2 Stomatin-like	protein	2,	mitochondrial 3.9
P05141 2 40 SLC25A5 ADP/ATP	translocase	2 3.9
Q71U36 10 408 TUBA1A Tubulin	alpha-1A	chain 3.7
P27694 6 154 RPA1 Replication	protein	A	70	kDa	DNA-binding	subunit 3.6
P48735 2 53 IDH2 Isocitrate	dehydrogenase	[NADP],	mitochondrial 3.6
P31939 2 57 ATIC Bifunctional	purine	biosynthesis	protein	PURH 3.5
P07437 2 459 TUBB Tubulin	beta	chain 3.5
P78527 10 266 PRKDC DNA-dependent	protein	kinase	catalytic	subunit 3.4
P61247 2 46 RPS3A 40S	ribosomal	protein	S3a 3.4
P13489 2 87 RNH1 Ribonuclease	inhibitor 3.2
P62081 2 36 RPS7 40S	ribosomal	protein	S7 3.1
P55060 2 86 CSE1L Exportin-2 2.9
Q04837 3 74 SSBP1 Single-stranded	DNA-binding	protein,	mitochondrial 2.6
P62258 9 374 YWHAE 14-3-3	protein	epsilon 2.5
P60174 7 203 TPI1 Triosephosphate	isomerase 2.5
O00571 3 82 DDX3X ATP-dependent	RNA	helicase	DDX3X 2.5
P31930 2 62 UQCRC1 Cytochrome	b-c1	complex	subunit	1,	mitochondrial 2.3
P07954 2 56 FH Fumarate	hydratase,	mitochondrial 2.2
Q13162 2 75 PRDX4 Peroxiredoxin-4 2.2
P63104 6 194 YWHAZ 14-3-3	protein	zeta/delta 2.1
Q92499 2 44 DDX1 ATP-dependent	RNA	helicase	DDX1 2.1
P60660 3 64 MYL6 Myosin	light	polypeptide	6 2.1
Q16576 2 79 RBBP7 Histone-binding	protein	RBBP7 2.0
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Figure	71:	Selection	of	proteins	with	enrichment	higher	than	4	or	lower	than	0.5	identified	in	Flag-CCNA2	IP,	
part	I.	
	
Accession
Unique	
peptides
Confidence	
score Name Description
Ogfod1	WT/	
control
Ogfod1	MUT/	
control
P55795 2 353 HNRNPH2 Heterogeneous	nuclear	ribonucleoprotein	H2 77.98 88.12
Q7L014 6 189 DDX46 Probable	ATP-dependent	RNA	helicase	DDX46 68.95 2.76
Q9BYN8 2 64 MRPS26 28S	ribosomal	protein	S26,	mitochondrial 47.59 63.52
O00299 2 49 CLIC1 Chloride	intracellular	channel	protein	1 46.40 67.65
P49591 2 55 SARS Serine--tRNA	ligase,	cytoplasmic 31.58 38.92
Q15637 2 41 SF1 Splicing	factor	1 30.96 57.78
P20674 2 59 COX5A Cytochrome	c	oxidase	subunit	5A,	mitochondrial 30.67 42.04
Q86VP6 3 61 CAND1 Cullin-associated	NEDD8-dissociated	protein	1 22.18 18.08
P30520 2 58 ADSS Adenylosuccinate	synthetase	isozyme	2 18.87 25.95
Q8N543 9 224 OGFOD1 Prolyl	3-hydroxylase	OGFOD1 18.10 16.01
P49755 2 72 TMED10 Transmembrane	emp24	domain-containing	protein	10 16.82 20.95
Q15181 3 86 PPA1 Inorganic	pyrophosphatase 14.69 19.46
Q99497 3 75 PARK7 Protein	deglycase	DJ-1 12.45 15.62
P30048 2 68 PRDX3 Thioredoxin-dependent	peroxide	reductase,	mitochondrial 11.73 10.62
P62937 3 90 PPIA Peptidyl-prolyl	cis-trans	isomerase	A 11.18 12.62
P62273 2 56 RPS29 40S	ribosomal	protein	S29 11.02 12.37
P35080 2 60 PFN2 Profilin-2 10.35 18.36
P15927 2 46 RPA2 Replication	protein	A	32	kDa	subunit 10.05 9.10
P27797 8 222 CALR Calreticulin 10.00 11.56
O43663 2 50 PRC1 Protein	regulator	of	cytokinesis	1 9.53 7.95
O95983 2 53 MBD3 Methyl-CpG-binding	domain	protein	3 8.84 7.32
P51858 2 52 HDGF Hepatoma-derived	growth	factor 8.71 10.18
P60174 8 273 TPI1 Triosephosphate	isomerase 8.71 10.28
P67775 3 100 PPP2CA Serine/threonine-protein	phosphatase	2A	catalytic	subunit	alpha	isoform 8.70 9.20
P54819 2 43 AK2 Adenylate	kinase	2,	mitochondrial 8.69 11.52
P22234 5 126 PAICS Multifunctional	protein	ADE2 8.66 8.65
P22695 2 42 UQCRC2 Cytochrome	b-c1	complex	subunit	2,	mitochondrial 8.27 9.23
P61204 4 119 ARF3 ADP-ribosylation	factor	3 8.19 9.98
P33316 3 89 DUT Deoxyuridine	5'-triphosphate	nucleotidohydrolase,	mitochondrial 8.18 9.97
P19623 2 39 SRM Spermidine	synthase 8.16 9.07
P62736 2 329 ACTA2 Actin,	aortic	smooth	muscle 7.94 6.44
O15347 2 73 HMGB3 High	mobility	group	protein	B3 7.60 8.29
P52565 2 44 ARHGDIA Rho	GDP-dissociation	inhibitor	1 7.25 7.86
O14929 4 127 HAT1 Histone	acetyltransferase	type	B	catalytic	subunit 7.16 8.84
Q92688 2 71 ANP32B Acidic	leucine-rich	nuclear	phosphoprotein	32	family	member	B 7.07 7.46
O15355 2 44 PPM1G Protein	phosphatase	1G 6.35 6.91
P13797 6 202 PLS3 Plastin-3 6.10 6.92
P00505 2 68 GOT2 Aspartate	aminotransferase,	mitochondrial 6.06 7.30
P51148 2 62 RAB5C Ras-related	protein	Rab-5C 6.06 5.85
O76003 2 45 GLRX3 Glutaredoxin-3 6.03 7.34
P30086 2 65 PEBP1 Phosphatidylethanolamine-binding	protein	1 6.03 7.25
P07737 5 144 PFN1 Profilin-1 5.53 6.82
Q9NQT5 2 56 EXOSC3 Exosome	complex	component	RRP40 5.52 6.11
P13667 9 277 PDIA4 Protein	disulfide-isomerase	A4 5.43 6.61
Q92973 2 50 TNPO1 Transportin-1 5.40 11.07
Q52LJ0 2 93 FAM98B Protein	FAM98B 5.32 7.23
Q8WUM4 3 97 PDCD6IP Programmed	cell	death	6-interacting	protein 5.24 6.16
Q16630 4 83 CPSF6 Cleavage	and	polyadenylation	specificity	factor	subunit	6 5.19 6.02
P20618 2 57 PSMB1 Proteasome	subunit	beta	type-1 5.03 5.76
Q15185 3 82 PTGES3 Prostaglandin	E	synthase	3 5.03 5.54
O14980 4 119 XPO1 Exportin-1 4.86 4.93
P00918 2 39 CA2 Carbonic	anhydrase	2 4.84 5.45
P27694 3 95 RPA1 Replication	protein	A	70	kDa	DNA-binding	subunit 4.74 3.72
Q9BRJ2 2 36 MRPL45 39S	ribosomal	protein	L45,	mitochondrial 4.56 5.42
P13693 2 70 TPT1 Translationally-controlled	tumor	protein 4.55 4.91
Q9UBS4 3 92 DNAJB11 DnaJ	homolog	subfamily	B	member	11 4.54 6.26
P31150 2 43 GDI1 Rab	GDP	dissociation	inhibitor	alpha 4.53 5.06
Q9NY27 2 57 PPP4R2 Serine/threonine-protein	phosphatase	4	regulatory	subunit	2 4.53 5.74
Q9UNZ2 2 41 NSFL1C NSFL1	cofactor	p47 4.49 5.39
Q13405 2 67 MRPL49 39S	ribosomal	protein	L49,	mitochondrial 4.49 4.56
O95684 2 44 FGFR1OP FGFR1	oncogene	partner 4.46 5.00
P24666 3 68 ACP1 Low	molecular	weight	phosphotyrosine	protein	phosphatase 4.45 5.05
P15531 4 87 NME1 Nucleoside	diphosphate	kinase	A 4.41 4.84
O14737 2 73 PDCD5 Programmed	cell	death	protein	5 4.39 4.34
Q9Y5L4 2 63 TIMM13 Mitochondrial	import	inner	membrane	translocase	subunit	Tim13 4.39 5.01
P40925 2 38 MDH1 Malate	dehydrogenase,	cytoplasmic 4.34 4.05
P55209 6 227 NAP1L1 Nucleosome	assembly	protein	1-like	1 4.26 4.32
P07237 4 131 P4HB Protein	disulfide-isomerase 4.17 5.00
Q15365 3 180 PCBP1 Poly(rC)-binding	protein	1 4.13 4.02
Q9Y2L1 2 38 DIS3 Exosome	complex	exonuclease	RRP44 4.10 4.28
P63208 4 121 SKP1 S-phase	kinase-associated	protein	1 0.50 0.42
Q9Y4P3 2 58 TBL2 Transducin	beta-like	protein	2 0.50 0.46
Q96HS1 9 257 PGAM5 Serine/threonine-protein	phosphatase	PGAM5,	mitochondrial 0.50 0.47
Q15208 12 418 STK38 Serine/threonine-protein	kinase	38 0.49 0.49
Q9Y2W1 25 861 THRAP3 Thyroid	hormone	receptor-associated	protein	3 0.48 0.55
O14744 26 868 PRMT5 Protein	arginine	N-methyltransferase	5 0.47 0.46
P62314 3 74 SNRPD1 Small	nuclear	ribonucleoprotein	Sm	D1 0.47 0.48
...
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Figure	72:	(Continued	list	from	Figure	71)	Selection	of	proteins	with	enrichment	higher	than	4	or	lower	than	
0.5	identified	in	Flag-CCNA2	IP,	part	II.	
	
Q16875 12 439 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	3 0.46 0.47
Q8TDN6 2 48 BRIX1 Ribosome	biogenesis	protein	BRX1	homolog 0.45 0.48
Q9Y3Z3 24 778 SAMHD1 Deoxynucleoside	triphosphate	triphosphohydrolase	SAMHD1 0.45 0.38
P35527 43 1377 KRT9 Keratin,	type	I	cytoskeletal	9 0.45 0.29
Q9BRP8 3 95 PYM1 Partner	of	Y14	and	mago 0.44 0.42
P62857 3 99 RPS28 40S	ribosomal	protein	S28 0.44 0.35
P16989 8 366 YBX3 Y-box-binding	protein	3 0.44 0.55
P98179 2 60 RBM3 RNA-binding	protein	3 0.44 0.44
Q9H211 5 149 CDT1 DNA	replication	factor	Cdt1 0.43 0.43
Q9UPP1 8 195 PHF8 Histone	lysine	demethylase	PHF8 0.42 0.35
P24941 7 291 CDK2 Cyclin-dependent	kinase	2 0.42 0.34
P67809 9 472 YBX1 Nuclease-sensitive	element-binding	protein	1 0.41 0.47
P04264 31 1183 KRT1 Keratin,	type	II	cytoskeletal	1 0.40 0.31
Q14681 7 265 KCTD2 BTB/POZ	domain-containing	protein	KCTD2 0.39 0.43
P35908 21 934 KRT2 Keratin,	type	II	cytoskeletal	2	epidermal 0.38 0.29
P13645 20 876 KRT10 Keratin,	type	I	cytoskeletal	10 0.37 0.32
Q9NXV2 7 323 KCTD5 BTB/POZ	domain-containing	protein	KCTD5 0.36 0.41
P23588 12 431 EIF4B Eukaryotic	translation	initiation	factor	4B 0.36 0.43
Q7RTV0 2 86 PHF5A PHD	finger-like	domain-containing	protein	5A 0.36 0.39
P02768 8 221 ALB Serum	albumin 0.35 0.29
P02647 2 70 APOA1 Apolipoprotein	A-I 0.34 0.27
P63220 5 169 RPS21 40S	ribosomal	protein	S21 0.34 0.31
Q02413 4 121 DSG1 Desmoglein-1 0.33 0.36
P46778 4 69 RPL21 60S	ribosomal	protein	L21 0.32 0.30
P09234 2 44 SNRPC U1	small	nuclear	ribonucleoprotein	C 0.32 0.18
P05109 3 62 S100A8 Protein	S100-A8 0.31 0.37
Q7Z353 2 39 HDX Highly	divergent	homeobox 0.31 0.51
Q8N5Z5 10 344 KCTD17 BTB/POZ	domain-containing	protein	KCTD17 0.29 0.33
Q96DR8 2 34 MUCL1 Mucin-like	protein	1 0.26 0.27
P07477 3 84 PRSS1 Trypsin-1 0.22 0.20
Q86YZ3 7 325 HRNR Hornerin 0.22 0.16
P31944 3 87 CASP14 Caspase-14 0.22 0.24
P06702 3 100 S100A9 Protein	S100-A9 0.18 0.26
P31025 2 51 LCN1 Lipocalin-1 0.16 0.07
Q9NZT1 2 102 CALML5 Calmodulin-like	protein	5 0.14 0.14
P81605 3 96 DCD Dermcidin 0.14 0.13
P25311 2 50 AZGP1 Zinc-alpha-2-glycoprotein 0.14 0.20
P29508 2 57 SERPINB3 Serpin	B3 0.12 0.22
Q6UWP8 2 94 SBSN Suprabasin 0.08 0.14
Q6N063 2 66 OGFOD2 2-oxoglutarate	and	iron-dependent	oxygenase	domain-containing	protein	2 0.06 0.04
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Figure	 73:	 Proteins	 with	 altered	 CCNA2	 binding	 behaviour	 identified	 in	 Flag-CCNA2	 IP	 with	 additional	
overexpression	 of	 OGFOD1	 wild	 type	 (WT),	 OGOFD1	 H155A,	 D157A	 (MUT),	 and	 OGFOD2	 Isoform	 1	
(OGFOD2I1,	„control“)	using	LC-MS/MS.	
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6.1.2 Ribosomal	profiles	for	knockout	cell	lines	
	
	
Figure	74:	Sucrose	gradient	A260	absorbance	ribosome	profiles	of	Hek293,	Hek293-OGFOD1	D2	+/-,	Hek293	
MINA53-KO#4,	 and	 Hek293	 NO66-KO#3	 ribosomes;	 two	 technical	 replicates	 of	 ribosome	 profiles	 from	 A)	
Hek293	 wild	 type	 (WT)	 cells,	 B)	 Hek293-OGFOD1-D2	 +/-	 cells,	 C)	 Hek293	 NO66-KO#3,	 and	 D)	 Hek293	
MINA53-KO#4;	the	positions	of	different	ribosomal	species	are	indicated.	
	
The	 wild	 type	 profiles	 display	 a	 typical	 polysome	 profile	 (Figure	 74	 A).	 The	 first	 peak	
detectable	with	this	experimental	setting	was	the	60S	peak	corresponding	to	the	large	(60S)	
subunit,	followed	by	the	monosome	peak	(80S)	and	several	smaller	polysomal	peaks.		
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6.1.3 MINA53	and	NO66	
	
Figure	 75:	 Clustal	 omega	 alignment	 of	 NO66	 protein	 sequences	 from	 H.sapiens	 (Uniprot:	 Q9H6W3),	
M.musculus	 (Q9JJF3),	 D.rerio	 (A3KP59),	 X.laevis	 (A0A1L8G801),	 C.elegans	 (O01658),	 D.melanogaster	
(E2QD64)	 and	H.vulgaris.	 The	 protein	 domains	 JmjC	 (blue),	 dimerization	 (yellow),	winged-helix	 (green)	 as	
well	 as	 the	 prospective	 iron-binding	 motif	 HxD…H	 (red)	 are	 indicated	 based	 on	 the	 human	 sequence6.	
Lengths	of	the	individual	N-terminal	extension	domains	are	indicated	(grey).		
	
	
H  D H
JmjC domain
dimerization domain
winged helix domain
                                                                             
H.sapiens           184aa RRVLAELNR-------IPSSRRRAARLFEWLIAPMPPDHFYRRLWEREAVLVRRQDHTYYQGLFSTADLDSMLR
M.musculus          146aa QQVLTELNG-------IPSSRRRAARLFEWLLAPLPPDHFYRRLWEREAVLVRRQDRSYYEGLFSTADLDSMLR
D.rerio             87aa  DILLTDLAK-------VNNSRDRANRLFQWLIHPVQDKSFFRDNWEKKPILIQRQNADYYKGLFSTAEFDRILR
X.laevis            133aa NTVLQDLGK-------IHNSKARAASLFEWLISPLAPADFFRDVWEQKPVLIKRHNHEYYDGLFSTKEFDRILR
C.elegans           284aa -----PAVDFDKFPFTDEDSVVTSSRAFGFMISPCDVQTFFDKFYQSNVLVVRRKQPTYFGNLFSTARLGELLE
D.melanogaster      196aa GNNNNDEKETETIETHKADSVEEGRRVLQWILFPVQTKVFFKDFWEHTACLVQRSNPKYFQSMISFKMLDEILI
H.vulgaris          167aa NQEKNDITNEHSKNKIKNLSSLSGKELFNWVLAPISSERFFSEAWQKKPLFIKRRQPLYNTNWFSTKKLDKILR
                                             *   .   : ::: *     *:   ::    .::* :  *  . :*   :. :* 
H.sapiens           NEEVQFGQHLDAARYINGRRETLNPPGRALPAAAWSLYQAGCSLRLLCPQAFSTTVWQFLAVLQEQFGSMAGSNVYLTPP
M.musculus          YEDVQFGQHLDAARYVDGRRETLNPPGRALPAAAWSLYRAGCSLRLLCPQAFSPTVWQFLAVLQEQFGSMAGSNVYLTPP
D.rerio             NDDVQYGVNLDVTSYTNGKRETHNPPGRALPYTVWDFYESGCSIRMLNPQAFSSTVWQVLSVLQEKFGSMAGANVYLTPP
X.laevis            EDNVQFGVNLDVTSYTDGNRETHNPPGRALPLVVWDYFKNGCSLRLLNPQSFCGPVWNVLSVLQELFGSMVGANTYLTPA
C.elegans           KNHLEYGRNINIAQYKNGVRTTLNGQGRAYPQIVKQHLHNMCSVQLVNPQTYDDRIWYLCEVIQEQFGCFVGANTYLTPA
D.melanogaster      RHHLDFTVNVDVTTYKNGKRETLNPEGRALPPAVWGFYSDGCSIRLLNPSTYLIRLRQVCTVLQEFFHCKVGANLYLTPP
H.vulgaris          EKNVQYTKNLDIAVYRNGQRETLNHEGRAFPSVVWKFYEDGCSIRLLNPQIFAKSVHQLTSRLQEYFGCLVGSNVYLTPP
                     ..:::  ::: : * :* * * *  *** *  .       **:::: *. :   :  .   :** * . .*:* **** 
H.sapiens           NSQGFAPHYDDIEAFVLQLEGRKLWRVYRPRVPTEELALTSSPNFSQDDL--GEPVLQTVLEPGDLLYFPRGFIHQAECQ
M.musculus          DSQGFAPHYDDIEAFVLQLEGRKLWRVYRPRDPSEELALTSSPNFSQEDL--GEPVLQTVLEPGDLLYFPRGFIHQAECQ
D.rerio             GTQGFAPHFDDIEAFVVQLEGRKHWRVYNPRCEDEVLSLVSSPNFSQDEI--GEPVMDVVLEAGDLLYFPRGFVHQGDCL
X.laevis            DTQGFAPHYDDIEAFIVQLEGKKHWRVYSPRNSSEFLPQFSSVNFRDRDI--GEPILETVLEAGDLLYFPRGFIHQGDCL
C.elegans           GSSGFAPHWDEIDAFLLQVEGRKYWRVWAPESAEEELPLESSDNFTEDDMKGREPVFEGWIEKGDMIYIPRGYIHQARTD
D.melanogaster      NSQGFAPHYDDIEAFVIQVEGRKRWLLYEPPKKADQLARISSGNYDQEQL--GKPIIDEVLSAGDVLYFPRGAVHQAITE
H.vulgaris          GSQGFAPHYDDIEAFVIQLEGKKHWKLYPPRNTNEVLARYSSENMQEENL--GEPILNKVLEAGDTLYFPRGVIHQASTL
                    .:.*****:*:*:**::*:**:* * :: *    : *   ** *  : ::   :*:::  :. ** :*:*** :**.       
H.sapiens           DGVHSLHLTLSTYQRNTWGDFLEAILPLAVQAAMEENVEFRRGLPRDFMDYMGAQHSDSKDPRRTAFMEKVRVLVARLG-
M.musculus          DGVHSLHLTLSTYQRNTWGDFLEAVLPLAVQAAIEENVEFRRGLPRDFMDYMGAQHSDSKDPRRTAFMEKVRVLVARLG-
D.rerio             PDAHSLHITISSYQRNSWGDLMLKLMPAALEVAMEEDVEFRKGLPLDYLQYMGVQNSEKEDPRRDRFMAHIQGLMKKLV-
X.laevis            PDAHSLHITISSYQRNSWADLLEKILPAALQVAVEEDVEFRKGLPLDYLDYMGVQNTDLEDPRRGTFIQQVQSLVKKLA-
C.elegans           SKVHSLHVTVSTGRQWSFANLMEKVVPEAIGVLTDTRHKLRRGLPTGLFDMGGVIDL--DYSQEDHFVEKFKMVVDRHMS
D.melanogaster      EQQHSLHITLSVYQQQAYANLLETLMPMVLKKAVDRSVALRRGLPLHTFQVLGNAYKGNDCGSRKQLVENVQKLVTNYLM
H.vulgaris          EDSHSLHITISLYQKSSWGDYLEKLIPLALQKAISENVMFREGLPIDFSSFVGVSNSEKKCPERDTFVKTVKKLMEKLI-
                       ****:*:*  :: ::.: :  ::* .:    .    :*.***    .  *      .   .  ::  .: :: .   
H.sapiens           ------HFAPVDAVADQRAKDFIHDSLPPVLTDRERALSVYGLPIRWEAGEPVNVGAQLTTETEVHMLQDGIARLVGE-G
M.musculus          ------HFAPVDAVADQRAKDFIHDSLPPVLTDRERALSVHGLPVRWEAGEPVNVGAQLTTETQVHMLQDGVARLVGE-G
D.rerio             ------SFAPVDAAVDQKAKDFLHDCLPPLLTAEEKAGSVYGAPARWGDSEALDVAVELKSQTRIKLVRAGAARLCSD-G
X.laevis            ------GYAPVDAAVDQKAKNFLHDCLPPVLTPVEKSHSVHGAPVMWDNGQVKDDTIELEADTKIRLLRGGIARLCSE-G
C.elegans           MLRNLVADQLLESSVDSLAKEFMKQALPPRLTEQEKKLSVLGSSTNLLGD----DLVDFTARTKVRLIRRHTQRLLMESE
D.melanogaster      -----PSEDDIDEAVDQMAKKFQHEALPPIVLPSEEVRTVHGARSDADEQGNCVCDYKFNKKTSVRLLRANILRLVTESD
H.vulgaris          ------DYVEIDEAGDELVLDHMEEFQPPYYSSDDVECSVFSKDGFWDGEVRRHHKIEL--STELRLVRPGIVRVIPA-D
                              ::   *. . .. .:  **     :   :* .               .:   * :::::    *:     
H.sapiens           GHLFLYYTVENSRVYHLEEPKCLEIYPQQADAMELLLGSYPEFVRVGDLP------CDSVEDQLSLATTLYDKGLLLTKM
M.musculus          GRLFLYHTVENSRVYHLEEPKCLEIHPQQADAMELLLRSYPEFVRVGDLP------CDSVEDQLSLATMLYDKGLLLTKT
D.rerio             DTVHLYYTTENSRVYHKEASKSFEMKTEHIDAMEFLIHSYPKFVSVASLP------CETAEAKMSLAELLFEKGLIFTAE
X.laevis            DACLLYFSSNNSRIYHREEPKYMEIAAEHVEAIEYLIHSYPKYVPVGSLP------CDQEEDKLTLATILFEKGLVTTRE
C.elegans           DACFISHRINNSRLFEGRPEQIVEYPISGIDAYRVLSNSYPEWRTLYEIFSLRETKTKSRKENLAAIQLLFQIGVLLVKN
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H.vulgaris          TELQVYYSVENSRQYKEVPLRVLRFSLEDADLLEYFLFSYPAYVVVENAP------GDDI-HKVDVANRLYNFGILRSKV
                        : .  :*.  :       ..   .  .  . :  :** :  : .         .    ::     *:: *::    
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6.2 Manuscripts	in	progress	
	
„The	 ribosomal	 oxygenase	Ogfod1	 binds	 Cyclin	 A2	 (CCNA2)	 directly	 and	 alters	 the	 CCNA2	
interactome"		
by	 Katharina	 E	 Bräuer,	 Olga	 Swolski,	 Juliane	Merl-Pham,	 Annette	 Feuchtinger,	 Stefanie	
Hauck,	Mukram	Mackeen,	Alexander	Wolf	(submitted)	
	
„Phylogenetic	 and	genomic	 analyses	of	 the	 ribosomal	oxygenases	Riox1	 (NO66)	 and	Riox2	
(MINA53)	provide	new	insights	into	their	evolution“		
by	 Katharina	 E	 Bräuer,	 Kevin	 Brockers,	 Jasmin	 Moneer,	 Annette	 Feuchtinger,	 Evi	
Wollscheid-Lengeling,	Andreas	Lengeling,	Alexander	Wolf	(submitted)	
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6.3 List	of	abbrevations	
	
A	 Alanine	
2OG	 2-oxoglutarate	
aa	 Amino	acid	
AxA	 Iron	binding	motif	HxD	mutated	to	Alanine	
bp	 Base	pair	
CRISPR	 Clustered	Regularly	Interspaced	Short	Palindromic	Repeats	
D	 Aspartic	acid	
DNA	 Deoxyribonucleic	acid	
DSBH	 Double-stranded	β-helix	
FCS	 Fetal	calf	serum	
FeII	 Iron	II	
g	 Gramm	
GFP	 Green	fluorescent	protein	
H	 Histidine	
h	 Hour	
IP	 Immunoprecipitation	
KO	 Knockout	
L	 Leucine	
LC-MS/MS	 Liquid	chromatography-	Mass	spectrometry/Mass	spectrometry	
M	 Mol	
MALDI-TOF-MS	 Laser	desorption/ionization	-	time	of	flight	mass	spectrometry	
min	 Minute	
NLS	 Nuclear	localization	sequence	
O/N	 Over	night	
P	 Proline	
PBS	 Phosphate	buffered	saline	
PCR	 Polymerase	chain	reaction	
PTM	 Post-translational	modification	
R	 Arginine	
RNA	 Ribonucleic	acid	
ROX	 Ribosomal	oxygenase	
RPM	 Rounds	per	minute	
RT	 Room	temperature	
S	 Serine	
SDS	 Sodium	dodecyl	sulfate	
sec	 Second	
SEG	 Single	exon	gene	
SG	 Stress	granule	
T	 Threonine	
WT	 Wild	type	
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